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Abstract
Hepatitis C virus (HCV) is responsible for most cases of non-A, non-B hepatitis. The persistent 
nature of this virus has been attributed to viral replication errors, which lead to a dynamic pool 
of antigenic variants that allow escape from the host immune response. A major part of this 
escape is due to the hypervariable region 1 (HVR1) of HCV, known to encode structurally 
flexible, isolate-specific neutralising epitopes which undergo successive genetic alterations. In 
a substantial number of cases, complications of HCV infection lead to end-stage liver disease 
for which the only treatment is orthotopic liver transplantation (OLT). Primary HCV infection of 
the allograft is an almost universal phenomenon associated with OLT. This study focused on 
the pattern of HCV variability in the context of immunosuppression, which is a feature of post- 
OLT treatment. Sequences of the HCV HVR1 derived from OLT recipients and from 
asymptomatic (presumably immunocompetent) carriers of the virus were compared over 
several time-points. A rapid turnover of sequences was found in the untreated subjects, in 
whom mean nucleotide and amino acid sequence diversity were 19.8% and 43.5%, 
respectively. In the immunosuppressed patients, the corresponding figures were 2.3% and 
2.3%. Untreated subjects showed a ratio of transitional to transversional mutations of 2.57,
^ compared with 0.98 for untreated subjects (p = 0.0165). Similarly, the replacement to silent 
mutation (R/S) ratios were 8.22 and 1.33 (p = 0.0069), respectively. The major differences 
between the two groups of patients were especially demonstrated by a subset of two 
immunosuppressed patients, in whom the HVRl showed almost 100% homogeneity 
throughout a year of follow-up. Both patients required re-transplantation within a year of the 
first OLT, and both died of HCV-related disease shortly afterwards. On the other hand, two 
other transplant recipients, who showed an HVRl mutation rate indistinguishable from that 
found in the untreated group, remain well 10 months and almost two years post-OLT. This 
investigation (1) demonstrated that the HCV genome becomes more homogenous post-OLT; 
(2) suggests that, at least in some patients, the lack of genetic heterogeneity may pre-date liver 
transplantation; (3) highlights the critical nature of host factors in determining the clinical course 
of post-OLT recurrent HCV infection; and (4) provides a model of hepatitis C viral kinetics in 
immunosuppressed and untreated individuals. The finding of HCV genomic sequences within 
the leukocytes provides molecular evidence for the existence of HCV in peripheral blood cells, 
and thus supports the hypothesis that peripheral blood lymphocytes act as HCV reservoirs for 
the reinfecting virions.
W  xvi
INTRODUCTION 
CHAPTER ONE
1.1 THE LIVER: OVERVIEW
1.1.1 Structure and function
The liver is a bilobular structure which arises from the endoderm of the developing embryo 
(Alberts et a i 1983). At 1.5 kg, or 2.5% of body weight, it is the largest solid organ of the 
body, as well as one of its most complex, with over 500 functions identified (Urdang and 
Swallow 1983). Due to its numerous metabolic functions and secretions into blood, it is 
classifiable as both an exocrine and endocrine gland. Like the lung, it is a segmented organ, 
with definite lines of cleavage between the different segments (Figure 1.1).
Fig 1.1 : Gross anatomy of the liver
FALCIFORM LIGAMENT 
I.
RIGHT
A line running through the bed of the gall bladder (GB.) to the left margin of the 
inferior vena cava (I. V.C.) divides it into right and left lobes. The right lobe is sub­
divided into anterior and posterior segments, and the left lobe into medial and lateral 
segments. Each segment is further divisible into upper and lower zones on the basis of 
the distributions of the hepatic artery, portal vein and bile ducts, giving 8 individual 
zones in theory, though boundaries are masked by the complexity of the liver.
Reproduction of FIG. 1, Chapter 1, of "Liver Disease" by A. Paton (1989), William Heinemann Medical 
Books Ltd., London
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Liver composition includes a variety; of. cell types adaptejjl to perform specific functions, such 
as the fibroblasts (which provide a conn^ive tissue framework); the phagocytic Kupffer 
cells; the fat-storing (Ito) cells; and hepatocytes. The extracellular matrix is a complex 
mixture of collagens, non-collagenous glycoproteins, proteoglycans and glycosaminoglycans 
which, far from being inert, acts as a sensitive radar for detecting fluctuations within hepatic 
microenvironments (Rojkind and Greenwel 1994). The multivalent matrix macromolecules 
form a dynamic interface for cell-to-cell signalling. Communication between the numerous 
cells within the liver is essential for maintaining homeostasis, arid mediators of effector 
functions include cytokines, growtfTfactors and metabolites. Liver functions include 
carbohydrate and lipid metabolism, interconversion of nutrients, secretion of most blood 
plasma proteins, synthesis of bile salts, degradation of bile pigments, detoxification of 
chemical compounds and storage of a large number of products such as vitamins and iron 
(Keeton and Gould 1986). The hepatocyte, a specialised cell which derives from the 
embryonic gut epithelium, is the main site for these activities.
The sponge-like structure of the liver serves as a reservoir in the regulation of blood volume 
and flow through the body. Blood is conveyed from the gut to the liver through the portal 
vein, which drains the whole of the alimentary tract from the lower oesophagus to the 
rectum, as well as the pancreas, spleen and gall bladder. Thus the human liver, which holds 
at any given moment 500 ml of blood (representing a third of cardiac output and 13% of total 
blood supply) stands at the crossroads of the nutrient distribution system of the body. As 
the first organ to "see" incoming nutrients from the gut, it has a rapid enzyme induction and 
repression system that must adapt continually to fluctuations in nutritional intake in order to 
maintain proper life function. -
Nutrients enter the liver in the bloodstream via the portal vein, and are distributed to the rest 
of the body, after processing by the hepatocytes, via the hepatic veins. Glucose is taken up 
and stored as insoluble glycogen, for later release when needed for maintaining normal glucose 
levels. Excess amino acids from protein digestion are broken down, the nitrogen removed as 
urea and excreted by the kidney, and the non-nitrogenous residue converted into glucose. In
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addition to nutrients, liver cells receive the full force of any noxious substances that may be 
absorbed in the intestines.
The liver is a very vascular organ, with a relatively sparse structure which is easily 
deformed by external forces including respiration and straining. Such forces also have an 
impact on blood flow. 90% of the hepatic blood is contained in the sinusoids, which form an 
extensive, apparently haphazard network of thin-walled spaces, the principal site for 
transvascular exchange between blood and hepatocytes (Paton 1969; McCuskey 1994). The 
functional unit of the liver, i.e., the minimum mass of tissue required to perform hepatic 
function, is the hepatic lobule. This is defined as a cone-shaped array of cells and 
interconnecting sinusoids bounded at its convex surface by terminal branches of portal 
venules and hepatic arterioles, and with its apex at the central vein (McCuskey 1994). Fully- 
oxygenated arterial blood reaches the sinusoids via the high-pressure (100 mmHg) hepatic 
arterial system as well as the low-pressure (8-10 mmHg) portal vein (Figure 1.2). The 
pressure from arterial blood flow is presumably dissipated during its spread through the 
sinusoids. The complex nature of intrahepatic blood is dependent on multiple factors, including 
genetic influences on the sinusoidal arrangements as well as specific circulatory adjustments. 
Microvascular injury leads to an inflammatory response manifested by leukocyte adhesion to 
the endothelial lining of venules and sinusoids. Platelet adherence is also found in more severe 
injury, causing plugging of the blood vessel as well as a decrease or cessation of blood flow.
Among the most fascinating features of the liver is its impressive capacity for regeneration, 
with restoration to normal size even after 80% removal reported in humans and animals 
(Paton 1969). Furthermore, this capacity does not diminish with age. Control of the various 
kinds of liver cells and extracellular matrix is as important as maintaining the dynamic 
equilibirum between the bloodbome products of liver metabolism.
The ability of the liver to withstand insults is determined by many interlinked factors, both 
external and internal, of which some are given in Table 1.1. Hepatic damage usually induces 
a short-lived, reversible illness. Despite this limited response, a wide range of functional
derangements occur. It is difficult to find a direct “cause and effect* toxic action of the liver, 
divergent symptoms of hepatitis probably arising from the variable interplay between the 
different factors. In a few individuals, liver damage leads to progressive and irreversible liver 
disease.
Figure 1.2: Scheme of liver sinusoid showing relative contributions of hepatic artery (HA) and 
portal vein (PV). HV = hepatic vein:
FLOW  IO O O M U M IN .  
PR ess u n  6  8 -< 0 M M . HGL 
W ID T H  la  M M .
S A TU R A TIO N  60-7S %
P V
HA
H V
Reproduction of RG, 2, Chapter 1, of ‘Liver Disease* by A. Paton (1989), William Heinemann Medical 
Books Ltd., London
A central question in chronic liver disease is whether the initial damaging agent is responsible 
for perpetuating the injury, or whether it merely sets off a self-damaging (imrhunological) 
reaction on the liver. At one end of the spectrum, alcoholic cirrhosis results from repeated 
assaults in susceptible individuals. In primary biliary cirrhosis, at the other end, immunity 
against glycoproteins from injured bile ducts is the major identifiable cause of liver damage, 
but may merely reflect an aggravated reaction to the original acute injury. The reason for 
continued damage is unknown. Inflammation may prevent proper nutrition of hepatocytes at 
the sinusoidal level. Another possibility is the activation of Kupffer cells to produce antibodies 
against the original antigen.
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Table 1.1: Factors influencing liver function
External Internal Genetic factors
Nutrition Blood flow Species
Infectious agents Blood pressure Enzymes
Alcohol Oxygen supply Anatomical peculiarities
Poisons CO2 concentration Age
Drugs Temperature Sex
Antigen/antibody Nutrient supply
Pregnancy
1.1.2 Causes of hepatic disease
Hepatitis, an inflammatory condition of the liver first described by Hippocrates, may be 
caused by bacteria, parasites, drugs, alcohol, toxins and transfusions of incompatible blood, 
as well as by viruses (Urdang and Swallow 1983). Table 1.2 shows some common and rare 
etiologies of liver disease. Symptoms may be mild and brief, or fulminant and life-threatening. 
A litre of bile is produced daily by the human liver, and comprises mainly conjugated bilirubin 
and bile salts, phospholipids and cholesterol. Bilirubin is produced at the rate of about 
300 mg/day, mostly as a breakdown product of haemoglobin in the reticuloendothelial system. 
Most is excreted in the stools as stercobilin. Obstruction of bilirubin excretion, or the 
occurrence in the liver of bilirubin loads greater than it can deal with, may lead to jaundice. In 
this diseased condition, the eyeballs, skin and urine become abnormally yellow as a result of 
bile in the blood.
Transaminases such as alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) are enzymes responsible for the transamination of amino acids. Found throughout the 
body, they are particularly abundant in muscle, especially heart muscle, and liver. Serum 
transaminase (most commonly ALT) levels are used as a screening test for liver 
dysfunction. Normal ALT levels in blood range from 7-50 international units (IU)/I, and may 
be as high as 500 - 5000 lU/l in acute viral hepatitis. However, a rise in serum ALT does not
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Table 1.2: Etiologies of liver disease
Etiology Selected agents or specific defects
Infections
Acute viral infections: HAV; HBV; HCV; HDV; HEV; CMV; EBV; HSV-1; HIV; 
HFV; HGV; VZV; mumps virus;-yellow fever virus
Chronic viral infections HBV; HCV; HDV; HGV
Fungi Candida; cryptococcus
Parasites Amoeba; schistosomia
Bacteria Salmonella; brucella; legionnella
Mycobacteria M. tutierculosis, M. leprae
Spirochetal Leptospira interrogans, Trepanema pallidum (syphilis 
agent)
Drugs and toxins
Ethanol
Chemicals Be;CCl4 ;As ;P
Heavy metals Fe; Cu
Physical agents Heat; hypoxia; ionising radiation
Genetic disorders Cystic diseases; Wilson's disease
Metat)olic disorders Porphyrias; metal storage disorders
Nutritional diseases Kwashiorkor
Pregnancy
Immunoloaic/unknown etiologv Primary biliary cirrhosis; autoimmune hepatitis
Adapted from Table 5.1 in 'Diseases of the Liver and Biliary Tract: Standardization of Nomenclature, 
Diagnostic Criteria and Prognosis' - International Hepatology Informatics Gmup, Leevy et at. (eds), Raven 
Press, New York 1994
necessarily reflect a purely hepatic .origin nor indeed signify liver damage. Hence neither 
serum ALT concentration nor the occurrence of jaundice can reliably be taken by itself as an
Chapter One: Introduction
indicator of liver function. Other non-specific symptoms of liver dysfunction include abdominal 
discomfort, vomiting and anorexia. More unequivocal signs include necrosis, chronic liver 
damage and hepatoma. "
Chronic hepatitis is defined as liver disease of viral or any other aetiology that persists for 
more than six months. Increasingly severe hepatitic states are classically designated chronic 
persistent hepatitis (CPH) and chronic active hepatitis (CAM). These are characterised by 
varying degrees of liver cell damage, starting with swelling and granularity of hepatocytes.
As disease advances, blood flow through the sinusoids is progressively impaired by the 
swelling of endothelial and Kupffer cells. The sinusoidal lumen is further constricted by 
attachment of granulocytes to the endothelium. Other impedances to blood flow include 
adherence of lymphocytes and platelets to Kupffer cells, and the inflow of extrahepatic 
monocytes into the sinusoids. Eventually, lesions are produced in which sinusoids are 
obliterated by swollen parenchymal cells (hepatocytes). With continuous activity (persistent 
hepatitis), fibrous tissue may extend into the lobule. Patchy (piecemeal) necrosis may occur 
at the periphery of the lobule, leading to groups of liver cells surrounded and isolated by 
inflammatory infiltrates. Some hepatic lesions, such as hepatocyte enlargement with 
sinusoidal encroachment, are reversible. Others, such as fibrosis, are irreversible.
The term chronic active hepatitis defines persisting activity of the hepatic inflammatory 
process, which is "aggressive", as opposed to the subdued course of continuing damage wbich 
occasionally follows virus infection. Cbronic liver disease of viral or any other aetiology can 
lead progressively to the development of liver fibrosis and ultimately cirrhosis. Cirrhosis is 
defined as a chronic illness characterised by fibrosis that distorts the liver architecture, in the 
presence of generalised damage and the formation of regeneration nodules (McCuskey 1994). 
Ito cells have been identified as the main source of the fibrillar matrix proteins observed in 
liver fibrosis (Arthur 1994). While the precise mechanism of liver fibrogenesis remains to be 
identified, the most likely routes are via T-cell mediated Kuppfer cell activation or immune- 
mediated hepatocyte damage. Hepatic function is crucially dependent on the maintenance of 
a proper balance of cells and extracellular matrix by the various metabolites, cytokines and
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growth factors. Disruption of this delicate ecosystem causes functional derangement. 
Damaged hepatocytes are known to release a factor which is mitogenic specifically for the 
hepatic lipocytes, transforming them to the fibrogenic myofibroblasts.
Methods for determining the extent of liver damage include radiology, hepatic ultrasonic 
scanning and histologic analysis of needle biopsies. As advances in the understanding of liver 
histopathology have been made, the need has arisen for a diagnostic system which more 
accurately portrays the complex stages of chronic hepatitis. Classification schemes 
reflecting the etiology, the extent of inflammation (grading) and the degree of progression 
(staging) have been proposed. The most widely used of these is the histological activity 
index, also known as the Knodell score, which consists of four separate scores for different 
components of the lesions (BegicJaneva and Boricic 1995; Callea et al. 1995). An expanded 
system incorporating additional components of liver pathology in chronic HCV infection was 
recently proposed (Wong etal. 1996).
. . .  ■
12 THE ROLE OF VIRUSES IN LIVER PATHOGENESIS
12.1 Definitions
Viruses are infectious agents which have a nucleic acid (DMA or RNA) genome (Jawetz et 
al. 1974) enclosed by a symmetric protein shell, termed a capsid. The unit thus formed 
constitutes the nucleocapsid (or core). The virion, which comprises the viral nucleic acid 
enclosed in a protein coat, composes a single infectious unit, and is identical with the 
nucleocapsid in some instances (e.g; picomaviruses). In more complex viruses, the virion 
includes the nucleocapsid plus a surrounding envelope. The primary nucleic acid structure 
refers to the sequence of bases in the nucleic acid chain, and the secondary structure to the 
spatial arrangement of the complete nucleic acid chain (e.g., whether circular or linear).
Other elements of fine spatial detail in the helix (such as presence of supercoiling, breakage 
points, catenation, gaps, regions of strand separation) contribute to its tertiary structure.
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A class of subvirai pathogens, termed viroids, was discovered in the 1970s. The smallest 
known class of autonomously replicating pathogens, viroids are single-stranded, circular RNA 
molecules of 246-375 residues with a unique secondary structure characterized by double 
helices separated by short, unpaired stretches (Riesner ef a/. 1979). Unlike virions, where the 
infectious unit includes the surrounding coat, the viroid RNA by itself constitutes the 
infectious agent. Common viroid features include the number of base pairs, high co- 
operativity and formation of very stable hairpins. These characteristics, found to be 
improbable in random sequences, imply that the various viroid species, although differing in 
nucleotide sequence, are structurally very similar. There is no evidence of any mRNA 
activity in viroids, implying that all required enzymic functions reside in the plant hosts.
Despite this apparent lack of protein coding capacity and the small size of viroids, they 
appear to be multigenic, with functions corresponding to structurally distinct, interchangeable 
domains (fig 1.3).
Figure 1.3: Model of five viroid domains (T1, P, C, V and T2):
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Reproduction of Fig. 1, Keese & Symons (1985).
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The unique structural features of viroids may represent an optimal compromise between 
stability and flexibility. The native viroid structure is completely stable below its sharp 
transition temperature of 49’C but opening of the structure, a necessary prerequisite for 
replication, is easier to induce in viroids than in com lately double-stranded RNA. On the other 
hand, the extensive base-pairing to give rod-like structures would allow a certain degree of 
protection against degradation.
Ribozymes are RNA molecules capable of cleaving RNA target molecules in a catalytic 
fashion (Lyngstadaas etal. 1995). The hammerhead ribozyme (HHR), one of the smallest 
RNA enzymes known, has been extensively investigated due to its potential as an antiviral 
agent. It is a small RNA motif comprising three base-paired stems connected by conserved 
sequences which are essential for catalysis. Distinguished by the "Y" shape of the three 
stems, HHRs are stabilised in the central core by a network of hydrogen bonds involving, in 
particular, two non-Watson-Crick G:A pairs (Laugaa etal. 1995). According to Ohkawa et 
al. (1995), HHRs belong to a class of molecules known as antisense RNAs. Due to short 
extra sequences that form the so-called catalytic loop, they can act as enzymes. Since the 
catalytic domain captures Mg2+, which can cleave phosphodiester bonds, HHRs are 
recognised as metalloenzymes. Autocatalytic ribozymes have been described in both natural 
and synthetic RNAs (Williams etal. 1995; Ekiand and Bartel, 1995). The genome of human 
hepatitis D virus (HDV) has been shown to have ribozyme properties.
An open reading frame (ORF) is a contiguous stretch of 50 or more codons uninterrupted by .. 
stop signals. The polarity of viral nucleic acid strands is defined such that the mRNA has 
plus (+) polarity. The protein-encoding strand of HBV DNA, which is transcribed into mRNA, 
therefore has (-) polarity, while the same strand in the RNA HCV genome has (+) polarity. 
Retroviruses can convert information in their RNA genomes to DNA using the virally-encoded 
enzyme reverse transcriptase. Reverse transcription of viral RNA into DNA is an essential 
step of the genomic replication in hepadnaviruses such as HBV, which have DNA genomes
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and are termed pararetroviruses, in contrast to orthoretroviruses such as HIV, which have 
RNA genomes.
1.22 Virus Taxonomy
The earliest efforts to classify viruses relied on filterability as the single physicochemical 
characteristic measurable, and classification was based on such features as common 
pathogenic properties. Viruses which shared the pathogenic property of causing hepatitis 
(HAV, HBV, YFV, and Rift Valley fever virus) were thus grouped together as the "hepatitis 
viruses."
The Baltimore classification scheme (Baltimore 1971) focuses on tho central role of mRNA in 
virus multiplication, organising the myriad animal viruses according to their modes of 
transcription and replication. According to this scheme, six classes of animal viruses are 
defined by the structural relationship between their mRNA and the nucleic acid in the virion:- 
Class I: double-strand DNA viruses (e.g. vaccinia), where the double-stranded DNA genome 
acts as template for RNA synthesis, as is the case with cells.
Class II: single-strand DNA viruses. If the mRNA is the same strand as the DNA, the 
intermediate sunthesis of a (-) strand DNA is needed to provide a template for mRNA 
synthesis.
Class III: double-strand RNA, e.g. reovirus.
Class IV: positive-strand RNA viruses (e.g. HCV), where the genome RNA and mRNA have 
the same polarity.
Class V: negative-strand RNA viruses - the virion RNA has a base sequence 
complementary to that of the mRNA.
Class VI: retroviruses, which direct the formation of DNA that acts as the template for 
making their RNA.
In the formal taxonomic system (International Committee on Taxonomy of Viruses or ICTV) 
applied universally today, viruses are classified into families on the basis of several 
parameters, the type and form of the nucleic acid genome (DNA or RNA, single- or double­
11
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stranded) being the most important (Jawetz etal. 1974). Next in significance are the size 
and morphology of the viral particle, including the type of symmetry (icosahedral or helical) 
and the presence of membranes.
Virus families, designated by terms with the suffix "-wr/dae," represent populations of 
viruses that share common characteristics and are distinct in many ways (Murphy and 
Kingsbury 1991). Subfamilies, whose designations are given the suffix -'‘virinae," have been 
introduced for four families {Poxviridae, Herpesviridae, Papovavlridae and Retrovirldae) to 
reflect the intrinsic complexity of their intrafamilial relationships. Within each family, virus 
genera represent subsets of species that share common characteristics. Terms representing 
genera are suffixed with " virus." The term "species' refers to individual viruses or clusters 
of viral strains with many features in common, and is currently defined to include the 
vernacular term "virus."
1.2.3 The compass of viral hepatitis
Viral hepatitis is a systemic disease primarily involving the liver, which can be caused by 
several agents. Clinical manifestations may also vary from one host to another. The most 
common types of acute viral hepatitis in humans are hepatitis A (infectious or short- 
incubation hepatitis), caused by hepatitis A virus (HAV); hepatitis B (long-incubation or 
serum hepatitis) which results from hepatitis B virus (HBV) infection; and hepatitis 0, 
associated with the recently discovered hepatitis 0  virus (HCV). HDV is a subvirai particle 
which requires coinfection with HBV for its own expression and replication, and HEV, like 
HAV, is usually transmitted enterically. Less well-characterised hepatitis viruses are 
hepatitis F virus (HFV), believed to cause acute sporadic hepatitis; and the chronic hepatitis 
agents HGV and the GB viruses. While HAV and HEV cause only acute hepatitis, HBV,
HCV and HDV frequently establish persistent infections, which with time can cause chronic 
inflammation and liver cirrhosis. Variants of the hepatitis viruses,,have been identified in
.C» ^
infected hosts. Although naturally occurring mutations have been found in all viral genes, 
they are usually concentrated in genes encoding the structural envelope and nucleocapsid
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proteins. The resulting viral variability is important as different mutations may correlate 
with different disease profiles. For^example, specific mutations may impede viral clearance 
by providing escape variants from host immunity or antiviral therapy (Blum 1995; Coppola 
and Rizzetto 1995).
Hepatitis is an occasional feature of the clinical syndromes characteristic of several other 
viral infections (White and Fenner 1986). Thus, yellow fever virus (YFV), a flavivirus, 
causes the very severe jaundice from which it derives its name. Hepatitis is also prominent in 
many of the haemorrhagic fevers, such as Lassa, Ebola and Cremean-Congo haemorrhagic 
fevers. It is a major feature of the widespread viral infections which overwhelm neonates or 
immunocompromised patients - (neonatal) herpes simplex and cytomegalic inclusion disease 
caused, respectively, by HSV and CMV (Brooks etal. 1991; Kosai etal. 1991). HIV infection 
is frequently associated with viral hepatitis, which may alter the course of infection (Duffy 
etal. 1986; Schneiderman etal. 1987; Kahn etal. 1991). Other well-characterized viruses that 
infrequently cause sporadic hepatitis are Epstein-Barr virus (EBV), rubella virus and the 
enteroviruses (Okano etal. 1991; Sugaya etal. 1988; Read etal. 1985). Occasionally, 
systemic diseases such as tuberculosis and gonorrhoea may have their principal clinical 
manifestation as liver injury. The pregnant state appears to make women more susceptible 
to hepatitis, perhaps due to aggravation of portal hypertension, or subtle changes in handling 
of bilirubin in the third trimester of pregnancy. Although pregnancy is not significantly 
associated with a worse outcome of most viral infections, a clear association between HEV- 
related fatalities and pregnancy has been shown, and this may be the case with other, 
identified and as yet unidentified, viruses. Liver injury associated with alcoholism may be 
related to acetaldehyde toxicity and/or nutritional deficiency, and may also be triggered by 
viral infection in genetically susceptible individuals. Finally, as yet undiscovered viruses may , 
be at the heart of many cryptogenic liver diseases such as primary biliary cirrhosis (PBC) 
and autoimmune chronic hepatitis (AIH), which are currently considered to have an 
autoimmune basis.
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1.3 MAJOR AGENTS OF VIRAL HEPATITIS
Viral hepatitis may be as old as recorded history (Alter and Seeff 1993). References from 
the Middle ages are plentiful, with some dating back to the biblical period. The unsanitary 
conditions surrounding recorded outbreaks of epidemic jaundice suggest that these descriptions 
referred to infection with HAV, or even HEV, both of which are oral-faecally transmitted.
The origin and evolution of of the transfusion-related HBV and HCV are unknown, although 
these may also have existed for centuries, perhaps transmitted by insect vectors. The 
incidence of transmission of both viruses has probably increased in the wake of modem 
technological advances such as use of the hypodermic needle, and blood transfusion. Today, 
viral hepatitis occurs in sporadic outbreaks as well as epidemics. Most viruses produce 
characteristic histopathological lesions in the liver. Although these are generally 
indistinguishable, specific serological tests enable the identification of individual agents. Some 
characteristic features of the most common hepatitis viruses, described in the following 
pages, are summarised in Table 1.3.
Table 1.3: Features of the most comrhon viral hepatitis agents
Virus Nucleic
add
type
Family Env­
elope?
Size
(nm)
Genomic
length
(kb)
Chronicity
HAV RNA Picomaviridae No 27 75 None
HBV DNA Hepadnavihdae Yes 42 3.2 5%
HCV RNA Flaviviridae Yes 30-60 10.0 >80%
HDV RNA Unclassified Yes
(HBV-
derived)
42 1.7 Coinfection
<10%;
Superinfection:
>80%*
HEV RNA Caliciviridae No 33 75 None
HGV RNA Flaviviridae?
* see section 1.3.3
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1.3.1 Hepatitis A virus (HAV)
This is a single-stranded, nonenveloped RNA virus of positive polarity, classified as a 
member of the Picomaviridae family, which was originally placed in the genus Enterovirus as 
enterovirus 72 (Robertson etal. 19Ô1). the  virion consists of the linear RNA genome and a 
protein shell comprising 4 proteins, VP1 - VP4 (Weitz and Siegl 1993). Although extensive 
homologies in protein structure exist with poliovirus, there is little nucleotide sequence 
homology between HAV and other members of its family, which led to its re-classification 
into a separate genus, 'hepatovirus' (Minor, 1991). Its 7500-nucleotide genome contains a 
single open reading frame (ORF) which runs between nt 734 and nt 7415, and is flanked by 
untranslated regions at the 5' and 3' ends. The coding region can be subdivided into three 
regions: P I, which specifies the structural proteins VP1-4; P2 , which codes for three 
nonstructural proteins (2A-C); and P3, which encodes four additional nonstructural proteins 
(3A-D).
One of the most distinguishing features between classical picomaviruses and HAV concemns 
replication: While viruses such as poliovirus or human rhinovirus replicated to high titres in 
susceptible cells, with replication cycles of 8  -18 h, HAV replicates slowly and inefficiently in 
cell culture (Siegl et al. 1984). Adaptation to culture may take months, and viral titres 
usually remain low therafter. It is also remarkable that HAV, unlike poliovirus, fails to shut 
down the host cell metabolism, leading to persistent infection in culture (de Chastonay and 
Siegl 1987).
Human HAV strains have been classified into four genotypes (I, II, III and VII) which, despite a . 
15-25% difference in nucleotide sequence of the PI region, define only one antigenic serotype, 
so that a single infection can confer lifelong immunity. Three additional genotypes (IV, V and 
VI) are unique simian strains which have significant antigenic differences from the human
fr:;- . .
strains (Lemon etal. 1992). -
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HAV has a worldwide distribution, although its prevalence variesj.n different geographic 
locations, probably reflecting socio&dnomic conditions. In developing countries such as 
Ethiopia and Brazil, over 90% of children are infected by 10 years of age. This contrasts 
with a figure of less than 5% prevalence by 25 years of age in Sweden (Zachoval and 
Deinhardt 1993).
HAV has a distinct resistance to antiviral agents, such as 2,4-dichloropyridine and guanidine, 
which are effective with other picomaviruses (Weitz and Siegl 1993). The strength of 
interaction between the capsid units and the viral RNA is the probable cause of this effect, 
and is also reflected in the high thermal stability of HAV: in the presence of 1 M magnesium 
chloride, it retains its structural integrity and biological functions even at temperatures up to 
80*C. Infection may, however, be prevented by sanitation, and by a timely administration of 
normal human immunoglobulin (NHIG) to individuals exposed to the virus. Killed hepatitis A 
virus vaccines are based on the demonstration that formalin-inactivated virus extracted 
from the liver of infected marmosets induced protective antibodies on challenge with live 
vaccine (Provost and Hilleman 1975). Current live attenuated vaccines require 
administration by injection. Advantages of such vaccines include ease of administration, 
relative low cost and long-term protection. Acute hepatitis A usually follows a benign course, 
and there is no documented human chronic carrier state or animal reservoir for HAV. The 
potential for eventual eradication of this virus from human populations is therefore high.
1.3.2 Hepatitis B virus (HBV)
HBV, the prototype for the family Hepadnaviridae, has an unusual genome - a small, partly 
double-stranded DNA molecule with a single-stranded region of variable length (Tiollais etal.
■r^ :, . . ■
1985). The long, or L(-) strand is linear and of fixed length, while the short, or S(+) strand, 
also linear, varies in length from isolate to isolate. At 3200 bp, it is the smallest of any 
known human DNA virus (Carman etal. 1993a). HBV infection is clinically important 
because of its high frequency of occurrence, often complicated by HDV superinfection (Sonigo 
and Tiollais 1985). The demonstrated presence of free and integrated forms of HBV DNA in
16
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infected host leukocytes (JianRen, etal. 1985) indicates the possible role of these cells in 
promoting the viral persistence which forms a frequent feature of HBV infection. Integration 
of the HBV genome within hepatocytes has been postulated as a trigger for the 
hepatocellular carcinoma with which this virus is significantly associated. The production of 
new vaccines by recombinant DNA techniques has been made possible by advances in 
understanding mechanisms of viral replication and integration in hepatocellular carcinoma 
(Tiollais etal. 1985). This and other aspects of HBV biology are discussed more 
comprehensively in Section 1.4.
1.3.3 Hepatitis delta virus (HDV)
The delta agent (HDV) is an unusual human virus first described in 1983 (Rizzetto 1983) 
which has many similarities to pathogenic RNAs of plants. Its many intriguing features 
include a circular, 1.7 kb RNA genome, a characteristic unique among animal viruses 
(MacNaughton etal. 1993); and the.requirement of the envelope from a helper hepadnavirus 
for hepatitis D viral particle assembly. Cultured cells co-transfected with a cDNA clone of 
HDV RNA genome and cDNA for woodchuck hepatitis virus (WHV, a hepadnavirus) were 
reported to release infectious D particles (Netter etal. 1995). In humans, the helper virus is 
usually HBV (De Wit and Coutinho 1983; Samuel etal. 1995).
The single-stranded RNA genome has a high (60%) G+C content, and has the ability to fold 
on itself by intramolecular base pairing to form an unbranched rod structure (Mason and 
Taylor 1989; Saldanha et al. 1990)f .Under the electron microscope, HDV RNA molecules in . 
the native conformation appear as compact rods, which convert to circular molecules under 
denaturing conditions (Kos etal. 1986). Due to its double-strandedness under native 
conditions, HDV RNA is relatively stable under a variety of manipulations. There is evidence 
that it can act as a ribozyme, autocaytically cleaving and ligating itself by an unusual 
mechanism (Bartolomé etal. 1995). The circularity, high degree of intramolecular base 
pairing and mode of replication of HDV suggest a close resemblance to viroids, discussed in 
section 1.2 .1.
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The viral particle is composed of the HBV-derived envelope (HBéAg) and a nucleocapsid 
comprising hepatitis delta antigen (HDAg) and the RNA genome (Lai 1995), both of which 
may play crucial roles in the viral life cycle. There are three structural regions, which 
comprise: the ORF for HDAg, which is the only encoded protein; a region with ribozyme 
activity; and a heterogenous region with no known structure or function. HDAg specifically 
binds both the genomic and antigenomic strands of the HDV RNA (Poisson etal. 1993), and is 
the basis of serological assays for the virus (Negro and Rizzetto 1995). The 0.8 kb 
antigenomic strand is postulated to be the mRNA for delta antigen (Polo etal. 1995), of which 
two forms appear sequentially in infected cells - the small form, which positively regulates 
HDV replication, and the large form, a negative regulator of replication which is essential for 
particle assembly and virion export (Cullen et al. 1995). At least three types of HDV have 
been identified, which have different pathogenicities and geographic distributions (Casey etal.
1993). Most published sequences, including those from North America, Europe, the Middle 
East and the South Pacific belong to a single genotype. A second genotype is represented by 
a single Japanese isolate. Sequences from S. America constitute a third genotype, 
associated with a particularly severe form of type D hepatitis
The delta agent is frequently found among drug addicts, haemophiliacs and multiply 
transfused patients, risk factors shared with HBV (Jilg etal. 1984). The importance of HDV 
resides in its ability to convert an asymptomatic or mild, acute or chronic HBV infection into 
a fulminant or severe, progressive disease, characterized by massive liver necrosis 
(Vigevani etal. 1985.) Simultaneous transmission of HDV with HBV (coinfection) usually 
leads to a clinical picture similar to that seen with hepatitis B alone. However, superinfection 
of a chronic HBsAg carrier results in a severe, sometimes fatal, acute hepatitis, followed by 
chronic liver disease in up to 40% of cases (Genesca et al. 1987; Jilg et al. 1985). HDV 
superinfection has also been linked with hepatocellular carcinoma (Cronberg etal. 1984; Wu et 
al. 1995). In addition to intravenous drug abuse and household contact with HBsAg-positive 
carriers, heterosexual activity seems to be an efficient route of HDV transmission
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(Stroffolini et al. 1994). In the absence of a specific therapy for delta agent infection, 
vaccination against hepatitis B is used as a prophylactic measure (Jilg etal. 1984).
1.3.4 Hepatitis E virus (HEV)
The first documented evidence of ET-NANBH came from New Delhi in 1955 (Purcell and 
Ticehurst 1988). It is a sporadic, epidemic form of acute viral hepatitis also found in Africa 
(Belabes etal. 1988; Bradley etal. 1993) and in the Indian subcontinent. South East and 
Central Asia, and N. America (Bradley etal. 1988; Bradley etal. 1993). Unlike HAV, it 
affects predominantly young to middle-aged patients. Always self-limiting, its clinical profile 
is similar to that of hepatitis A, with the striking distinction of a 20% case mortality rate in 
pregnant women. This unexpectedly high fatality rate may reflect a unique feature of viral 
replication or liver pathogenesis in these individuals. Identification by immune electron 
microscopy of the etiological agent (Humphrey etal. 1988) was followed by its further 
characterization and designation in 1990 as hepatitis E virus (HEV) (Reyes etal. 1990). HEV 
is responsible for more than 50% of symptomatic acute hepatitis cases in developing 
countries (Purdy and Krawczynski 1994). This is consistent with the postulate of an 
enterically transmitted agent because environmental conditions in the most endemic areas 
favour a faecal-oral transmission route.
HEV is a spherical RNA virus 27-34 nm in diameter, with a morphology and biophysical 
properties most similar to those of the family Callciviridae (Wattre 1994; Bradley 1995). Its 
genome comprises an approximately 7.5 kb positive-sense, single-stranded RNA molecule with 
three distinct ORFs (0RF1,0RF2 and 0RF3). Isolates can be broadly divided into two 
serotypes, represented by isolates from Mexico (HEV-M) and Burma (HEV-B); of which 
HEV-B appears to be more common. Genetic analysis of cDNA clones representing nearly 
the entire genome revealed nucleotide sequence variation, including an HVR region in 0RF1.
A nucleotide sequence diversity of 58% has been reported between the two serotypes in this 
region. Cross-challenge studies show, however, that animals infected with HEV-B are 
immune from reinfection by HEV-M.
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An additional peculiarity of this virus is the relatively low frequency of clinical disease which 
develops in case contacts, an unusual feature for an ènterically-transmitted agent: A 2.4% 
HEV transmission rate was reported during an epidemic in Nepal, which contrasted with the 
10-20% rate observed in household contacts of patients with hepatitis A occurring in the 
same region (Bradley etal. 1993).
1.3.5 Hepatitis F virus (HFV)
A novel agent, designated HFV, was recently reported to be the cause of a sporadic form of 
non-A, non-B hepatitis (Deka et al. 1994). Described as comprising 27 - 37 nm particles, the
jÜr • il-.
presumed agent was serially transmitted in rhesus monkeys by intravenous inoculation of the 
stool extract from a French patient. The genetic material of HFV is a 20-kb, double-stranded 
DNA molecule which, upon partial sequence analysis, was found to resemble none of the other 
enterically transmitted viruses. A more definitive description awaits the sequencing of the 
entire genome.
1.3.6 Hepatitis G virus (HGV) & the GB Viruses
10 - 20% of non A, non-B hepatitis Js caused by nomC, non-E etiologic agents. One potential 
agent, associated with serum from a surgeon (GB) who developed acute hepatitis and 
designated the GB agent, was able to induce hepatitis in experimentally infected tamarins. 
Two novel flavi-like viruses, designated GBV-A and -B, have recently been cloned and 
characterized from the GB agent (Schlauder etal. 1995; Simons et al. 1995). A third agent, 
designated GBV-C, was isolated from a different human specimen (Simons etal. 1995). 
GBV-A, -B and C share limited overall sequence identity, but have a genomic organisation 
similar to other flaviviruses. An additional RNA virus, designated hepatitis G virus (HGV), 
was recently isolated from the plasma of a patient with chronic hepatitis (Linnen et al. 1996). 
HGV, which has a 9392-nucleotide genome encoding a putative polypeptide of 2873 amino 
acids, is closely related to GBV-C, and distantly related to GBV-A and -B. A transfusion- 
transmissible agent, it has a global distribution, and is closely associated with both acute and 
chronic hepatitis.
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1.3.7 Hepatitis C virus (HCV)
The single-stranded RNA genome of HCV contains a large translational open reading frame 
(ORF), which encodes a polyprotein of about 3,000 amino acids. The main cause of 
parenterally-transmitted hepatitis, it is an enveloped virus 30-60 nm in diameter (Plagemann
1991). Phylogenetic analysis shows a strong resemblance between HCV and both 
flaviviruses and pestiviruses, leading to its current classification as a separate genus within 
the family Flaviviridae (Weiner etal. 1991). Although hepatitis C is is often mild, HCV 
infection is remarkable for its high frequency of progression to chronicity (over 50%), with 
end-stage liver disease developing in up to 20% of carriers (Alter 1988). HCV is described in 
detail in Section 1.5.
1.4 HEPATITIS B VIRUS: A MODEL HEPADNAVIRUS
1.4.1 Historical background
Two types of human hepatitis were recognised before the 1960s, distinguishable by their 
modes of transmission - enteric (type A) and parenteral (type B) - and designated hepatitis 
A and B, respectively. In 1963, a search for polymorphic serum proteins led to the discovery, 
in the blood of an Australian aborigine, of an unknown antigen - later named the Australia 
antigen (Blumberg et al. 1967). Immune electron microscopy studies by D.S. Dane showed 
that the antigen was present on the surface of particles with three different morphological 
forms and was associated with the disease serum hepatitis, now known as hepatitis B (Dane 
etal. 1970). The 22-nm Australia antigen particles, subsequently renamed hepatitis B 
surface antigen (HBsAg), were found to be noninfectious, but the 42-nm particles were 
shown to be infectious virions containing an endogenous, DNA-dependent DNA polymerase 
within their cores (Kaplan etal. 1973). The virus, named hepatitis B virus (HBV), was 
subsequently characterised in 1974. as a small, circular DNA which was partially double­
stranded and partially single-stranded (Robinson and Greenman 1974a; Robinson etal. 1974b). 
Other HBV-like agents have been discovered in the woodchuck, ground squirrel, Pekin duck
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and heron. Together with HBV, these viruses comprise the virus family Hepadnaviridae, a 
name derived from their hepatotropism and DNA genome (Gerlich 1993).
1.4.2 Structure and molecular biology
The HBV virion is a spherical particle 42 nm in diameter, consisting of a 27-nm icosahedral 
core within a closely adherent "envelope" containing virus-specific surface antigen (HBsAg). 
The core contains two additional antigens, HBcAg and HBeAg, plus DNA polymerase and 
viral nucleic acid. The genome consists of a circular, double-stranded DNA with a molecular 
weight of about 2.2 x 10®, a length of 3200 nucleotides and a most unusual structure: One of 
the DNA strands is incomplete, leaving 15 - 50% of the molecule single-stranded, but the gap 
is repaired in situ by a DNA polymerase carried in the core (White and Fenner, 1986; Collier 
and Oxford, 1993).
Figure 1.4: Structure of HBV DNA
EcoRI
center
3221/1
+ s trcn d - s trc n d
DNA In 
virions
Numbering begins at a cleavage site of EcoRI. DR1 and DR2 represent two directly 
repeated sequences.
Reproduction of Fig. 6.3, p.90, Chapter 6, Section 2, of 'Viral Hepatitis: Scientific basis and clinical 
management,' by A. J. Zuckerman & H.C. Thomas, eds. (1993), Churchill Livingstone, Edinburgh
The complete (long, or (-)) strand contains a discontinuity at a unique site, and has attached 
to its 5' end a covalently bound protein (primase), which primes (-) strand synthesis (fig. 1.4). 
It also has a terminal redundancy of 9 bases, where the ends ovelap slightly. The (+) strand 
is connected with the HBV DNA polymerase at its 3' end. Its 5' end is formed by 18
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ribonucleotides, which are capped in the same way as mRNA. There is also a short triple­
stranded region at the point where the (+) strand bridges the discontinuity of the partly 
overlapping (-) strand ends.
HBV shows two deviations from the usual classification criteria: it contains both DNA and 
RNA, and its genome contains partly single-stranded, partly double-stranded and even triple­
stranded DNA. The mechanism of HBV attachment to and penetration of host cells is 
unknown. Even less is known about the way in which the viral genome is released within the 
cell.
A fundamental difference between hepadnaviruses and retroviruses lies in the fact that the 
-form of the genome present in mature virus particles is DNA, and not RNA. Hepadnaviruses 
replicate by reverse transcription of RNA intermediates from the positive-sense DNA 
contained in the virion. This is accomplished by a virus-coded reverse transcriptase (Seeger 
et al. 1986). The RNA serves as the template for a new (-) strand DNA. This in turn is 
transcribed by a DNA-dependent DNA polymerase to positive-stranded progeny DNA for 
incorporation into the new virions. It is currently assumed that replication requires conversion 
of the virion DNA into a double-stranded, covalently-closed circle (an episome), a reaction 
which is possibly mediated by the virion polymerase.
As shown in figure 1.5, HBV has four ORFs, designated S (for the three surface, or 
envelope, proteins); C (encoding the core proteins hepatitis B c and e antigens - HBcAg and 
HBeAg, respectively); P (which specifies the viral DNA polymerase); and X (transcriptional 
transactivator). HBV makes very efficient use of its small genome, with much overlap of the 
different ORFs. In addition, a single ORF is sometimes used to code for several proteins, 
through the deployment of different initiator codons within the same ORF. Thus, two 
translation start codons (AUG) are found in ORF C. Translation from the first gives rise to 
a long protein, of which the first 19 amino acids are a signal peptide, enabling secretion from 
the coll, after modification, as HBeAg. The core protein, HBcAg, is translated from the 
second AUG of this gene. In addition to B and T cell epitopes peculiar to HBcAg or HBeAg,
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both peptides contain shared epitopes, a resuit of the large number of shared amino acids.
For this reason, HBeAg has been postulated to play a role as a tolerogen in nenonates born 
to infected mothers, as well as an immunomodulator after infection in adults.
Figure 1.5: Genetic map of the three HBs proteins (subtype ayw)
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Reproduction of Fig. 8.3, p. 144, Chapter 8, Section 2, of "Viral Hepatitis: Scientific basis and clinical 
management,' by A. J. Zuckerman & H.C. Thomas, eds. (1993), Churchill Uvingstone., Edinburgh
The envelope gene contains three domains, each encoding a different protein (see figure 1.5). 
The small protein, or hepatitis B surface antigen (HBsAg), is encoded by the S domain and 
comprises 226 amino acids. A terminal extension of HBsAg forms the middle protein, which is 
HBsAg plus an additional 55 amino acids encoded by the pre-S2 domain. The largest hepatitis 
B surface protein (large protein), which is about 400 residues long, contains 3 domains - pre- 
S2  (encoding 108-119 amino acids); pre-SI; and S. All three proteins are translated from 
distinct mRNA molecules (Yamamoto et ai. 1994). The pre-SI domain is one of the most 
variable regions of the HBV genome. This may be a reflection of intensive selection by 
immune pressure. However, unlike the hypervariable regions of HCV or HIV, pre-SI is not 
mutated within a chronically infected person.
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1.4.3 Pathogenesis
Although HBV is poorly cytotoxic per se, host defence mechanisms bring about the death of 
HBV protein-expressing cells. This, and the neutralisation of circulating virus, are the cause 
of acute and chronic hepatitis B. Proof of the immune-mediated nature of HBV-related liver 
damage lies in the observation that immunologically immature or deficient individuals become 
chronic carriers of the virus without developing typical hepatitis (Gerlich 1993). High viral 
titres ( I0 8 - 1 0 1 0  particles/ml serum) are characteristic, and are accompanied by 
antigenaemia, in which the viral surface proteins are secreted by infected cells as particles of 
variable morphology and size. Most HBV-infected adults suffer symptomatic or 
asymptomatic hepatitis, and clear the virus. Less than 5% develop persistent infection with 
chronic hepatitis. During chronic infection, changes occur in all HBV genes, some of which 
result in evasion of the immune response. In a few individuals, an efficient cytotoxic immune 
response is followed directly by persistent infection with high-level viraemia and antigenaemia. 
The mechanism(s) whereby HBV suppresses or escapes immune pressure is (are) unknown. 
Surface protein variability does not play a major role, as is the case with HCV. Such 
variation is apparently distinct from the substitutions which define the subtypes of HBV. 
Although integration into the host genome is not essential for HBV replication, as is the case 
with orthoretroviruses, such an event often occurs, and may lead to disturbances of genetic 
elements of growth control. HBV therefore has oncogenic potential.
1.4.4 Genomic variability
Reverse transcription in viruses is a highly error-prone process, due to the lack of
■■■■%
proofreading enzymes. Thanks to^an intermediate reverse transcription step during 
replication, HBV evolves rapidly for a DNA virus, and is estimated to have a variability 
midway between that of DNA and RNA viruses (Wallace etal. 1994). One antigenic 
expression of this variability is seen in subtypes, which are defined by monospecific, 
polyclonal antisera against HBsAg. HBsAg has one common antigenic determinant, a, and 
one member of each of two pairs of mutually exclusive subdeterminants cf or y, and wor r, to 
give 4 main antigenic subtypes: adw, adr, ayw and ayr. Additional subspecificities assigned
ifi \ •; ■ . • •• f
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to the IV determinant led to a 9-member classification: adw2 and 4, ayiv1-4 , adrq+ and q-, 
and ayr. Figure 1.6 shows the predicted structure for the a determinant, which occupies the 
region from amino acids 124 to 147, and is the main neutralising epitope cluster for HBV. 
Antibodies against a are a major component of the anti-HBs response following infection or 
immunization. In all serotypes, amino acid positions 139-147 are highly-conserved, and 
cyclical synthetic peptides of this nonapeptide have been shown to induce high-affinity 
antibody production (Karthigesu etal. 1994). As well as type-specific residues characterising 
particular sites (such as position 126, which is threonine in subdeterminant wand isoleucine 
for r), there are invariant residues. Four cysteines at positions 124,137,139 and 147, are 
predicted to form disulphide bonds (Cys 124-137 and 139-147) resulting in a double loop 
structure. The presence and conservation of these residues implies that strong secondary 
structural constraints operate in this region. The a determinant is found in all subtypes, so 
that HBV infection can be prevented by vaccination with a preparation of a-derived antigen 
(Waters ef a/. 1992).
Figure 1.6 : Proposed double loop structure of the HBsAg a determinant
A \ / \  [ n S T G p c
Circles represent normal residues; hexagons and triangles represent reported vaccine-induced mutants; squares 
depict insertion mutations Ref: Carman et al. (1995) - Lancet 245:1406
1.4.5 HBV immunity: significance of the a determinant
The main marker antigens for HBV infection are produced sequentially as follows: Surface 
antigen (HBsAg), a non-infectious particle found in acute and chronic infection; core antigen
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(HBeAg), whose presence implies infectivity; and core antigen (HBcAg), readily detectable 
only in hepatic nuclei, and not in blood. Patterns of infection are variable, and are influenced 
by age, sex and the state of the immune system. Typically, the incubation period for HBV is 
two to three months, and leads to a prodromal phase followed by overt jaundice, after which 
90% of patients recover uneventfully. Antibodies appear in the order anti-HBc, anti-HBe and 
anti-HBs. Anti-HBs, the major protective antibody, appears only after HBsAg has vanished, 
and is therefore a reliable indicator of recovery and immunity to'reinfection.
10% of HBV-infected individuals become chronic HBsAg carriers, in whom HBsAg, and often
virions, circulate consistently in the blood. There are two. kinds 6t'HBsAg carrier state:-
• In chronic antigenaemia, the patient fails to form anti-HBs, and production of anti-HBe Is 
delayed. In these "healthy" or "asymptomatic" carriers, HBsAg may persist in the blood 
for many years, but the patient is well, and does not infect others.
• Chronic active hepatitis B is distinguished by disease progression, as indicated by liver 
damage and persistently elevated serum levels of transaminases. Patients with this 
condition produce neither anti-HBs nor anti-HBe. Persistence of HBeAg, HBV DNA 
polymerase and Dane particles implies active viral replication, high infectivity, 
progressive liver damage and poor prognosis.
Testing for HBeAg , which may persist for years in chronically infected patients, is therefore
of diagnostic value, as the antigen is a marker of virdi replication (Martin etal. 1993).
In escape mutation, an antigen that has attracted immune attention is altered to become 
antigenically different from the initial epitope (Carman etal. 1993b). A virus bearing such an 
altered epitope may persist in the presence of an adequate immune response against the 
original epitope. The best known HBV mutants are those with mutations in the pre-core 
region for aborting HBeAg secretion. These mutants prevail as the host seroconverts to 
anti-HBe, because hepatocytes infected with HBV and surface expression of HBeAg are 
selectively eliminated. The link bet\)veen severity of liver disease and such pre-core mutations 
is not well-defined - mutations are found both in patients with progressive disease and those 
with normal liver biochemistry (Hsu etal. 1995). It is unclear whether such substitutions 
predispose patients to progressive hepatitis or occur as a result of severe disease (Boner et 
al. 1995).
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Variants of HBV with altered antigenicity of the envelope protein have been described. These 
are especially important because the a determinant bears potent HBV-specific B and T cell 
epitopes which form the basis of current vaccines and antibody-based assays for HBV. In a 
recent survey involving 1000 blood samples from individuals infected with HBV (Wallace et ai.
1994), 0.8% were untypeable due to alterations in a. While representing a relatively low 
value, this figure is highly significant from clinical and epidemiological viewpoints. A variant 
of a with a substitution of Arg for Gly at amino acid position 145 was found in a patient who . 
developed fulminant hepatitis after withdrawal of chemotherapy for lymphoma, despite 
previous vaccination (Carman etal. 1995). The patient had been anti-HBsAg seronegative in 
a widely used monoclonal antibody-based ELISA, but was found to be strongly seropositive 
by polyclonal assay as well as positive by PCR for HBV DNA. The Gly-Arg substitution, it 
should be noted, would significantly affect the hydropathy profile of the peptide, as well as its 
secondary and tertiary structure. Corroborating data showing that this variant evades the 
known protective anti-HBs response came from a study in which a vaccinated child born to 
an HBV-infected mother was found to harbour HBV with the point mutation predicting the 
Argi45 variant as the only mutation. This, and other changes involving single amino acid 
substitutions, as well as deletions from, or insertions into a, have been described (Waters et 
al. 1992; Karthigesu etal. 1994; Yamamoto etal. 1994).
Escape mutants, especially those affecting HBsAg and the a determinant in particular, pose 
a significant risk to the community because vaccines and immunoglobulin preparations are not 
effective in preventing infection with such mutant strains. ' Failure by current serological 
assays to detect HBsAg may lead to transmission through blood transfusions or organ 
transplants. Orthotopic liver transplantation (OLT) remains a useful method of treatment 
for end-stage liver disease caused by HBV, and is normally followed by administration of 
hepatitis B immunoglobulin (HBIG) in order to prevent recurrent infection. If OLT were 
performed on an individual carrying a mutant strain, HBIG preparations administered to 
prevent recurrent disease would be ineffective, and fulminant hepatitis could occur.
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15 HEPATITIS C VIRUS: RNA AGENT OF HEPATITIS
15.1 Historical background
By the mid-1970s, routine testing for HBV carried out in blood banks world-wide had greatly 
reduced the incidence of hepatitis B transmission. Such testing also helped to underline the 
occurrence of other forms of hepatitis, known collectively as non-A, non-B hepatitis or 
NANBH (Bradley 1985; Tabor 1985). Two major forms of NANBH were prominent in the 
1980s: those which were enterically and those which were parenterally transmitted (ET- and 
PT-NANBH, respectively). Physicochemical and histological studies showed significant 
differences between the two agents, such as sensitivity or resistance to chloroform, and 
type of liver lesion formed.
Similar to hepatitis B in its percutaneous route of transmission, the etiologic agent of PT- 
NANBH eluded detection for more than a decade, until the first definitive description by Choo 
et al. (1989), who based their work on pioneer experiments carried out with experimentally- 
infected chimpanzees. Previous work had shown a lack of abundant poly-A mRNA in the 
presumed viral agent (Linke etal. Î&88 ). Underlying the Investigation of Choo etal. was the 
assumption that the virus, although present in infectious serum, circulated in such low 
amounts that conventional immunological techniques had failed to detect it. Hence, as a viral 
source, plasma from a chimpanzee known to have a high degree of infectivity was used.
After extensive ultracentrifugation, to ensure pelleting of even a small viral particle, nucleic 
acid was extracted from the pellet and completely denatured, and reverse transcription 
carried out on the assumption of either a DNA or RNA template, using random primers of 
reverse transcriptase. The resulting cDNA was cloned into a X g tll library, and screened 
with presumed antisera. This led to the isolation of the first NANBH-associated clone (5-1- 
1), the product of which was used with first-generation ELISA tests for anti-HCV antibodies 
(Kuo etal. 1989). Most cases of post-transfusion NANBH were found to be associated with 
anti-c100-3 antibody, and this response was used to define infection with a new virus. The full 
genome of the etiologic agent, termed HCV, was subsequently cloned and characterized 
(Choo etal. 1991). Although other parenterally transmitted viral agents of hepatitis are now
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known to exist (Schlauder etal. 1995; Simons etal. 1995; Simons etal. 1995; Linnen etal. 
1996), HCV still accounts for the majority of cases.
15.2 Epidemiology and risk factors for HCV infection
HCV is encountered worldwide, with relatively high prevalences in Japan, southern USA, the 
Mediterranean countries of Europe, Africa and the Middle East, where 0.1 -1.5% of blood 
donors are anti-HCV positive. In the northern USA, Canada and northern Europe, 
prevalences are lower, at 0.01 - 0.05% (Van der Poel etal. 1991). Transmission is mainly by 
the parenteral route.
Screening assays for evidence of infection with HCV are usually based on commercial kits 
which detect antibodies against epitopes of the capsid (c22) and non-structural (c33, c l 00-3 
and 5-1-1) proteins. The origins of the cloned antigens are depicted in Fig. 1.7.
Figure 1.7: Schematic depiction of HCV genome showing origin of antigens used in 
commercial anti-HCV antibody detecting systems
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The implementation of anti-HCV antibody screening assays in blood banks around the world 
has led to a marked drop in the number of post transfusion hepatitis cases, with intravenous 
drug abuse (IVDA) now being the major risk factor for developing HCV infection. 
Transmission rates are especially fiigh among haemophiliacs and dialysis patients (Allain et 
al. 1991; Ng etal. 1991; Brackmann et at,. 1993; Lampertico etal. 1995). Other risk factors
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include tattooing (Ko etal. 1992), and needlestick injuries (Kiyosawa etal. 1991). Vertical 
and sexual transmission constitute uncommon but significant transmission routes (Alter ef al. 
1989; Melbye etal. 1990; Tedder ef a/. 1991; Inoue etal. 1992; Weiner etal. 1993). The 
demonstrated presence of HCV in body fluids such as saliva, urine, seminal fluid and ascites 
(Liou etal. 1992; Numata etal. 1993) indicates that these may play some role in 
nonparenteral HCV transmission. HCV is transmitted rapidly and efficiently to transplant 
recipients from infected donor organs (Wreghitt etal. 1994; Maple etal. 1994; Pereira etal.
1995).
1.5.3 Genomic organization
Alignment with sequences available from databases worldwide showed a significant 
resemblance between the newly-discovered HCV genome and those of flavi- and pestiviruses, 
as well as plant potyviruses and carmoviruses (Koonin 1991). The resemblance was 
greatest in areas encoding the enzymes of viral replication and expression, prompting the 
postulate of a common evolutionary ancestry for these positive-stranded RNA viruses 
(Koonin and Doija 1993). According to this view, the genes for essential proteins (including 
RNA-dependent RNA polymerases, putative RNA helicases, chymotrypsin- and papain-like 
proteases, and methyltransferases)Torm a relatively stable core of "housekeeping" genes, 
interspersed with more variable domains. Limited but significant amino acid sequence 
homology was found in regions of HCV corresponding to the NS3 and NS5 proteins of 
flaviviruses (Miller and Purcell 1990). These included a nucleoside triphosphate (NTP) binding 
motif, as well as the putative (chymo)trypsin-like serine protease motif of flaviviruses and 
pestiviruses. In addition, the 3' end showed the Gly-Asp-Asp motif which is highly conserved 
among viral-encoded RNA-dependent RNA polymerases. The colinearity of these homologies, 
together with the overall resemblance of hydropathy profiles for the gene products, led to the
JVr ,r : . .
proposal of a similar genomic organisation for HCV, flaviviruses and pestiviruses (Choo et al. 
1991; Plagemann 1991; Takamizawa etal. 1991), with structural proteins encoded by the 5' 
terminus, and non-structural proteins by the 3' end of the genome. Fig 1.8 schematically
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depicts HCV, bovine viral diarrhoea virus (BVDV, a pestivirus) and the representative 
flavivirus YFV (yellow fever virus).
Figure 1.8: Genomic organization of HCV: Comparison with representative flavi- and 
pestiviral genomes
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The 10 kb HCV genome contains a non-coding region (NCR) (or untranslated region, UTR) at 
the 5' end, which is highly conserved among all isolates. The following 9033 nucleotides 
constitute a major open reading frame (ORF) for the synthesis of a large polyprotein of 3010 
or 3011 amino acids, which is further processed by cellular and viral genes to give the 
functional (three structural and four non-structural) proteins. The ORF is followed by a 3'- 
poly-A or poly-U NCR of variable length.
The 5'-UTR is a region of approximately 341 nucleotides (Takamizawa etal. 1991), which is 
highly conserved among variants of HCV worldwide, and bears some resemblance to a 
corresponding region in Picomaviridae. Picomavirus RNAs are uncapped messengers with 
unusually long 5' UTRs (610 -1200 residues) which contain many silent AUG sequences - 
features which seem incompatible with efficient translation by the ribosome scanning
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mechanism used in most eukaryotic cellular and viral mRNAs. Initiation of translation in 
picomaviruses involves binding of ribosomes to an internal sequence within the 5' UTR, called 
the internal ribosome entry site (1RES). In its possession of a fairly long 5' UTR harbouring 
three or four AUG sequences, HCV is more similar to picomaviruses than to Flaviviridae. 
Evidence that this domain in HCV constitutes an 1RES was provided from studies using mono-
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and dicistronic expression vectors, in vitro translation and deletion mutagenesis (Brown et al.
1992; TsukiyamaKohara et ai. 1992; Wang et ai. 1993). As well as demonstrating the 5' UTR 
involvement in translational control, these studies showed that the sequences immediately 
upstream of the initiator AUG are essential for 1RES function during translation. Computer- 
assisted and biochemical analyses generated a thermodynamic model of the secondary 
structure of the HCV 5' UTR which was comparable to that found in picomaviruses.
Depicted in figure 1.9, it composes a large conserved stem-loop structure (Brown et al. 1992).
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Other studies refuting the presence of an 1RES in HCV indicate that the virus may employ an 
alternative, distinctive control strategy, involving the generation of subgenomic viral mRNA 
in infected cells (Yoo etal. 1992). The consensus remains, however, that translation 
strategies in HCV are different from those of other flaviviruses. This has prompted 
suggestions for the creation of a new virus family for classifying HCV.
The products of the entire coding region have been characterized by various groups (Eckart 
etal. 1993; Grakoui etal. 1993a; Ralston etal. 1993; Selby etal. 1993). Host signal 
peptidases are believed to effect cleavage between C and El and between El and E2, while 
processing of the NS proteins is by a virus-encoded protease. 9 distinct cleavage products 
are generated, viz:-
NH2-C-E1-E2-NS2-NS3-NS4a-NS4b-NS5a-NS5b-COOH 
As schematically depicted in figure 1.10, the basic nucleecapsid, or core, protein (p22) 
comprises 190 amino acids and is the first translated product. The predicted C gene product 
has a high (16-23.5%) Arg-Lys content, as do other flaviviral core proteins, and may be
jlCl ■ • ■ „ I. K' '
capable of binding to the RNA genome (Takamizawa etal. 1991; Okamoto etal. 1992). It is 
followed by regions encoding the hydrophobic envelope 1 protein gp33 (El, 190 amino acids) 
and the second envelope protein gp70 (E2) of 350 amino acids. Although these are the most 
highly variable parts of the genome, they show a significant number of characteristics 
common to all variants, such as a constant number of cysteine residues, located at identical 
positions in the genome, and a remarkable conservation of potential N-linked glycosylation 
sites (Choo etal. 1991). A signal peptide motif (Perlman and Halverson 1983; von Heijne 
1985) precedes each envelope protein. MS2 (p23) is a metalloprofeinase which mediates NS2- 
NS3 cleavage. NS3 (p72) has proteolytic activity responsible for some processing of the 
precursor polyprotein into mature products (Grakoui etal. 1993b). The function of NS4 is 
unknown, although it is known to be processed into NS4a (plO) and b (p27).
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Figure 1.10: HCV precursor polyprotein showing cleavage products
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Although the precise mechanism cf HCV replication remains to be elucidated, it is significant 
that no DMA intermediates have been detected in serum or liver cf infected individuals. This 
implies direct RNA to RNA replication, mediated by a virus-encoded RNA-dependent RNA 
polymerase. Antigencmic (■) RNA strands have been detected in liver (Takehara eta l.
1992), plasma (Feng eta l. 1991) and PBMG (Muller eta l. 1993). Theoretical evidence for the 
polymerase role cf NS5 has been reported (Takamizawa e ta l. 1991). Like NS4, NS5 is 
processed into a and b parts (p56 and p70). NS5b contains the GDD motif peculiar to RNA- 
dependent RNA polymerases cf positive-strand RNA viruses and is assumed to encode the 
viral replicase (Kocnin 1991). Taken together these data indicate that the HCV genome is 
replicated by a direct RNA-to-RNA mechanism, in which the RNA-dependent RNA 
polymerase encoded by NS5b catalyses the synthesis of the (-) strand on the (+) strand 
template, possibly mediated by host or viral factors which act as primers or initiation 
factors. The S' UTR shows significant variations in both length and sequence in different 
reports, and may have a poly-U tail (Takamizawa e ta l. 1991).
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Although overall nucleotide and amino acid sequence homologies between HCV and 
pestiviruses are few, a number of similarities point to a closer ancestral relationship to them 
than to flaviviruses. These include the similar size of the 5'-UTR (fig. 1.8), as well as the 
presence of nucleotide homology and of several short ORFs in this region. Also, both HCV 
putative envelope proteins resemble the pestivirus envelope glycoproteins. On the basis of 
the accumulated evidence, HCV is assumed to be an unusual virus that is most related to the 
pestiviruses.
1.5.4 Phylogeny and genomic diversity
RNA viruses are traditionally divided into positive-stranded viruses (in which the input 
genome is translated into protein); negative-stranded viruses (with genome complementary to 
the message sense); and double-stranded RNA viruses. As discussed in section 1.2.2, 
subdivisions into virus families are based on factors including virus structure, hosts and 
epidemiology. Comparative sequence analysis has revealed striking homologies among 
otherwise disparate groups, leading to the designation of taxonomic groupings such as the 
seven •superfamilies': the Sindbis-like, picomavirus-like, negative-stranded, double-stranded, 
flavivirus-like, coronaviridae and unassigned RNA viruses (Strauss etal. 1991). A 
hierarchical alignment of representative amino acid sequences from RNA-dependent RNA 
polymerases of all groups of positive-stranded RNA viruses was recently described (Koonin 
1991). The exercise led to the delineation of three large supergroups of RNA viruses, 
designated I, II and III (Table 1.4).
Table 1.4: Supergroups of RNA viruses
I .V  . B m
Picoma-, noda-, como-, poty- Carmo-, tombus-, pesti-, and Tobamo-, tobra-, boralei-,
and sobemoviruses flaviviruses; HCV; single- tricoma-, potex-, toro- and
stranded bacteriophages rubiviruses; HEV
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Unexpected clusters of sequences included the grouping of HCV and pestiviruses with 
carmoviruses and related plant viruses in supergroup II, and constitute strong evidence of a 
common ancestry. Extant viruses may have arisen from a single protovirus by a 
combination of linear divergence, genetic recombination and gene duplication.
HCV, like flaviviruses and pestiviruses, is a small, enveloped virus which, on the basis of the 
similarities described above, together with other, unique, features, has been classified as a 
separate genus within the family Flaviviridae (Heinz 1992). A comparison of full-length and 
partial sequences from around the world revealed the existence of different variants, which 
originally posed problems for detection of the virus. Experiments using PCR primer sets 
corresponding to different areas of the genome showed that primers derived from the non­
coding region (NCR) gave the most reliable results (Bukh etal. 1992). The discovery of 
significant genomic diversity between different HCV isolates suggested the existence of 
distinct viral genotypes, and led to attempts to classify the virus. Comparisons of published 
sequences of HCV were carried out by several groups, leading to the identification of distinct 
viral types' which differed from each other by up to 33% over the entire viral genome (Choo 
etal. 1991; Chan etal. 1992; Okamoto etal. 1992; Bukh etal. 1993). Table 1.5 is a 
concordance of the major classification systems for HCV.
The Okamoto method for classifying HCV was based on differential PCR amplification using 
type-specific primers. In the two-stage PCR process, universal primers were first used to 
generate the template for second PCR. In the second stage, a universal sense primer was 
used in connection with a mixture of four antisense primers, each corresponding to a different 
HCV genotype (designated type I, II, III or IV). The generated DNA fragments were run on a 
gel and stained with ethidium bromide in order to visualise the type-specific PCR product, 
whose size was unique for each of the four genotypes. A fifth genotype (type V) was later 
identified (Okamoto et al. 1993). Primer sequences were based on a 341 -nt sequence within 
the putative C gene. Nucleotide sequence identity within each genotype lay between 95.1% 
and 97.6%, a range significantly greater than that of 77.9 - 91% observed between any two 
types. This method was successfully used to type all of 256 serum samples tested, revealing
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incidences of multiple infection by the presence, in each case, of multiple PCR bands 
(corresponding to different genotypes) within the same sample.
To identify evolutionary relationships between HCV variants, comparisons of nucleotide 
sequences from the 5' NCR were carried out on several isolates originating from different 
geographic areas (Chan etal. 1992). Phylogenetic analysis revealed the existence of three 
distinct groups of sequences, corresponding to designated HCV types 1,2 and 3. As shown in 
figure 1.11, these phylogenetic groupings were maintained and further defined in the other 
regions analysed, NS3 and NS5.
Table 1.5: Concordance of major HCV classification schemes*
Proposed
name
Published
example Cha Simmonds Enomoto Okamoto
Tsukiyama
-Kohara
la HCV-1, -H 1 la K-PT 1 NC**
1b HCV-J, -BK 1 1b K-1 1 1
1c — NC NC NC NC NC
2a HC-J6 Q 2a K-2a Dl 1
2b HC-J8 ID 2b K-2b IV 1
2c -------------- ID NC NC NC NC
3a Ta, E-bl IV 3 NC .  V NC
3b Tb IV NC NC VI NC
4a NC 4 NC NC NC
5a ________ V NC NC NC NC
6a NC NC NC NC NC
‘ Sequences from the following sources; Cha etal. (1992); Simmonds etal. (1993a); Enomoto 
etal. (1990); Okamoto etal. (1992); Tsukiyama-Kohara etal. (1991)
Adapted from Table 3, Simmonds et al. (1993a).
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Figure 1.11: Phylogenetic groupings (types) of HCV, based on analysis of the non-coding 
region (NCR), as well as nonstructural proteins 3 and 5 (NS3 and NS5) regions
39
Chapter One: Introduction
In later studies, NS5 was chosen for phylogenetic analysis due to the abundance of 
comparative sequence data for this region which was, in addition, sufficiently variable to 
allow differentiation between different HCV isolates (Simmonds etal. 1993a). Pairwise 
comparisons of 76 HCV variants allowed a detailed definition of the three overlapping groups 
into which the evolutionary distances were arranged (figure 1.12). The first ranged from 0.38 
- 0.84 (mean 0.543); the second from 0.16-0.32 (mean 0.248); and the third 0-0.12 (mean 0.061). 
Of the 2850 pairwise comparisons made, no evolutionary distances of intermediate value 
between these distinct ranges were found, nor did the mean value of any distribution overlap 
with any other (figure 1.13).
Figure 1.12: Distribution of evoiutionary distances (a) and percentage sequence simiiarities 
(b) upon pairwise comparison of 76 nucleotide sequences of HCV variants in the NS5 
region, (a) No. of calculated evolutionary distance measurements recorded on y axis, 
(b) No. of observed sequence simiiarities recorded on y-axis. Mean ±3 S.D. for each 
distribution shown by horizontal bar
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Correspondingly, three levels of sequence diversity were observed in a phylogenetic tree of 
NS5 sequences. As depicted in figure 1.13, many types were found to contain groups of more 
closely related sequences, called subtypes and designated a, b, c etc. (Simmonds 1995). From 
these studies, it emerged that a 222-bp NS5 fragment was sufficient to distinguish among 6 
equally divergent main groups of sequences, or types (designated 1 - 6).
Figure 1.13: Evolutionary relationships between HCV variants (represented as numbered 
dots) based on NS5 sequence comparisons. 6 main groups (types) of sequence 
variants are shown (1-6). Types 1-3 each comprise groups of more closely related 
subtypes (designated a, b, c)
P Simmonds, 1995
Ref: P. Simmonds (1995) INTERaction 3(1):5
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A typing method based on amino acid sequence homologies was proposed by Bukh etal.
(1993). Using this method, it was possible to distinguish between at least 12 HCV types 
based on an 11-residue stretch of residues at the carboxyterminal El (amino acids 341 to 
351). The practicability of the amino acid-based typing system led to its application in 
serological studies of the immune response during HCV infection using type-specific synthetic 
peptides or recombinant proteins. Results showed that HCV was classifiable into serological 
subtypes (Simmonds etal. 1993b; Orito etal. 1994).
In an extensive analysis of samples from 12 countries (Germany, ttaly, Denmark, Sweden, 
USA, South Africa, Dominican Republic, Zaire, Hong Kong, Taiwan, India and Peru), HCV 
subtype 1b was found to be the most globally prevalent (Bukh etal. 1993). Certain 
(sub)types were nearly exclusive to particular geographic locations, such as the African 
types 4 and 5, and type 6 in Hong Kong. Interestingly, Denmark was found to have the 
highest number of subtypes, including the unique subtype 4d. Additional HCV groupings 
continue to accrue (such as types 7-9 in Vietnam), in step with ongoing attempts to clarify 
the significance of these variations (Bukh et al. 1995). Although two regions of 
hypervariability have been described for HCV, HVR2 is evident only in subtype 1b (Okamoto . 
et al. 1993). The sequencing of additional HCV isolates from different parts of the world 
would outline the range of variability and substantiate classification based on a phylogenetic 
tree. Since HCV genotypes are associated with severity of liver disease and response to 
IFN, it is worth determing novel HCV types for correlation with liver disease and therapeutic 
efficacy, and for the development of serological assays and future vaccines.
The major mechanisms for creating sequence divergence in RNA vjruses are reassortment 
(which only occurs in viruses with segmented genomes) and mutation. Mutations result from 
the fact that most RNA polymerases (replicases) lack proofreading activity, which leads to 
an inherent error frequency of 1 in 10*^  (Ogata etal. 1991). This, combined with the large 
number of replication cycles a virus can undergo in a year, and the occurrence of infection at 
high multiplicity (many viral particles/cell), makes for a very high rate of divergence. The 
rate of genomic sequence divergence in RNA viruses has been estimated at 0.03-2%/yr,
42
Chapter One: Introduction
which approaches a million times the rate for eukaryotic DNA genomes (Holland etal. 1982). 
Although this figure may be overestimated, it is agreed that the overall mutation rate is so 
rapid that the sequence homologies found between, for example, plant and animal viruses can 
only be explained by common evolutionary pressures, which imply a common origin.
The issue of nomenclature of genetic variation is unresolved. The term "mutant" is used if a
• V
previous isolate from the same patient is shown to be different. For HBV, the term "variant" 
has been defined to mean a genome with altered biology (Carman etal. 1993a). The term 
"quasispecies' refers to the tendency of many viruses to circulate as a collection of distinct, 
albeit closely related, genomes, rather than a single population of homogenous sequences. All 
viruses consist of a mixture of viral genotypes, although the phenomenon is especially 
prominent in RNA viruses and retroviruses due to a lack of the proof-reading enzymes that 
assure fidelity of DNA replication (Holland etal. 1982). Mutation rates range from 10'^ to 
10'3 point replacements, deletions or insertions per nucleotide per round of copying (Carman 
et al. 1993a,b). Each mutant progeny genotype in a heterogenous population can undergo 
any of 3 fates:-
• negative selection, a process in which mutants carrying changes lethal or deleterious to 
the virus are eliminated;
• random sampling of genomes with equal fitness for the environment. This results from 
the degeneracy of the amino acid codon which ensures that many individual point 
mutations have no phenotypic effect, or that changes do not affect RNA or protein 
secondary structure;
• positive selection by the host, in which mutants optimally fit for a new environment (such 
as escape mutants from immune pressure or mutants with a replicative advantage) 
dominate or replace the original genotype.
Random mutations, caused by errors of the viral polymerase, lead to the production of 
variants which are transmitted together and then replicate independently at different levels 
until one predominates. Positive selection, strongly represented by the host immune pressure 
in humans, is the major force which shapes the composition of a vims population within a
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host. In immunocompetent hosts, the virus population usually consists of a single dominant 
sequence (master sequence), in coexistence with a spectrum of less well-represented 
sequences, designated minor variants. The development of antibodies against the major 
sequence allows one or more minor variants to selectively expand, a process that repeats 
itself as antibodies are sequentially produced against the sequentially emerging escape 
mutants. The quasispecies existence of viruses probably represents an evolutionary 
advantage, as it optimises the possibility of rapid selection of a variant with optimal fitness 
for any new environment, thus promoting viral persistence.
The HCV 5' non-coding and NS3 regions both have a confirmed “quasispecies" nature 
(Martell et al. 1992). The sequence heterogeneity rises to a peakjn an 81-nucleotide 
hypervariable region of E2, designated HVR1 (Hohrie ef a/. 1994; Kao etal. 1995). The 
composition of genomic variants in patients with chronic hepatitis 0  was found to change 
sequentially, either gradually or drastically (Honda etal. 1994; Kurosaki etal. 1994). The 
implication is that a population-based approach is vital in any studies to determine how the 
HCV genome evolves. For an accurate representation of the viral population in a host at 
any given time point, sequences from at least 10 clones must be determined for each region 
studied.
V
1.5.5 Evolution of genomic sequence during chronic infection
Early experiments aimed at characterising the HCV genome revealed that, although the 
nucleotide substitution rate of about 10-3/site/year corresponded to that expected for an 
RNA virus, the changes were not uniformly distributed along the genome (Ogata etal. 1991). 
Rather, regions of high mutability were interspersed with relatively homogenous areas.
Table 1.6 shows the observed nucleotide and amino acid sequence divergence between two 
HCV isolates, giving the values for different parts of the genome.. These two isolates, which 
had been derived from the same cKronically infected patient but separated by 13 years, 
showed an average nucleotide sequence divergence of 2.5%. However, values ranged from
0.7% in the NCR to 4.6% in E2. Furthermore, a 39-nt segment in the E2 was responsible for
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30% of the observed changes. While changes in the other regions Were predominantly (62%) 
in the third codon position, 100% of the changes in the highly variable region of E2 were in the 
first or second codon positions. Since nucleotide substitutions in most genes are known to 
occur preferentially at the third codon position, these results were strongly indicative of 
immune selection. Non-uniformity of nucleotide variation along the HCV genome was 
corroborated by others (Kremsdorf et al. 1991). In addition, the presence of two HVRs 
(HVR1 and HVR2) in the putative E2 was reported (Hijikata etal. 1991). A hypervariable 
domain, composed of 25 putative amino acids and designated region V, was reported for 
HCV, and mapped to the probable E1/È2 junction (Weiner et al. 1991 ). Region V, which 
included the 30 nucleotides of HVR1 - encoding 10 amino acids - as defined by Hijikata etal. 
(1991), represented 8% of the nucleotides sequenced, but accounted for up to 50% of the 
observed nucleotide changes, implying its being under immune selection or 
evolutionary/molecular constraints.
Table 1.6: Differential variability of HCV genomic domains in two sequential isolates from a 
single patient
Region
Nt
Changes (%)
aa
% replacement 
mutations
5' NCR 0.7 NA
Core 1.4 1.4 33
El 2.4 1.3 18
E2 4.6 72 52
NS2 3.1 15 20
NS3 15 12 20
NS5 15 15 25
Ret: Ogata etal., (1991): Proc. Natl. Acad. Scl. 88:3392-96
Comparisons of HCV genomes of different subtypes confirmed the even distribution of 
nucleotide sequence variability throughout most of the genome. As shown in Table 1.6,
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exceptions are the core (invariably the most conserved) and non-coding regions, where 
sequence diversity is exceptionally low, and the highly variable envelope genes. The presence 
of a hypervariable region makes HCV unique among the Flaviviridae. The numerous features 
common to both region V3 of gp120 in the human immunodeficiency virus (the principal 
neutralising domain for HIV) and the HCV HVR1 have prompted attempts to clarify the 
clinical significance of the latter region by studying the nature and rate of sequential 
nucleotide changes therein.
It appears that the HCV genome remains remarkably stable in the period immediately 
following transmission. Vertical transmission studies reported a child with a homogenous 
population bom to a mother with multiple HVR1 variants (Weiner etal. 1993), with similar 
results obtained from experimental transmission of HCV to chimpanzees (Van Doom et al. 
1994). When HCV sequence analysis was carried out on chronically-infected patients, 
however, serial samples were shoWn to undergo dramatic changes of nucleotide sequence 
(Kurosaki etal. 1993). The observed strong preference for nonsynonymous mutations 
constituted indirect evidence of in vivo positive immune selection. The results of a 28-patient 
study reported in 1994 indicated that the degree of intrapatient HVR1 heterogeneity 
increased significantly with progression of liver disease (Honda etal. 1994). In this report, a 
total of 280 clones (10 per patient) were sequenced in the region corresponding to the HVR1, 
now defined as an 81-nt region encoding putatively 27 amino acids from positions 384 - 410, 
which includes the 25 amino acids of region V. Multivariate analysis showed that histological 
diagnosis was the strongest indicative factor affecting nucleotide diversity, so that in acute 
hepatitits few variants were detected, while in patients with cirrhosis and hepatocellular 
carcinoma, all 10 clones were different, with no master sequence.
1.5.6 The El and E2 domains
The enormous diversity of RNA viruses probably leads to mutations introduced uniformly
along the genome. However, mutations in regions where a high degree of conservation is
; . . .
absolutely required would give rise'to defective viruses, which would rapidly disappear. The
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observation of a highly variable envelope region, for example, may indicate that envelope 
proteins are more tolerant of amino acid mutations than other proteins, and therefore persist. 
The envelope proteins of viruses play a major role in stimulating protective immunity against 
them, as discussed for HBV in section 1.4. In order to investigate possible targets for the 
host immune response, the envelope glycoproteins of HCV have been extensively studied.
Both El and E2 are heavily glycosylated proteins (Grakoui etal. 1993). Cleavage positions 
for El and E2 have been mapped at approximately amino acid positions 190 and 380, 
respectively (Matsuura etal. 1992).
El : The putative product of the HCV E1 gene is a glycosylated protein comprising amino acid 
positions 192 to 383 of the initial polyprotein. 192 residues in length, it contains a moderately 
variable domain between amino acid positions 215 and 255 (Weiner etal. 1991). The El 
protein has a size of 31 kDa, and at least 5 potential acceptor sites for N-linked 
glycosylation, represented by the sequence Asn-X-Thr/Ser, where "X" = any residue 
(Grakoui et al. 1993). Underlying the apparent diversity of this glycoprotein is the occurrence 
of certain invariant features, including a 15-residue stretch from amino acid 315 to 329, 
depicted below:-
GHRMAWDMMMNWSPT . _
This stretch of amino acids is absolutely conserved in all HCV isolates, except for the 
substitution of Leu for Met at position 324 in HCV type 2 (see section 1.5.4) (Okamoto et al. 
1992). Potential glycosylation sites are well-conserved in El. Disulphide bond formation plays 
an essential role in determining the three-dimensional structure of E l, however variable the 
intervening amino sequences. This is reflected in the invariant number and positions of its 8 
Cys residues (Okamoto etal. 1992). Processed El protein expressed in mammalian and 
insect cells was examined for antigenicity in a Japanese study (Matsuura etal. 1992). In a 
population of 360 samples from patients with hepatitis C of varying severity, the prevalence 
of anti-El antibody was generally low at about 20% (compared with 90% for anti-core 
protein antibody). The reason for this discrepancy could be the low immunogenicity of E l, or 
hypervariability in this region.
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Proteolytic processing of the E1, E2 and core proteins is dependent only on host signal 
peptidase (Ralston etal. 1993). A signal sequence Is a labile peptide, 13 to 36 amino acids 
long, found at the amino terminus of nearly every presecretory polypeptide, which is cleaved 
from the mature protein after initiating transport. A target of signal peptidase, it is 
invariably composed of three structurally dissimilar regions: a positively-charged amino- 
terminal domain (n); a central hydrophobic core (/?); and a more polar carboxyl terminus (c) 
that apparently defines the cleavage site. The minimal length of a signal peptide substrate of 
a eukaryotic enzyme has been defined as 13 amino acids, comprising n, h and c regions of 1,7 
and 5 amino acids respectively (von Heijne 1985).
A comparison of flaviviral, pestivlral and HCV hydropathy plots indicated the likely presence 
of a signalase cleavage site in the region of HCV encoding amino acids 371 - 377 (Weiner et 
al. 1991). Named region SP, this could represent the hydrophobic core h of the signal peptide. 
The same study revealed the presence of a hydrophobic domain between amino acids 328 
and 368. The residues involved ar%
PTTALVMAQLLRIPQÂILDMIAGAHWGVLAGIAYFSMVGN 
in the prototype HCV isolate HCV-1 (Choo etal. 1991). This region, which is located directly 
upstream of SP, could serve as a membrane anchor sequence, as hypothesised for 
flaviviruses, and lends support to the postulated function of region SP. Alanine, the most 
abundant protein associated with signal peptide cleavage (Perlman and Halverson 1983), is 
found five residues downstream of region SP, and a (positively-charged) Lys residue 
precedes it. Together, these data indicate that the signal sequence for E2 cleavage is as 
follows:-
KVLVVLLLFAGVDAIET,
running between residues 370 and 383, where region SP is emboldened, and “!“ indicates the 
signal peptidase cleavage site. The residues E (Glu) and T (Thr) are the first two amino 
acids of a known hypervariable region (HVR1, discussed below). The study of Weiner et al. 
was useful in pinpointing this site of cleavage between El and E2. It should be noted that
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cleavage at the position indicated would place HVR1 at the extreme amino terminus of the 
mature E2 protein (see fig. 1.14).
E2: The E2 gene product is a 70 kDa glycoprotein comprising about 350 amino acids (Grakoui 
etal. 1993). Formerly designated E2/NS1 to reflect the role of analogous proteins in 
flaviviruses and pestiviruses, its heavy glycosylation, together with the fact that it is not 
secreted into the culture medium by transfected mammalian cells, constitute strong evidence 
that it is a second envelope protein. Its 11 potential N-linked glycosylation sites are well- 
conserved, and represent many more than the number of such sites in its putative analogs - a 
maximum of 5 in the flaviviral NS1, or 6 in pestiviruses (Spaete etal. 1992). Other fixed 
features indicating the presence of conformational restraints include the possession of 
exactly 26 Cys residues at identical positions in different isolates, and an abundance of Gly 
and Pro residues. Thus E2, as well as El, appears to have a complex three-dimensional 
Structure. Four hydrophobic sections between residues 715 and 779 are believed to compose a 
single, membrane-spanning domain. In the proposed topology of Spaete etal. for the E2 
protein, this would place the glycoprotein in a conventional orientation with the N-terminus out 
of and the C-terminus within the cell membrane. Thus, the N-terminus would be subject to 
immune surveillance.
Hypervariable regions of E2: Two hypervariable regions (HVR1 and -2) have been identified 
in E2, which account for its being the most diverse domain of the HCV polypeptide. Most of 
the observed diversity is contributed by HVR1, which encodes a 27-residue polypeptide 
occupying amino acid positions 384 to 410 of the polypeptide. HVR1 has been shown to be a 
target of the immune response which stimulates the production of neutralizing antibodies 
(Shimizu etal. 1994; Zibert etal. 1995). Although neutralizing, the antibodies do not prevent 
chronic infection in most cases because of the rapid changes which occur progressively, 
behind which the isolate-specific antibodies lag. Amino acid alterations in HVR1 occur 
sequentially during chronic hepatitis at a rate of 0.5 -1.7 amino acids/month (Kato et al.
1994).
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The HVR2 domain is a nonapeptide or heptapeptide, depending on HCV type, whose product 
occupies amino acid positions 474 - 482 of the type 2 HCV isolate HC-J8 (Okamoto et al.
1992). HVR2 apparently occurs in only one subtype (1b) of HCV, and its product does not 
appear to be a target of the immune response (Okamoto et al. 1993).
The result of computer-generated secondary structural predictions for the E2 protein is 
shown schematically in figure 1.14). The amino acid sequence for E2 was determined for two 
HCV genome isolates obtained from the same chronically infected host, one during acute 
infection and the other 8.2 years later (Taniguchi etal. 1993). The 27 amino acids of HVR1 
constitute less than 0.1% of E2. However, the changes in amino acid sequence between the 
two isolates were concentrated in this region, which contained 9 of the 14 observed 
substitutions. The secondary structure of the HVR1 domain was significantly different at 
the second time point, while the bulk of E2, that part outside HVR1, showed no alteration in 
predicted secondary structure despite 5 amino acid changes. These findings helped to 
reconcile the apparent constraints on secondary structure of the envelope glycoproteins with 
the ease of escape from neutralising antibody that makes hepatitis C infection predominantly 
chronic in nature. HVR1 appears to be the single "loophole" in the highly conserved 
architecture of E2. Its presumed orientation outside the cell membrane would render it easily 
accessible to neutralising antibodies, while its occurrence at one terminus of the protein 
means that many changes may be tolerated without affecting overall secondary structure. 
Antigenic shift during the course of chronic infection leading to escape from neutralising 
antibodies is one of the most probable mechanisms of HCV persistence.
E2 protein could be the structural analogue of hog cholera virus (HoCV) gp55, which has been 
shown to elicit protective antibodies against hog cholera when vaccinated into swine (Hulst et 
al. 1993). In one experiment designed to check this theory, truncated and full-length versions 
of the E2 domain were stably expressed into OHO cell lines (Spaete etal. 1992). While the 
full-length form appeared to be exclusively intracellular, the C-terminally-truncated forms 
were detectable in extracellular media as fully processed glycoproteins containing terminal
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sialic acid additions. These truncated proteins could be biologically relevant targets of the 
immune response, and therefore constitute potential subunit vaccine candidates.
Other regions of E2 have been investigated for immunogenicity. The antibody response to 
structural and nonstructural proteins was studied in immunocompetent patients, and 
compared to the response with immunosuppressed patients, all HCV-infected (Lok etal.
1993). It was found that most immunocompetent hosts with chronic hepatitis C were highly 
reactive to all antigens tested (derived from the core, El, E2, NS3 and NS5 regions). 
Reactivity was much decreased in immunosuppressed patients, but this effect was less 
pronounced with core- and envelope-directed antibodies. This study highlighted the 
advisability of incorporating assays for additional antigens, including El and E2, into 
serological assays, at least until more sensitive PCR-based tests become commercially 
available.
In a study to further characterize the antigenic structure of E2, 70 synthetic, overlapping 
peptides spanning E2 were used in serological assays for specific antibodies. Two major 
antigenic areas were found, occupying amino positions 484-499 and 554 - 569 (Zhang etal.
1994). The sequences, which were almost totally conserved among the isolates tested, were 
found in 50% of 131 patients with acute, past or chronic HCV infection. However, there was 
little evidence suggesting that antibodies directed against these regions are neutralizing.
Experiments using purified E1-E2 complexes revealed that they are recognised at high 
frequency by HOV-positive human sera (Ralston etal. 1993). The antigenicity of El 
appeared to be affected by co-expression of E2 in cis. The molecular basis of E1-E2 complex 
formation was unclear in these studies. Although Grakoui etal. (1993a) had earlier reported 
the occurrence of intermolecular disulphide linkages, this finding was not corroborated by the 
results of Ralston etal. The requirement for E1-E2 co-expression for high antigenicity 
provided a possible explanation of the weak immune response to recombinant El expressed 
from constructs lacking E2, and implied that both El and E2 might be necessary components 
of an HCV vaccine. Indeed, further studies showed that chimpanzees vaccinated with
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vaccinia-expressed E1 and E2 were completely protected from infection after intravenous 
challenge with the homologous HCV-1 isolate (Choo etal. 1994). The combined results form 
an encouraging basis for the development of anti-HCV vaccines which are universally 
applicable.
1.5.7 HCV immunity: role of HVR1
Two peculiarities which distinguish HCV from members of other Flaviviridae genera are the 
frequent chronicity of HCV infection, and the extreme heterogeneity of the N-terminus of the 
E2 polypeptide. The idea of a correlation between these two facts was pursued through 
investigations into the possible immunogenicity of the hypervariable region. In accordance 
with the general rule that linear epitopes are associated with less-structured regions of 
proteins, such as the ends, or surface loops, secondary structure analysis of the N-terminal 
E2 HVR was carried out. Resulting data indicated a relatively unstructured nature of this 
region, which had <50% probability of a-helix, p-turn or p-sheet character (Weiner etal.
1992). The lack of secondary structural motifs in the hypervariable region, designated region 
V by Weiner etal., implied a tolerance for sequence changes compatible with its putative role 
in escape from immune pressure, and antibody-epitope binding studies showed the presence of 
isolate-specific linear neutralising epitopes in region V (Weiner etal. 1992).
Further investigations of the antigenic potential of predicted HVR1 peptides obtained from 
serial samples revealed a successive appearance of mutants with antigenically distinct amino 
acid sequences within this domain (Taniguchi etal. 1993). Each amino acid substitution was 
associated with alteration of the predicted local secondary structure of the epitope region, 
implying a high degree of structural flexibility and antigenic variability. These properties, 
which would facilitate ease of escape from host immunity, may well account for the high 
persistence rates of HCV.
In an assay for HOV-specific neutralising antibodies, cultured cells were incubated with either 
high- or low-infectivity titre samples (HITS or LITS) as an HCV source (Shimizu et al.
1994). The LITS, known to be antibody-complexed, were unable to sustain intracellular viral
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replication, implying that the complexed immunoglobulins were neutralising antibodies.
Although the particular epitopes involved were not identified, it seemed reasonable to assume 
that they would be located in the viral envelope, as is the case with many other viruses, 
including Flaviviridae. Both the pestiviral E2 and flaviviral NS1 proteins elicit protective 
antibodies against the respective viruses when used as vaccines (Weiner etal. 1992), and 
pigs vaccinated with the purified hog cholera virus (HoCV) El product were protected 
against hog cholera (Hulst etal. 1993). With HCV, in vitro experiments, in which humoral 
responses to HVR1-derived peptides were evaluated with expression vectors producing such 
peptides, pointed to a key role of the HVR1 in the immune response. Immunoprécipitation 
occurred upon the addition to this system of homologous, but not heterologous, sera. These 
findings led to the identification of immunological epitopes specific for the homologous viral 
isolates (Kato etal. 1994). Two distinct, overlapping epitopes of at least 11 peptides each 
were identified, running from amino acid positions 11 - 21 and 14 - 24 of HVR1. Variants 
altered within these epitopes could escape recognition by pre-existing antibodies, implying that 
HVR1 is the major site affecting genetic drift in HCV. Corroborating evidence came from 
physicochemical studies which revealed the presence of two populations of HCV particles 
(high-density and low-density) in sera of chronically-infected HCV hosts, the high-density 
component deriving from association of the virion with immunoglobulin. Sequence analysis 
showed that only the low-density particles accumulated base substitutions within HVR1, 
implying that such changes can lead to accumulation of immunoglobulin-free viral particles 
(Choo et al. 1995). In a further experiment to test the hypothesis that these antibodies 
recognised specifically HVR1,13 clones derived from an HCV-contaminated anti-D 
preparation were sequenced (Zibert et al. 1995). The expression products of the four 
identified HVR1 variants were used in an ELISA assay for anti-HVRI antibodies. Such 
antibodies were found in 67% of serum samples from 30 recipients of the anti-D source, 
versus in 0% of 60 negative controls.
A major difference between HCV and other Flaviviridae is the apparent lack of protection 
from infection by antibodies to envelope proteins. Previous HCV infection did not protect
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chimpanzees experimentally inoculated with the virus from hepatitis - seroconversion and 
liver alterations developed regardless of whether the reinfecting strain was homologous or 
heterologous to that of the original inoculum (Farci etal. 1992; Prince etal. 1992). A similar 
phenomenon has been described in humans: A patient became superinfected with a type III 
(subtype 2a) HCV strain despite pre-existing subtype 1b infection (Kao etal. 1993).
1.5.8 Chronic hepatitis C: Mechanism of pathogenesis
Little is known about the pathogenesis of HCV, a virus which is strongly associated with 
liver injury in infected humans. Studies of this phenomenon are complicated by the absence of 
an efficient in vitro culture system, or convenient animal model. Early indications of a 
positive correlation between HCV viraemia levels and abnormal liver histology were confuted 
by clear evidence of persistently high hepatitis 0  viraemia in the absence of liver disease 
(Brillanti etal. 1993; Navas etal. 1994; Barrera éf a/. 1995). Thdse findings imply that a 
direct cytopathic effect is not the major cause of liver damage in hepatitis 0, a view 
supported by the fact that the virus lacks oncogenes and does not replicate via a DNA 
intermediate.
Studies on congenitally immunocompromised patients have provided further clues to the 
nature of HCV pathogenesis. Patients with primary hypogammaglobulinaemia who were 
treated with contaminated immunoglobulin rapidly became infected with HCV, and 
experienced a severe and rapidly progressive course of hepatitis which was poorly responsive 
to IFN (Bjoro etal. 1994). Sequence analysis of the HVR1 in an agammaglobulinaemic 
patient revealed absolute homology of consensus sequences at three different time points 
spanning a two and a half year period (Kumar etal. 1994). These observations imply that a 
humoral immune response against HVR1 is not a necessary accompaniment to HCV-related 
disease. However, the host immune system may play a role in HCV-related liver injury via 
its cellular branch. Possible mechanisms include T-cell-mediated cytotoxicity; and the release 
of inflammatory cytokines, mediated by HCV within leukocytes.. ^
J?-'- • •. . • -• ' ■■■'
55
Chapter One: Introduction
Investigations into the nature of cellular immunity in HCV infection, which revealed the 
existence of HOV-specific cytotoxic T lymphocytes (CTLs), have answered some of the 
questions concerning the mechanism of HCV persistence and pathogenesis. Human 
histocompatibility antigen (HLA)-restricted CTL recognising epitopes from various parts of 
the HCV genome have been isolated from both chronic HCV patients and asymptomatic anti- 
HCV positive subjects (Ferrari etal. 1994). The highly-specific HLA class ll-restricted T cell 
responses described in the study of Ferrari et al. were directed against the core protein, 
which appears to be the most potent T cell antigen for both chronic HCV patients and 
asymptomatic, anti-HCV-positive subjects. In another study, HLA class I-restricted CD8+ 
CTLs were isolated from liver-infiltrating lymphocytes of persorts with chronic HCV hepatitis
i "
(Koziel et al. 1993). A key aspect of this finding was the confinement of the CTL to the sites 
of tissue injury, which supports the hypothesis of CTL-mediated liver injury. The complexity 
of the subject is highlighted by the fact that HCV-specific, HLA class l-restricted CD8+ cells 
could also be isolated from lymphocytes in the peripheral blood circulation (Kita etal. 1993).
It is clear from the above that both HLA class I- and class ll-restricted T cell responses to 
HCV occur, directed against antigens from various parts of the genome. The fact that 
significant variation existed in some of the epitopes described, particularly those within E2 
and NS2 (Koziel etal. 1993), implicates mutations within CTL epitopes as a mechanism for 
viral persistence through escape from the cell-mediated immune response. Antagonism, a 
phenomenon whereby mutations within T cell epitopes prevent binding or recognition of the 
original peptide, may also play a role. Natural amino acid substitutions within the HBV core 
region in HBV-infected patients were found to affect CTL function through the antagonistic 
effect of variant peptide-HLA complexes on TCR recognition of the wild-type peptide 
(Bertoletti etal. 1994). Such a mechanism could operate in HCV which, like HBV and HIV,
è ■ ■■
displays uncommonly high mutation rates, and could prove problematic in developing 
universally applicable therapeutic strategies. One encouraging finding was the widespread 
occurrence of HCV core-derived CTL epitopes in infected patients, common to all studies 
described in the above paragraph. In addition, a highly conserved antigenic site in HCV core
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has been described (Shirai etal. 1994); Recognised by both human and murine CTLs in 
association with the highly prevalent HLA class I molecule A2, this conserved nonapeptide 
may be a valuable component of HCV vaccines against a broad range of HCV isolates.
Immunosuppression, of congenital or therapeutic origin, is associated with higher viral titres 
and more severe liver injury than usual. These features are especially severe in the post­
transplantation setting when immunosuppression is increased for the treatment of rejection 
(Sheiner etal. 1995). The source of graft infection in these patients is unclear. While virions 
remaining in the blood at the time of transplantation may play a role, the finding of HCV 
within peripheral blood mononuclear cells (Bouffard etal. 1992; Moldvay etal. 1994; Navas et 
al. 1994) suggest these as a possible reservoir. There is increasing evidence for differential 
pathogenicities of the different HCV subtypes, with subtype 1b being particularly virulent 
(Hino etal. 1994; Pozzato etal. 1994; Simmonds 1995). However, this may merely reflect the 
time of infection. HCV infection has been associated with autoimmune disease in certain 
patient populations (Carson etal. 1991; Agnello etal. 1992; Bloch 1992; Michel etal. 1992;
■V. . ■ ■
Agnello 1995). A strong correlation has also been found between HCV infection and 
hepatocellular carcinoma (Hasan etal. 1990).
1.5.9 Therapeutic strategies for chronic hepatitis C
At present, the only effective method for treating hepatitis C is interferon therapy. The 
interferons (IFN) are naturally occurring peptides with antiviral, antitumour and 
immunomodulatory properties which have significant biochemical and histological effects when 
used to treat viral hepatitis (Shindp etal. 1991; Lucey 1995). In HCV treatment, although 
IFN was able to restore normal liver biochemistry and reduce or eliminate HCV viraemia 
during therapy in most cases, it had a high relapse rate, with less than 20% of treated 
patients achieving a sustained response (Hoofnagle et al. 1986; Garson et al. 1992; Diamond 
et al. 1994). Also, viraemia levels and IFN response may vary among HCV types due to 
differential replication or differential host susceptibilities (Yoshioka etal. 1992). Intraisolate 
HCV genomic heterogeneity was associated with persistent infection and resistance to IFN,
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while prognosticators for a sustained response included absence of subtype 1b, low nucleotide 
sequence diversity, youth, female sex and low-level viraemia (Enomoto et ai. 1994; Hino et 
al. 1994; Kanazawa et al. 1994; Koizumi et al. 1995). Rates of sustained response may be 
increased by increasing the period of therapy (Shindo etal. 1991).
Ribavirin (1 -p-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a non-IFN-inducing guanosine 
analogue with a broad spectrum of activity against DNA and RNA viruses, including 
flaviviruses (Reichard etal. 1991; Sherlock 1995). It acts at the level of translation by 
disrupting cap formation. The first drug to offer potentially effective oral treatment for 
chronic hepatitis C, it induces a clearcut biochemical response, but has no effect on viral 
RNA, and biochemical relapse invariably occurs after ceasing therapy (Reichard etal. 1991; 
Camps etal. 1993).
Reports at a recent conference indicated that a combination of IFN and ribavirin was much 
more effective than IFN monotherapy (Alberti and Chemello 1995; Brillanti 1995; Weiland etal.
1995). This effect was apparently synergistic, and was especially remarkable among 
relapsed responders to IFN monotherapy. In a pilot study of combination therapy in 
immunosuppressed graft recipients, a sustained response was observed in 12 of 14 liver 
transplant recipients with post-transplantation HCV reinfection. These results were 
particularly encouraging because the post-transplantation situation combines the worst 
prognosticators for successful IFN'monotherapy: high viral titres of HCV subtype 1b in 
immunosuppressed patients (Bizollon etal. 1995; Main 1995). However, the exact nature of 
the relationship between viral titres and severity of liver disease is not clearcut.
1.5.10 Orthotopic liver transplantation as management strategy
A transplant is tissue (an organ or part thereof) which is removed from its original site and 
transferred to a new location on the same (autograft) or another person (allograft). A graft 
transfer between identical twins is an isograft, and a heterograft, or xenograft, is 
transferred from one nonhuman animal to a human. Autografts and isografts are accepted
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indefinitely by recipients, allografts may be successful when special efforts are made to 
prevent rejection, and xenografts are usually rejected. In an orthotopic transplant, the organ 
is grafted into its usual position, in contrast to heterotopic transplantation, where the organ 
occupies an auxiiliary position.
Rapid advances in the treatment of liver disease have been made possible by the 
development of transplantation procedures. Orthotopic liver transplantation (OLT), 
pioneered by Thomas Starzl in the mid-50s in the USA, and later by a University of 
Cambridge/Kings College London consortium, is now used as a last resort in most cases of 
lethal hepatic disease (Starzl etal. 1989a; Caine 1993). The most common diseases treated 
are chronic active hepatitis (CAR)',‘primary biliary cirrhosis (PBC), alcoholic cirrhosis and 
inborn metabolic errors (IME).
Despite reports of permanent or prolonged liver graft acceptance by untreated pigs or 
minimally suppressed dogs, there is evidence of graft rejection in at least 70% of human 
cases (Starzl et al. 1989b). Rejection is prevented by the administration of 
immunosuppressive drugs, of which there are several available (Starzl etal. 1989b; Rees and 
Lockwood 1993). Cyclosporine, the most commonly used maintenance drug, is part of a novel 
group including FK506 and rapamyciri, which acts by disrupting signal transduction from T 
and B cell receptors. Its dosage is limited by its nephrotoxicity, and standard 
immunosuppressive regimes achieve a lowered cyclosporine dosage by supplementation with 
drugs which have complementary effects on the immune system. These include the 
thiopurines azathioprine and 6-mercaptopurine, which may act by inhibiting the primary 
antibody response; and steroids, which have a widely disseminated effect, especially on 
cytokines. Since basic homeostatic mechanisms in host defence are compromised by 
immunosuppressive agents, the risk of opportunistic infections is a major concern in the post- 
OLT setting. In addition, studies of immunosuppressed Individuals showed a 100-fold greater 
incidence of malignant disease than in the general population. There is therefore an ongoing 
need to tailor treatment to disease activity.
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In Cambridge, a triple regimen of azathioprine, corticosteroids and cyclosporine is 
administered post-OLT and donors, who are scarce, are not selected by HLA typing (Caine
1993). Ht_A typing of both donors and recipients is however carried out post-transplantation, 
for retrospective analysis. Also, only organs from HCV-negative donors are used. In 
addition to the improved quality of life of liver transplant recipients, their short-term (five- 
year) survival rates are high, and the prognosis improves markedly after 5 years survival, 
many recipients being still alive and enjoying good health after 19 years of follow-up (Starzl 
ef a/. 1989b). ^
There is very little need for OLT in cases of acute hepatitis, especially when caused by 
HAV or HEV, where the native liver usually recovers given time. With the more complicated 
sequelae of hepatotrophic virus infection, however, liver transplantation plays a significant 
management role. HBV-related fulminant hepatic failure (FHF) is characterised by massive 
hepatocyte necrosis accompanied by an intense immune response, which leads rapidly to low 
viral loads. This explains the much lower rate (15%) of HBV recurrence post-OLT for FHF 
than for chronic liver disease (70%) (Tibbs and Williams 1995). HCV can be transmitted by 
donor organs, such as heart, liver, kidney, and pancreas, to transplant recipients (Lau et al. 
1993; Maple etal. 1994; Pereira etal. 1995). OLT for the treatment of HCV-related end- 
stage liver disease almost always leads to recurrent HCV infection in the patient (Wright et 
al. 1992; Pons 1995). HCV RNA is detectable in 87% of graft recipients by one year post- 
OLT (Konig etal. 1992), with viraemia often detectable within days of grafting (Maple etal.
1994). The course of post-OLT hepatitis C is different for acquired and recurrent infections. 
Post-OLT acquired HCV infection has a similar profile to PTH in immunocompetent patients, 
except that antibody response is greatly attenuated in the context of post-OLT 
immunosuppression, with seroconversion rates of about 40% for newly-infected patients vs. 
85-90% in PTH cases (Poterucha et al. 1992). This effect is apparently HCV-specific, as 
transplanted patients remain capable of generating high-titre antibodies against such 
pathogens as herpes simplex virus (HSV), cytomegalovirus (CMV) and rotavirus (Hsu et al. 
1994; Maple etal. 1994). This is similar to observations in congenitally immunocompromised
60
Chapter One: Introduction
patients with PTH, in whom the appearance of anti-HCV antibodies was delayed for over 
three years (Cornu etal. 1994). Recurrent HCV infection post-OLT is indistinguishable 
virologically and histologically from acquired infection in the same context (Chazouilleres et 
al. 1994; Gretch etal. 1995). In both cases, OLT is followed by a dramatic increase in HCV 
viral titres, up to 16-fold the pre-OLT levels. The absence of allograft damage in some 
immunosuppressed patients impies that high levels of circulating virions may be tolerated 
without direct hepatic damage.
The clinical consequences of post-OLT recurrent HCV infection are highly variable, ranging 
from asymptomatic to a disease tempo exceeding that in de novo infection. Three general 
patterns of recurrent disease occur in this setting:-
• In the short term, recurrent post-OLT HCV infection is usually benign (Shiftman et al. 
1994; Chemello etal. 1995). Unlike recurrent hepatitis B dr D, which are usually 
accompanied by impaired allograft function and serious morbidity, the risk of acute organ 
damage due to HCV infection is low in most transplant recipients (Martin etal. 1991; 
Konig etal. 1992; Pons 1995). The mean time to the first sign of disease is 95 days, and 
there is evidence of persistently normal graft function in reinfected patients followed up 
for up to 10 years(Boker et al. 1995). The combined evidence indicates that in most 
patients, anti-HCV seropositivity pre-OLT does not significantly affect graft outcome.
• Approximately 5% of OLT recipients appear to clear HCV, so that sensitive and 
repeated testing by PCR for the presence of the virus in serum gives negative results 
(Konig etal. 1992; Sallie etal. 1994; Boker etal. 1995)
• In a third group of patients, recurrent hepatitis C shows a remarkably rapid progression 
to cirrhosis, with patients requiring re-transplantation within two years (Martin et al. 
1991; Belli etal. 1993; Lerut etal. 1995).
Patients with end-stage cirrhosis show significantly lower HCV titres than those with less 
advanced disease, probably due to4he marked decrease^d in hepatic mass associated with 
liver disease (Duvoux et al. 1995). HCV reinfection, on the other hand, is characterised by 
high-titre viraemia in the initial post-OLT period, often accompanied by graft damage
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(Gretch etal. 1995). The significance of this highly efficient replication is unclear. In one 
study, no correlation was found between RNA titre and histology^jmplying that post-OLT, 
HOV-mediated liver damage is not dependent on viral titres alone (Herrero et al. 1995). 
Another report indicated a positive correlation between HCV RNA levels and severity of 
post-OLT hepatitis C (Zeinef al. 1995). The possibility exists that the varying results are 
type-dependent, i.e., different HCV genotypes may have differential pathological profiles.
The development of primary liver cancer, for example, has been shown to occur earlier in 
patients infected with type 1 than type 2 HCV (Boker et al. 1995). This may indicate that 
certain subtypes replicate more efficiently.
The outcome is benign for most OLT recipients. It is nevertheless important to clarify the 
relationship between types and disease profiles, in order to administer appropriate 
prophylaxis. The risk of recurrent disease is apparently independent of levels of 
immunosuppressants administered (Farges et al. 1995). Studies have linked the male sex, 
advanced age and infection with HCV subtype 1b as independent risk factors for 
hepatocellular carcinoma development (Bruno etal. 1995; Marin etal. 1995).
Two studies have been carried out on HCV genomic variation following OLT. One study 
demonstrated the near-identity of paired pre- and post-OLT samples from individual patients, 
and constituted the first direct evidence of HCV reinfection of previously infected OLT 
recipients (Feray etal. 1992). In the second study, a post-OLT decrease in quasispecies 
complexity was described for variants of the NCR and E2/NS2 regions (Martell et al. 1994). 
The coincidence of decreased HCV genomic heterogeneity with post-OLT immunosuppression 
indicated that immune pressure might be the dominant force controlling the dynamic behaviour 
of HCV in infected individuals. However, the probable involvemerit of other factors was
V V ' I  ■ . . .  -  ■■ .  .  “
suggested by the finding, post-OLT, of variants that had not been detected pre­
transplantation.
The current study was aimed at clarifying the role of the immune response in 
immunosuppressed liver transplant recipients. Despite the mild nature of most hepatitis C
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cases, the persistent nature of HCV infection constitutes a major clinical problem, 
exacerbated by the dearth of efficient experimental models or culture systems for studying 
the virus. Orthotopic liver transplantation, routinely used to treat HCV-related end-stage 
liver disease, is accompanied by the administration of immunosuppressive drugs. By 
eliminating or attenuating the host immune response, the post-OLT immunosuppressive 
regimen offers a model for the study of direct pathogenic effects of the virus on the grafted 
liver, HCV recurrence being an almost inevitable sequel to transplantation. The fact that 
transplant recipients are monitored closely means that abundant clinical and laboratory data, 
from which further evaluations can be made, are generated. These include concentrations of 
serum AST and ALT, bilirubin, and albumin, derangement of which occurs in liver damage. 
Hence, the OLT model offers the possibility of clarifying which viral and host factors are 
important in the pathology of HCV-related disease.
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1.6 OBJECTIVES
The aims of this investigation were as follows:
1. To investigate the role of the immune system in the genomic diversity of HCV by
comparing mutations in the HVR1 of two groups of infected patients:-
(a) patients receiving immunosuppressive treatment after OLT;
(b) patients with chronic HCV-related hepatitis not undergoing any treatment.
2  To attempt to differentiate the respective roles of the host immune response and
Immunosuppressive treatment in HCV genomic variability.
3. To derive from these studies a better understanding of the mechanisms of host-virus
interaction underlying HCV graft Infection and HCV genomic variability.
•H--
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21 MATERIALS
21.1 Patient samples
Plasma samples for the preliminary part of this study came from archives held at the East Anglian 
Blood Centre. The anticoagulants heparin, EDTA or acid citrate dextrose were used to prevent 
blood coagulation. In addition, whole blood was freshly-drawn from candidates for orthotopic liver 
transplantation (OLT) at the Addenbrooke's Hospital Department of Surgery, or from asymptomatic 
HCV carriers referred to the consultant hepatologlst at the Department of Medicine. Table 2.1 lists 
all Individuals from whom blood samples were drawn for this study. They fell Into three categories: 
HCV-infected candidates who had received, or were scheduled to undergo liver transplantation 
following HCV-related end-stage chronic liver disease; asymptomatic blood donors found to be HCV- 
positive by antibody and PCR tests; and negative controls.
Table 2.1; Patients involved in study
Patient Age (yrs) Origin Sex Category
A l 59 Italy M T x
A2 62 Italy M T x
B1 NK Italy F T x
Cl 56 Italy M T x
C2 NK ' /  ' Italy ■ F T x
C3 58 ' Italy M T x
De 35 Italy M T x
FI NK Italy F T x
LI 66 Italy M T x
L2 48 Italy M T x
L3 46 Italy F T x
Ml 52 Italy F T x
M2 NK Egypt M T x
W1 NK UK F T x
V 32 IV UK ' M PC
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w 38 UK M PC
X 35 UK M PC
Y 37 UK M PC
z 24 UK M PC
Ad 21 UK M Ref
Dix 44 UK ..,.M Ref
Fra 37 . UK F Ref
Har 42 UK M Ref
Wad 32 UK M Ref
D1 NK UK NK NC
*Tx = OLT candidates or recipients; PC = HCV PCR positive controls from blood bank archives; Ref = HCV-positive blood 
donors from whom nucleotide sequences corresponding to multiple time points were obtained for comparison with OLT- 
influenced samples. NK = not known, NO = negative control.
21.2 Buffer recipes
Compositions for the buffers described in the text are given below.
Buffer
Eco RI buffer (10 x, New England 
Biolabs))
"Basic EDTA"
Guanidinium buffer
Ligation buffer (10 x, Invitrogen)
PBS
PCR buffer (10  x)
Composition
50 mM NaCI; 100 mM Tris-HCI (pH 7.5); 10 mM MgCl2; 
0.025% Triton X-100.
2 M NaOH; 2 mM EDTA.
4 M guanidinium thiocyanate; 0.8% 13-mercaptoethanol; 25 
mM sodium citrate (pH 7); 1% sarkosyl and 0.2 M sodium 
acetate (pH 4).
60 mM Tris-HCI, pH 7.5; 60 mM MgCl2; 50 mM NaCI;
1 mg/ml BSA; 70 mM p-mercaptoethanol; 1 mM ATP;
20 mM DTT; 10 mM spermidine.
125 mM NaCI; 25 mM NaH2P0 4  (pH 7).
50 mM KCI; 100 mM Tris-HCI (pH 8.3); 15 mM M gC t
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Pst I buffer (10 x, New England 
Biolabs)
RBC lysis buffer
SOC bacterial growth medium
SSC stock solution (2 0 x) 
"Salty PEG"
5 x  TBE 
TE buffer 
TErase 
Tri-dye
X-gal stock solution
100 mM NaCI; 50 mM Tris-HCI (pH 7.9); 10 mM MgCl2;
1 mM DTT.
155 mM NH4CI; 10 mM KHCO3; 0.1 mM Na2EDTA.H2 0 .
1% tryptone; 0.5% yeast extract; 10 mM NaCI; 2.5 mM 
KCI; 10 mM MgCl2; 10 mM MgS0 4 ; 20 mM glucose; pH 7.0.
3 M NaCI; 0.3 M Sodium citrate
20% PEG; 2.5 M NaCI.
0.225 M Tris-borate; 0.005 M EDTA.
10 mM Tris-HCI pH 8 ; 1.0 mM EDTA.
50 p,g/ml RNase A in TE buffer.
0.25% (w/v) bromophenol blue; 0.25% (w/v) xylene cyanol; 
0.5% (w/v) orange G; 50% glycerol; 1 x TBE buffer.
100 mg/ml X-gal in dimethyl formamide.
2.1.3 Bacterial culture media
The basic bacterial growth media 2  x TY and SOC (Sambrook et al. 1989) as well as all agar 
culture plates were obtained from the LMB core facility. Agar plate^contained 100p,g/ml ampicillin 
(AMP) and, for NovaBlue cells (Invitrogen) only, 15 |ig/ml tetracycline (TET). 2 x liquid medium, 
containing 100 p,g/ml AMP, was used for growing selected colonies.
2.1.4 PCR and sequencing primers
In the design of PCR primers for the NCR and E2 regions, consensus sequences spanning the desired 
segments were derived from 88  and 45 HCV sequences, respectively, obtained from the sequence 
database. Primer sequences are given in Table 2.3.
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22 HCV ANTIBODY ASSAYS: ELISA & RIBA
Antibody to HCV in serum or plasma samples was detected in routine screening assays carried out 
at the East Anglian Blood Centre using the ABBOTT HCV EIA 2nd Generation kit (EIA-2), which 
detects antibodies expressed by putative structural and non-structural regions of the HCV genome. 
Diluted human serum or plasma samples were incubated with recombinant (£  coli, yeast) HCV 
antigen. Any specific antibody present was affixed to the bead-bound antigen. Unbound material 
was washed off, and human immunoglobulins detected by incubating the bead-antigen-antibody 
complex with a solution containing horseradish peroxidase-labelled goat antibodies directed against 
human immunoglobulins. The substrate for the subsequent enzymatic reaction was o- 
phenylenediamine.2HCI (OPD). A yellow-orange colour developed in proportion to the amount of bound 
anti-HCV antibody.
Confirmatory assays for samples positive by EIA-2 were carried out with the Chiron RIBA HCV 3.0 
Strip Immunoblot Assay (SIA) kit. This assay was designed as an additional, more specific test on 
specimens found to be repeatedly reactive using the ELISA kit. Antigens included were recombinant 
c33c and NS5; and synthetic 5-1-1, c100 and c22, immobilised as individual bands onto test strips. 
Since recombinant c33c and NS5 weré produced as fusion proteins with human superoxide dismutase 
(hSOD), recombinant hSOD was included as a control band on each strip, to allow detection of 
antibodies against hSOD which are not specific for the HCV-encoded portions of the recombinant 
HCV antigens. Low- and high-concentration immunoglobulin internal control bands were also blotted 
onto each strip. In the standard protocol, the diluted specimen was incubated with the strip. HCV- 
specific antibodies, if present, bound to the corresponding antigen and/or peptide bands on the strip. 
Unbound material was removed by aspiration and washing. The strip was then incubated in the 
presence of peroxidase-labelled anti-human IgG conjugate, which bound to the human IgG portion of 
the antigen-antibody complex. The colorimetric enzyme detection system involved incubation with 
hydrogen peroxide and 4-chlro-1-naphthol, to give an insoluble blue-black reaction product at each 
specific HCV antigen, peptide or control band, giving a visual band pattern on each individual strip.
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Anti-HCV reactivity and specificity ws'cîetéiTTtined by comparing the intensity of each antigen band 
to that of the human IgG internal control bands on each strip, and visually graded from -1 to 4+. A 
sample was considered negative if no bands, or if the hSOD band only, was present with a grading of 
1+ or higher; indeterminate if a single band, with or without the hSOD band, was 1+ or higher; and 
positive if two or more hands had a reactivity greater than 1+.
23 LEUKOCYTE EXTRACTIONS
Centrifugation is often used for the fractionation of biological material. ' In isopycnic centrifiguation, 
particles are separated on the basis of their density. Metrizoic acid (3-acetamido-5-(N- 
methylacetamido)-tri-iodobenzoic acid, molecular weight 628) belongs to a family of compounds that 
have been used extensively for density gradient separations. The behaviour of metrizoate solutions 
in a centrifugal field is intermediate between those of sucrose and CsCI. Thus, sodium metrizoate, 
unlike sucrose, does sediment to give a density gradient, but at a much slower rate than CsCI. 
Lymphoprep^^ consists of a 9.6% (w/v) Na metrizoate solution containing 5.6% polysucrose, an 
erythrocyte aggregation polysaccharide. The density of the solution is 1.077 g/cm^. In the standard 
leukocyte fractionation procedure, heparin- or EDTA-treatecI blood, diluted with an equal amount of 
PBS, is layered over approximately half its volume of Lymphoprep™ to give a discontinuous gradient. 
After spinning at low speed for about 30 mins, erythrocytes are pelleted, together with granulocytes. 
Platelets and mononuclear cells, including lymphocytes, monocytes and some basophils, form a 
distinct band at the interface between the sample layer and the Lymphoprep solution, from where - 
they can be harvested.
2.3.1 PBMC extraction from whole blood samples
Whole blood (10-20 ml) was spun down (1,000 rpm 20 min in a Centra-3C centrifuge). The cell 
fraction, from which the plasma had been carefully drawn off, was made up to the original whole 
blood volume in PBS. The diluted cells were mixed, avoiding air bubbles, with a 10 ml pipette, and 
layered gently onto an equal volume of the Ficoll®/sodium metrizoate solution Lymphoprep™ 
(Nycomed Pharma AS, Oslo, Norway). Leukocytes were separated by spinning at 1,500 rpm for 
30 min (rapid acceleration, brake off). The buffy layer, containing leukocytes, was transferred to a
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fresh 50 ml tube which was topped with PBS for a first wash. This involved mixing 10 times with a 
10 ml pipette, followed by a 1200 rpm, 10 min spin. Two additional washes were carried out in 30 ml 
and 10 ml PBS. The final wash was carried out in 1 ml PBS. The supernatant was aspirated off, 
and the cell pellet stored at -40°C.
2.3.2 Isolation of white blood cell subpopulations
A 20 ml volume of whole blood was collected for each patient, in 20 U/ml heparin anticoagulant (CP 
Pharmaceuticals) and 0.6% (w/v) dextran (M.W. 156,000, Sigma). Following incubation at 37°C for 
45 min, the WBC-enriched top layer was eased onto an equal volume of Lymphoprep™, then spun, 
with rapid acceleration, at 1500 rpm for 30 min. The top layer was aspirated off, and the buffy 
layer, containing lymphocytes, collected in a fresh 50 ml tube. The third layer was decanted, and the 
pellet (containing polymorphs) was dissolved in 5 ml RBC lysis buffer. It was then incubated for 5 min 
on ice. The solutions containing lymphocytes and polymorphs were each made up to 50 ml with PBS, 
and spun at 1200 rpm for 10 min. Additional washes were carried out in 30 ml, 25 ml and 2 ml PBS.
A final spin (2000 rpm in 1.5 ml PBS in an Eppendorf tube) resulted in cell pellets containing 
predominantly lymphocytes or polymorphs, verified by visualizing under a light microscope, and by an 
electronic cell counter (Serono System 9000* Diff model). Lymphocyte preparations were 60 - 92% 
pure (mean 75%), with 6 - 30% granulocyte contamination, while polymorph preparations were 48 - 
81% pure, with 7 - 27% (mean 13%) lymphocyte contamination (see appendix C). The cell pellets 
were stored at -40°C until analysis.
2.4 RNA EXTRACTION
In nucleic acid extraction from prokaryotic and eukaryotic sources, the two major problems are 
deproteination and inactivation of nucleases. Phenol-, proteinase K- or guanidinium-based protocols 
are routinely used. The inactivation of nucleases is especially important for RNA, which is rapidly 
degraded by ubiquitous RNAses, present in sources as varied as glassware, hair and dust (Cox 
1968). In the classic protocol, phenol extraction was followed by alcohol precipitation (MacDonald et 
al. 1987). This method was more efficient than the common method involving SDS for cell disruption 
followed by proteinase K digestion.
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The efficacy of guanidinium salts in RNA extraction was first demonstrated in the 1950s.
Advantages included the selective dénaturation of protein in nucleoprotein complexes - while proteins 
readily dissolve in the highly electrostatic guanidinium chloride, becoming denatured at 4 M, nucleic 
acid secondary structure remains relatively intact, with DNA retaining its double helical form even at 
70°C. Thus, the method allows both deproteination and RNase destruction in a single step. The high 
efficacy of guanidinium salt action enables nucleic acid extraction from even nuclease-rich sources 
such as lymphocytes. The most common and consistently successful methods for isolating pure, 
intact total RNA are modifications of the original guanidinium thiocyanate method of Chirgwin etal. 
(1979). One such modification involves the coextraction with phenol at decreased pH to remove 
protein and DNA (Chomczynski and Sacchi 19|87). It is often the method of choice when multiple 
RNA extractions are performed.
2.4.1 Proteinase K-based RNA extraction from piasma sampies
To 250 |xl thawed plasma sample was added an equal volume of 2 x PK lysis buffer (0.1 M Tris-HCI 
pH 8.4; 0.02 M EDTA; 0.4 M NaCI; 4% SDS; 2 mg/ml proteinase K). The mixture was incubated at 
60°C for 1 h. 500 \i\ phenohchloroform (1:1) were then added, and the tubes were revolved for 20 min 
on a rotating wheel at room temperature. Following a 5-min spin to separate the phases, the aqueous
iC-y  • ‘ . f  i I  ■ ■ .
phase was re-extracted once with phenohchlorbform, and once with chloroform alone. RNA in the 
aqueous phase was precipitated overnight at -20°C in 2 volumes ethanol and 20 |ig glycogen carrier 
(Boehringer Mannheim). It was washed in 70% ethanol, freeze-dried and re-dissolved in 10 |il RNase- 
free water.
2.4.2 GTG-based RNA extraction from plasma or WBC samples
RNA extraction solution was made up by mixing 250 \i\ plasma with 500 ^il each of water-saturated 
phenol (Appligene) and guanidinium buffer (4 M guanidinium.thiocyanate (GTC), 0.8% 13- 
mercaptoethanol, 25 mM sodium citrate (pH 7), 1% N-lauroyl sarcosine (Sarkosyl®, BDH) and 0.2 M 
sodium acetate (pH 4.0). RNA in the aqueous phase was propanol-precipitated overnight at -20°C 
with 20 |j,g glycogen (Boehringer Mannheim, Germany). After a wash with 250 |il 80% ethanol and 
being left to dry at room temperature, the RNA pellet was dissolved in 20 iJ,l DEPC-treated water
71
J i f
' Chapter Two: Materials & Methods
(Ultraspec™ water, Biotecx Labs Inc., USA, supplied by AMS Biotech). The solution was incubated 
5 min at 70°C to ensure complete RNA dissolution.
2j 5 r e v e r s e  TRANSCRIPTION OF HCV RNA
Traditional RNA detection methods - such as Northern blots and RNA dot/slot blots - require very 
large amounts of total RNA. RT-PCR provides a more sensitive method requiring much smaller 
amounts of RNA, and is the only feasible method for HCV, which is present in the circulation of 
infected individuals only in very low amounts. The cDNA template for PCR is generated by reverse 
transcription. The reverse transcriptases of both avian myoblastosis virus (AMV) and Moloney 
murine leukaemia virus (MMLV) have been shown to give comparable results (CLONTECH 
Laboratories Inc. 1991 ; Hu et al. 1993). To obtain maximal yields, it was important to include human 
placental RNase inhibitor in the cDNA synthesis reaction.
Priming of HCV RNA for cDNA synthesis in this study was carried out by two methods. In the 
random priming method, the entire RNA population was converted into cDNA by priming with random 
hexamers. Two gene-specific PCR primers were then added for PCR amplification. Alternatively, 
the HCV-specific 3' (antisense) primer was annealed to genomic RNA for site-specific synthesis of 
the sense strand. Its extension with reverse transcriptase generated a cDNA template for the 5' 
(sense) primer during subsequent PCR.
25.1 cDNA synthesis from RNA obtained by PK lysis \
10 ^il RNA solution (see 2.2.1) were heated 5 min at 65®C. To the heat-denatured RNA, which was 
rapidly chilled on ice, were added 10 pJ 2 x RT buffer I (0.2 M Tris-HCI pH 8.4 (at 42°C); 0.28 M KCI; 
0.02 M magnesium II chloride; 0.8 M dNTPs; 0.02 M DTT; 1.5 pg random primers (Promega) and 
approximately 14 U each of RNasin® and AMV RT. RNA/primer annealing was carried out by a 
10 min room temp incubation; cDNA synthesis at 42°C for 90 min; and RT inactivation at 80°C for
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10 min. oDNA samples were stored at -20°C after mixing with 2.5 pg yeast tRNA (Boehringer 
Mannheim).
25.2 oDNA synthesis from RNA obtained by GTC-based extraction
3 pi RNA solution obtained as in 2.4.2 were incubated 30 - 45 min at 42°C in a total volume of 20 pi 
containing 1 x RT buffer II (0.15 mM dNTPs; 15% DMSO; 1.5 pM antisense oligo; 14 U RNAse 
inhibitor (RNasin®, Promega); and 10 U MMLV reverse transcriptase (HT Biotech). The stock 10 x 
RT buffer II used comprised 0.5 M Tris-HCI pH 8.0; 0.5 M KCI; 50 mM MgCl2, 50 mM DTT; and 
0.5 mg/ml RNase-free BSA in aqueous solution.
26 PCR AMPLIFICATION OF HCV cDNA FROM THE NCR AND THE E1/E2 CODING 
REGIONS
Thermal cycling parameters were optimized for each primer set and PCR target as follows:
Program I of Table 2.3, with its relatively low number of cycles, was found to be sufficient to amplify 
the HCV NCR, a well-conserved and easily accessible target. Programs V - VI! were used in 
(unsuccessful) early attempts to amplify E1/E2 sequences based on low-stringency annealing 
parameters. Program IV was used in the one-step amplification protocol described in section 2.6.3(a) 
(J. Saldanha, personal communication). Programs II and III, devised by Dr. Juraj Petrik for nested 
PCR, were found to amplify E1IE2 more consistently than program I. The relatively high annealing 
temperature of 55"C (program II) was used in order to minimise non-specific binding, and was lowered 
slightly for nesting PCR (program III) to permit rapid amplification of specific sequences derived from 
first PCR. Rigid control over contamination of PCR reactions by HCV sequences was exercised by 
adherence to the Kwok-Higuchi guidelines where possible (Kwok and Higuchi 1989). Thus, disposable 
gloves, changed frequently, were used; deionized water used in RNA extraction and reverse 
transcription reactions was treated w #  diethylpyrocaitonâtè (DEPC), and that used for PCR . 
amplification was filter-sterilized or autoclaved; pre- and post-PCR solutions were handled with 
separate, dedicated pipettors; aerosol-free (plugged) pipette tips were used; reagents were divided
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into aliquots to minimize the number of repeated samplings; "premixtures" were formed from reagents 
before dividing into aliquots, minimizing the number of sample transfers; PCR and cloning procedures 
were carried out in separate laboratories; DNA was added last to reaction tubes; and non-DNA 
negative controls were added to each set of reactions. In addition, for the semi-automated protocol 
described in Section 2.7, where up to 60 samples were processed at one time, dUTP was substituted 
for dTTP in the first amplification experiment. In subsequent experiments, reaction mixtures were 
treated with uracil N-glycosylase, which cleaves the dUTP-containing nucleotides carried over from 
the previous experiment, thereby preventing their use as PCR templates (Longo et al. 1990). For 
this set of experiments, the different stages of the protocol (reagent preparation, RNA extraction, 
first and second PCR) were carried out in separate, custom-designed hoods.
In nested PCR, a second set of internal primers is used to amplify a portion of the first amplification 
product. The specificity achieved by this method is equivalent to that from a hybridization reaction - 
non-specific priming is eliminated by accepting only samples with bands of the precisely correct size on 
the EtBr-stained gel.
The rapidity and simplicity of the PCRjassay was .increased by combining the reverse transcription
. j ' ’"
Step with the first PCR round in the same reaction mix. This also decreased labour intensiveness 
and potential for contamination.
Hot-start PCR was employed as an alternative to nested PCR, in order to decrease the risk of 
contamination due to the transfer from first- to second-round amplification. The reaction consists of 
an upper and lower portion separated by a wax barrier. The final components only mix when the 
temperature reaches 80‘C. The method had previously been demonstrated to show equivalent 
sensitivity to conventional nested PCR'^aldanha and Minor 1994).
All PCR, unless otherwise stated, was carried out on a TRIO-Thermoblock (Biometra) or on a 
Perkin Elmer Cetus DNA thermal cycler.
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Table 2.2: Oligonucleotide primers used for sequencing and nested ampiification of HCV genome
Na Posltioni Sense Sequences
2nd PCR 
product 
size (bp)
3762 63-82 outer +
Set 1 (NCR):-\
4^ / TTÇ ACG GAG AAA GYG YCT AG '
3764 321-339 outer - TGC ACG GTC TAG GAG AGG T
3763 83-102 inner + GGA TGG GGT TAG TAY GAG TG
3765 295-319 inner- GAG TGG GAA GGA GGG TAT G 237
3768 1284-1303 outer +
Set 2 (E1/E2):-
GGI GAY GGY ATG GGI TGG GA
3769 18891908 outer - GIRTGGGTIGTIGGGAGBAG
3766 1300-1319 inner + GGGAYATGA TRA AGTGG
3770 1851-1870 inner- GAG TAIAGY GGR GGR GAY AG 571
3958 1287-1306 outer +
Set 3 (E1/E2)2:.
, y ATA M G  CTT^-GAG-GGG ATG GGA TGG GAT AT
3959 1867-1886 outer - GAG GAA TTC GGG GGT GGG AGT GAA GGA AT
3960 1293-1312 inner + GGT AAG CTT ATG GGA TGG GAT ATG ATG AT
3961 1854-1873 inner- GTG GAA TTC AAG GAA TAT AGG GGA GGA GA 581
3771 1436-1453 +
Set 4 (E2)4:-
GGG lAAYTGGGG lAAGGT
3778 1436-1453 + GTG AGG GTG GGG lAA RGT
9078 1689-1706 ATG TGG GAG GTG GGR TTG
Nucleotide positions given correspond to those ofl-IC-JS (Okamoto et ai. 1992)
Primer sequences for this set were as previously described in the literature (Farci et al. 1992) 
Italicized sequences represent non-HCV restriction enzyme sites for Eco RI (GAATTC) and 
Hind III (AAGCTT)
Primers in this set were used for bi-directional sequencing of the HCV HVR.
26.1 Nested PCR for HCV NCR and E1/E2
A description of all oligonucleotides used in the study (Protein & Nucleic Acid Chemistry facility, 
University of Cambridge) is given in Table 2.2. The lyophilised primers, of specified absorbance units.
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were dissolved in water to give master solutions of about 5 mM. From these, dilutions were made to 
obtain working solutions of 25 jiM (for PCR) or 5 |u,M (sequencing). For the first round of the nested 
PCR procedure, 2 \l\ cDNA prepared as in 2.5.2 were added jo  a reaction mix to give final 
concentrations of 0.5 p,M each of sense and antisense outer primers; 31.25 p,M dNTPs; 1 x PCR 
buffer (10 X "Cetus" PCR buffer was made up to contain 0.5 M KCI, 100 mM Tris-HCI pH 8.3; and 
15 mM MgCb); and 2.5 U AmpliTaq® (Perkin-Elmer (USA), supplied by Applied Biosystems) in a 
total reaction volume of 20 |il.
Table 2.3: PCR programmes for amplification of various parts of the HCV genome
Name
Pre­
heating Cycling; parameters
# Of
cycleb
Final
extension
time
Prog 1 94°C 1 min 30 
s
94°C 25 s (dénaturation) 
50°C 35 s (annealing) 
68°C 2 min (extension)
25 10 min
Prog II 94®C 1 min 95°C 25 s (dénaturation) 
55°C 35 s (annealing) 
72°C 1 min 30 s
(extension)
35
Prog III 94°C 1 min 95°C 25 s;
51 °C 30 s;
72°C 1 min 30 s
35 9.5 min
Prog IV 94°C 3 min 94°C 30%;r \ 
SO'^ C 30 s;
72°C 1 min
40 3 min
Prog V 95°C 3 min 95°C 20 s; 
48°C 25 s; 
72°C 30 s
30 7 min
Prog VI 94°C 1 min 95°C 25 s;
37°C 30 s;
72°C 1 min 30 s
35 9.5 min
Prog VII 94°C 1 min 94®C 30 s; 
4 2 X  30 s; 
72°C 1 min
35 6 min
PCR reaction conditions were as follows:- dénaturation at 94*C for 25 s; annealing at 50*C for 35 s; 
and elongation at 68‘C for 2 min 30s. The cycle was repeated 25 times, followed by a 10 min final 
extension step. The second round of PCR (PCR2) was carried out using 2 \l\ first PCR product as
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template, in a total reaction volume of 40 \l\ containing PCR buffer, 0.5 |xM each primer; 37.5 p,M • 
dNTPs and 1.0 U Amplitaq. PCR conditions were the same as for PCR1, and corresponded to 
Prog IV of Table 2.3.
26.2 Combined RT-PCR and nesting
To 5 pJ RNA solution prepared as described in Section 2.4.2 above were added 45 pi of RT-PCR 
solution, to give a final concentration, in 50 pi aqueous solution, of 0.2 mM dNTPs, 1 x PCR buffer, 
and 0.5 pM each outer primer, also containing 2.5 U AmpliTaq® polymerase, 10 U reverse 
transcriptase ("Super RT," HT Biotech Ltd.) and 14 U RNase inhibitor (RNasin®, Promega). The 
reaction mix was overlaid with mineral oil and RT-PCR was carried out on a thermocycler 
(Biometra) programmed to Incubate the samples for one hour at 42'C for the initial reverse 
transcription step, then for 1 min 30 s at 94"C to denature the resulting cDNA and inactivate the 
reverse transcriptase, followed by 35 cycles of amplification as detailed in Prog II of Table 2.3. RT- 
PCR 1 products were stored at -20’C. PCR2 was carried out on 2 pi of DNA template from the 
first round of PCR, in a total volume of 40 pi containing PCR buffer; 0.5 pM each inner primer;
37.5 pM dNTPs; and 1.0 U AmpliTaq®. PCR reaction conditions used were as given in Prog III of 
Table 2.3.
2.6.3 Hotstart PCR
(a) Single-round PCR for NCR amplification: For each reaction, a 25 pi aliquot of PCR bottom mix 
containing 8 mM dNTPs, 1 x PCR buffer, 8 mM magnesium chloride and 2 pM each of 
forward and reverse primer was topped with 45 pi melted liquid paraffin or a single wax 
bead (Speci-microsystems). Æ^min, 80’C incubation served to (re-)melt the wax, giving a 
solid seal upon re-cooling. Onto this seal were dispensed 65 pi of top mix (1 x PCR buffer 
and 1.0 U AmpliTaq). Final concentrations of components, after the addition of 10 pi cDNA 
prepared as in Section 2.5.1, were 0.2 mM dNTPs; 1 x PCR buffer; 2 mM MgCl2 and 0.5 pM 
primers. PCR reaction conditions were as detailed in Prog IV of Table 2.3.
— ) .i’f.
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(b) Hotstart RT-PCR & "nesting" for NCR and E1/E2 fragments: 5 pi RNA were added to 20 pi of
a bottom mix containing 1 x PCR buffer, 0.4 mM dNTPs, 1 pM antisense outer primer, 4% 
DMSO and 0.5 pi each of RNasin® and Super RT. The mix was covered with a wax bead 
as in Section 2.6.3 (a), then reverse transcription was carried out on a PCR machine set to 
incubate samples at 42‘C for 90. min,. followed by a 94’C 1-min incubation (for RT 
dénaturation). The (25 pi) top mix contained 1 x PCR buffer, 1 pM outer sense oligo and
2.5 U AmpliTaq®, to give a total combined concentration of 1 x PCR buffer; 0.5 pM each 
primer; approximately 0.2 mM dNTPs; and 2% DMSO. PCR conditions were as for Progs I 
and VI in Table 2.2 for amplification of NCR and E2 fragments, respectively. PCR2 was 
carried on 2  pi of the initial amplification product using the appropriate inner primers and 
other PCR components In the same concentrations and volumes as described for PCR2 in 
Section 2.6.1. Cycling parameters were as detailed in Prog IV.of Table 2.3.
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27 HCV DETECTION USING AVIDIN-BIOTIN TECHNOLOGY
The principle of avidin-biotin technology is the remarkably strong interaction between the tetrameric 
protein avidin and the water-soluble egg white vitamin biotin (Fig 2.1). The Ka o f 10^  ^ 4^-1 implies a 
Gibbs free energy value of about 21 kcal mol"i, a staggeringly large value for the noncovalent 
interaction of a protein with a small molecule (Richards 1990;4/Vilchek and Bayer 1990)
The interaction is so strong that even biotin coupled to proteins (through its valeric acid side chain) is 
available for binding by avidin. Streptavidin is a product with avidin-like activity isolated from 
various Streptomyces species.
Batch processing of serial samples obtained from OLT patients in this study was facilitated by the 
use of a novel, semi-automated method developed in our laboratory by Dr. Juraj Petrik (Petrik, Allain 
& Pearson, International Patent Application No. PCT/GB96/01768; Petrik etal. 1996). The method 
utilizes the strong interactive force belweèn streptavidin ahdtiotin to selectively isolate HCV RNA 
from plasma or serum samples. HCV is virtually unique among RNA viruses in having a poly-U (as
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opposed to the more common poly-A) stretch of bases at the 3' end of the genome. Hence, a stretch 
of nucleotides comprising 40 adenine residues and biotinylated at the 5' end (designated dA40) was 
used to capture positive-stranded, HCV RNA genome. Any background would be eliminated by 
subsequent amplification using HCV-specific PCR primers.
COOH
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Fig 2.1: Structum of bkiUn - fused 
tftlophene and Imidazole ring wSh 
five-cart)on caitxixylated side chain
Southern hybridization of PCR amplicons to nylon membrane (Boehringer Mannheim) was followed by 
a sinsitive chemoluminescent detection assay involving the use of Lumi-Phos™ 530. This formulation 
contains Lumigen™ PPD (a stable 1,2-dioxetane) and an enhancer forchemiluminescent detection of 
alkaline phosphatase. Enzymatic dephosphorylation of PPD produces an unstable intermediate which, 
as it decomposes, emits blue light (at 477 nm) in direct proportion to the amount of alkaline 
phosphatase present. The signal is enhanced by the presence of fluorescent micelles formed by 
cetyltrimethylammonium bromide and 5 -N-tetradecanoyl-amino-fluorescein. The fluorescein acceptor 
emits a bright yellow luminescence at 525 nm, which can be recorded on X-ray film.
All batch extractions and subsequent manipulations were carried out by Gavin Pearson.
- ..
Bead preparation: To prepare a stock solution of the capture oligonucleotide, dA40,5 ml streptavidin- 
coated paramagnetic particles, designated PM P/S (Promega), were concentrated on a magnetic 
stand. The supernatant was discarded, and the beads washed twice with 2  ml 0.5 x SSC. After 
each wash, the supernatant was discarded after magnetic stand concentration of the beads. 5'- 
biotinylated dA40 (50 pmoles/well) was mixed with 1 ml 0.5 x SSC, and the resulting solution used to
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resuspend the PMP/S. The remaining steps were a 3-min room temp incubation, followed by a brief 
agitation by vortexing; a 0.5 x SSC wash; one wash with 5 x binding buffer (0.05 M Tris-HCI, pH 7.4;
2.5 M LiCI; 0.01 M EDTA); and resuspension in 2 ml binding buffer. The mix was stored at +4°C until 
needed.
RNA extraction: For each sample, 30 pJ of bead-bound capture oligo prepared as described above 
were mixed with 15 |xl 10 x lysis buffer (0.1 M tris-CI, pH 7.4; 1.4 M NaCI; 0.05 M KCI; 10% triton X- 
100; and freshly added DTT (50 mM) and RNasin® (20 U)). The 45 \i\ mixture was added to 105 \l\ 
plasma in a single well of an Abbott 60-well diagnostic plate, which was shaken for 10 min on an 
Abbott Commander dynamic incubator set to 37°C. The particles, with bound HCV, were 
concentrated using MAG60 (a novel magnetic stand designed for the Abbott diagnostic plate). The 
supernatant was discarded and the particles were resuspended in 0.5 x SSC and shaken at room 
temperature. They were concentrated on MAG60, and the supernatant discarded. The wash was 
repeated, and the sample resuspended in 13 p.1 DEPC-treated water containing 12.5% DMSO, and 
incubated for 5 min at 45°C with shaking. The particles were concentrated on MAG60, and 12 \l\ of 
eluate were transferred to a System 9600 MicroAmp tube (Applied Biosystems).
RT-PCR: All the RNA obtained as detailed above was used directly in a combined RT-PCR reaction 
by adding to it 8 \i\ of reaction mix, to give a 20  \l\ solution containing final concentrations of 1 x 
PCR buffer; 0.2 mM dNTPs; 2.25 mM MgCl2; 5 mM DTT; 1 jiM each primer; 20 U RNasin®; 8.2 U 
Super RT; and 1.0 U AmpliTaq®. Reactions were carried out on a GeneAmp PCR System 9600 
cycler (Perkin Elmer), programmed to pre-incubate the samples at 37°C for 30 min (for cDNA 
synthesis) followed by 95°C for 3 min jtb  destroy RT). thermal cycling parameters were as for 
Prog V of Table 2.2. 1 \i\ aliquots of the PCR1 reaction products were transferred to a second set 
of 9600 tubes, and 19 |il PCR2 mix (containing PCR buffer, MgCl2, dNTPs, inner primers and 
AmpliTaq® in the same concentrations as for PCR1) added to each. A 10-min room temp and 10-min 
98®C Incubation were followed by the same cycling parameters as for PCR1.
Product detection: PCR products were run on a Hybaid Electro-4 Gel system and visualized by 
illuminating the EtBr-stained gels with UV light. Southern blotting served both to confirm the gel
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results and to increase sensitivity where no band was visible by EtBr staining. The Genius non­
radioactive nucleic acid labeling and detection system (Boehringer Mannheim) was used. Briefly, the 
DNA in gel was denatured for 30 min in a 0.5 M NaOH/0.15 M NaCI solution; neutralized by a 30-min 
incubation in 1.5 M Tris-HCI pH 7.5/0.15 M NaCI; blotted onto Hybond paper for 1 h at about one-tenth 
atmospheric pressure (75 - 80 mmHg using a Stratagehe pressure control station); air-dried for 
30 min on Whatman 3 mm paper; wrapped in Saran Wrap and transilluminated on a UV light box for
3.5 min. At this stage it could be stored indefinitely at -20°C. The membrane containing transferred
DNA was pre-hybridized in 25 ml buffer comprising 5 x SSC,1% blocking reagent (Boehringer 
Mannheim), 87.5p,l 30% N-lauroyl sarcosine and 50 |liI 10% SDS. Hybridization followed in the same 
buffer containing 10 pmole/ml primer 3792, at 50°C for 5 min. The membrane was washed twice at 
room temp In 2 x SSC/0.1% SDS, for 5 min each time. Two further 5-min washes at 50®C followed, 
in 0.5 X SSC/0.1% SDS.
■ j"  ' ■
The sequences of the primers used for hybridization are given below:-
3792: DÎ-GGA GAG CCA TAG TGG TCT GC;
4068B: Dl-CAC TCG CAA GCA CCC TAT C;
where Dl = digoxigenin.
The digoxigenin-labelled probes were prepared from random hexanucleotides including digoxigenin- 
conjugated d-UTP by polymerase (Klenow)-mediated transcription using linear denatured DNA of the 
opposite sense as template strand. Detection was based on the use of Lumiphos-530. For each 
assay, the membrane carrying the hybridized probe was blocked for 3 h at room temp in 2% (w/v) 
blocking reagent. It was then gently shaken for 30 min (room temp) with 150 mU/ml high-affinity 
sheep anti-digoxigenin Fab fragments conjugated to alkaline phosphatase. The membrane was 
washed twice for 15 min each in Buffer A (0.1 M Tris-HCI, pH 7.5; 1.5 M NaCI) and equilibrated for 2 
min in buffer C (0.1 M Tris-HCI pH 9.5; 0.1 M NaCI; 0.05 M MgCy. The membrane carrying the 
hybridized probe and bound antibody conjugate was reacted with the Lumi-Phos™ 530 substrate for 
30 min at 37'C. It was then exposed to X-ray film (Kodak XAR) to record the chemiluminescent 
signal.
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28 VISUALIZATION & EXTRACTION OF PCR AMPLICONS
The fluorescent dye EtBr contains a planar group that intercalates between the stacked bases of 
DNA. Dye bound to DNA displays an increased fluorescent yield compared to unbound dye 
(Sambrook etal. 1989), which means that small amounts of DNA may be detected even in the 
presence of unbound EtBr.
28.1 Analytical gel electrophoresis of DNA
. i'- \  '■
This was carried out with general purpose agarose having a low coefficient of electro-endoosmosis 
(BRL ultrapure DNA grade, (-mr = 0.1 - 0.15). Gels were cast at 1.5 - 2%. 50 ml 1 x TBE buffer 
containing 0.8 -1 g agarose were heated in a microwave to dissolve the agarose. After the addition 
of 1 \l\ stock EtBr solution (at 10 mg/ml), the gel was cast in a gel mould with gel combs in place.
Gels were run submerged (Uniscience Minigel System) in 1 x TBE buffer. Samples (usually 10 \i\, or 
25% of the nested PCR product) were loaded in 1 x tri-dye buffer (5 x stock solution contained 0.25% 
each of bromophenol blue and xylene cyanol, 0.5% orange G, 50% glycerol and 1 x TBE) and were
run at a constant voltage (116V, Atto Crossppwer 500) for 17 min, or until the orange G marker dye
.... .
reached the end of the gel. It was then photographed on a UV transilluminator onto video copy 
processor paper (Mitsubishi thermal paper) using the GDS 5000 gel documentation system (model 
P68B, Ultra-Violet Products Ltd).
28.2 Preparative gel electrophoresis
This was carried out as for analytical gels, except that LMP (low melting point) agarose 
(SeaPlaque, FMC, supplied by Flowgen) was used, and dissolution was carried out in 1 x TAE buffer. 
The gel was run at 75 V for 30 - 35 min in the same buffer, and photographed as described above. 
Appropriate DNA fragments were excised and purified, where necessary, by agarose digestion and 
EtOH precipitation.
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23 RECOVERY AND PURIFICATION OF FOR FRAGMENTS
Purification involved a modification of the method described in the GELase™ (Epicentre Technologies, 
USA, supplier Cambio) protocol. Gel slices containing the DMA bands of interest were weighed in 
tared 1.5 ml Eppendorf tubes, and an equal volume UHP water added (1 mg gel being equivalent to 
1 \i\ molten agarose). One-fiftieth volume 50 x GELase™ buffer was then added, to give a total final 
concentration of 40 mM bis-Tris, pH 6; 40 mM sodium chloride). The gel slice was melted at 70°C fpr 
45 min, and equilibrated 15 min at 45°C. 1.0 U GELase™ enzyme was added, and incubation 
continued at the same temperature for 1 h or more. 1 volume 5 M ammonium acetate was added, 
followed by 2 volumes absolute ethanol. DMA was precipitated, in the presence of 20 ^g glycogen 
carrier, by centrifugation at 14,000 rpm for 40 min. It was resuspended in 5 \i\ water, of which 1 p,l 
was run on an analytical gel to assess yield.
Alternatively, aliquots of the digested agarose solution containing DNA were used directly in ligation 
reactions.
In cases where only a faint PGR band was visible on the analytical gel, all of the remaining PGR 
product was first concentrated using a Microcon concentrator (Microcon 30, Amicon) before being run 
in a preparative gel.
210 CLONING OF HCV GENOMIC FRAGMENTS
Many commercial kits are available for the direct cloning of PGR amplicons. All aim at a rapid, one- 
step strategy for the direct insertion of a PGR product into a plasmid vector. They operate on the 
fact that Taq polymerase has a non template-dependent activity which adds a single deoxyadenosine 
(A) residue to the 3‘ ends of PGR products. Advantages are the elimination of enzymatic 
modifications of the PGR products; and that the method does not require the use of PGR primers 
which contain restriction sites. The three kits tested all used the blue/white screening method, whose
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molecular basis is the insertional inactivation of the galactokinase gene. The enzyme product of this 
gene acts on the chromogenic substrate X-gal to give B-galactoside, a compound which imparts a blue 
colour phenotype to colonies spread on agar plates containing the indicator X-gal in the presence of 
the enhancer IPTG. 3 TA cloning kits were assessed for efficacy of cloning of the HCV E1/E2 
fragment. Except where stated, all materials were supplied with the respective kits. In all cases, the 
insert DNA was E2 PCR product that had been previously gel-purified as described in Section 2.9.
The DNA was roughly quantified, and its size determined, by measurement against known amounts 
of 123-bp ladder (Gibco-BRL) run on the same gel.
Plasmid DNA was prepared from cultures of cells containing vectors with cloned inserts, and the 
region corresponding to the E1/E2 junction was sequenced by the Sanger method. Simple minipreps 
are often contaminated by DNA polymerase inhibitors and srfiall oligos which serve as random 
primers, leading to "ghost" bands, strong stops and other artefacts. As high-purity DNA templates 
are essential for efficient sequencing, a protocol involving additional purification steps was 
simultaneously assessed for its effect on the quality of the indicating autoradiograph.
210.1 Cloning of E1Æ2 region of HCV using commercial kits
(a) Invitrogen cloning method: The ligation reactions were carried out according to manufacturers' 
instructions. For a typical reaction, a total volume of 10 |il was used, comprising 4 U T4 
DNA ligase; 1 x ligation buffer; 20 hg‘pCR™ll vector; and about 50 ng insert DNA in sterile 
water. Ligation was performed overnight, or for a minimum of four hours. In a typical 
transformation protocol, first 2 \i\ of 0.5 M B-mercaptoethanol and then 1 - 2 |liI of ligation 
reaction were added to a vial containing 50 \i\ thawed OneShot^“  competent E. co//cells 
(remaining ligation mixture was stored at -20*0). The cells were incubated on ice 30 min, 
heat-shocked by a 30 s incubation in a 42*0 water bath, then transferred to ice for 2 min. 
450 \i\ pre-warmed SOC medium were added, and the vial containing the cells was shaken 
for 1 h at 225 rpm on a rotary shaker in a warm • (37'C) room. Meanwhile, LB agar plates 
containing 50 |ig/ml ampicillin were prepared by spreading 25 p,l X-gal (50 mg/ml) with a 
glass spreader. The X-gal was allowed to diffuse into the agar for about 1 h. 150 \i\ from
84
Chapter Two: Materials & Methods
each transformation vial were glated, using a sterile spreader, on separate, labelled LB agar 
plates. The plates were inverted and placed in a 37*C incubator overnight. White colonies 
were picked for plasmid isolation, restriction analysis and sequencing.
(b) Novagen pTTBIue T-Vector K it Protocol! Ligation mixtures contained 1 pJ ligase buffer (200 mM
Tris-HCI pH 7.6, 50 mM MgCl2), 5 mM DTT, 0.5 mM ATP, 50 ng pT7Blue(R) T-Vector (@
50 ng/pl), 2 - 3 Weiss units T4 DNA ligase (New England Biolabs) and 1 - 2 pi GELase'd 
DNA (0.2 pmol). The mixture was incubated at 16’C 2 h to overnight. 1 p,l ligation reaction 
was added to 20 p.1 NovaBlue ^prnpetent cells, which were then chilled and heat-shocked for 
40 s as in Section 2.10.1. This was followed by a 2-min ice incubation, then 80 p.1 SOC were 
added. Subsequent steps were as for Section 2.10.1 except that the LB agar plates 
contained the additional antibiotic tetracycline (15 p.g/ml).
(c) Stratagene pCR-Script^(SK(+) cloning k it protocol: This one-hour method utilized the cutting
properties of the novel restriction enzyme S r / / , which recognises the octapeptide sequence 
5'-GCCCGGGC-3'. The reaction mix in contained both Srf\ and T4 DNA ligase (New 
England Biolabs), which effect ^ cutting and religation j respectively, of the plasmid vector. 
Incorporation of the PCR fragment into the vector would eljrniriate the Srf I cutting site in an < 
irreversible reaction. At the same time, the dynamic equilibrium between cut and religated 
vector would be shifted so as to produce more cut vector for amplicon incorporation, thus 
increasing ligation efficiency. The 11 pi ligation mix contained 10 ng pCR-Script™ SK(+) 
vector, reaction buffer, 0.5 mM rATP; 5 U Srf I, 1 p.1 T4 DNA ligase and 50 ng insert DNA.
A 2 p.1 aliquot of the ligation reaction was used to transform 40 p.1 of Epicurian coli® XLI-Blue 
MRP Kan supercompetent cells, pre-chilled on ice in Falcon 2059 tubes after the addition of B- 
ME to a final concentration of ^5 mM. The mixture was left on ice for 10 min, and was heat- 
pulsed (45 s) and quenched on ice as above. Cells (50 -150 pJ) were plated onto LB-amp-X- 
gal-IPTG plates as described above.
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210.2 PCR screening for recombinant clones (colony screening)
Prior to growing colonies overnight for plasmid isolation, the presence of the appropriate insert was 
checked by PCR. Universal PCR primers, based on pUC/M13 sequences, were obtained from the 
LMB and were as follows:-
Primer 41 (reverse primer): d(CAG GAA ACA GCT ATG AC)
Primer 40 (forward primer): d(GTA AAA CGA CGG CCA GT)
PCR analysis was by one of three methods:-
(a) Method 1: Starter culture templates: "Minicultures" were prepared by inoculating 150 pi aliquots
of culture medium (2 x TY + AMP) dispensed in microtitre dish wells with individual white . 
colonies using a cocktail stick. The plate was incubated on a shaker maintained at 37*C.
After 4 - 8 h, 1 pi of each culture was diluted in 20 p.1 water. 1 pi of the dilution was added 
to 25 p.1 PCR reaction solution comprising 0.2 mM dNTPs, 0.1 p.M each of primers 40 and 41,
1 X Promega PCR buffer and 1 U Promega Taq. PCR was carried out in 96-well plates 
(Falcon 3911) on an MJ Research PTC-100 cycler.
(b) Method 2: Direct colony PCR: PCR was carried out as in 2.10.2 (a) above except that the
inoculating toothpick was dipped first in the PCR mix and then in the culture medium. Plasmid 
DNA was isolated only from those cultures whose corresponding PCR inoculum indicated the 
presence of the right insert.
(c) Method 3: Novagen method: Each selected colony was transferred, by toothpick, into 55 p.1
sterile water in a 1.5 ml Eppendorf tube. After briefly vortexing the tube, a 5 p.1 sample was 
transferred into 2 ml 2 x TY + AMP and set aside. The tubes containing remaining 50 p.1 
aliquots were floated on boiling water for 5 min and briefly spun in a microcentrifuge 
(13,500 rpm, 1 min). This was followed by the transfer of 10 p.1 supernatant into a microtitre 
dish well or 0.5 ml Eppendorf tube containing 40 pJ PCR mix, to give final PCR reaction 
components as in section 2.10.2 (a).
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2.10.3 Preparation & restriction analysis of plasmid DNA
(a) Simple minipreps: These were carried out according to Sambrook etal. (1989). Cells from a 3
ml, 18 h culture of One Shot™ cells were pelleted in a 1.5 ml Eppendorf tube (13,000 rpm,
1 min, room temp spin). The cell pellet was resuspended in 100 pi GTE (50 mM glucose;
25 mM Tris-HCI (pH 8.0); and 10 mM EDTA (pH 8.0)). After 5 min at RT, 200 p.1 soln II (0.2M 
NaOH, 1% SOS) were added. Mixing by inversion was followed by a 5 min incubation on ice. 
150 ^il soln III (a mixture of potassium acetate and acetic acid to give a final concentration of 
3 M K+ and 5 M acetate) were then mixed in as before, and the mixture incubated a further 
5 min on ice. Cell debris was pelleted by spinning (12,500 rpm, 15-20 min) in a refrigerated 
centrifuge. The supernatant, decanted into a fresh Eppendorf .tube, was precipitated with
• • • .  • 1 ,  .-I
two volumes absolute EtOH. The DNA pellets were dried at room temp for 5 -10 min then 
resuspended in 20 p.1 UHP water.
(b) Phenol-purified plasmid preparations (Novapreps): The steps followed in this protocol were as for
simple minipreps in Section 2.10.3(a) up till the addition of soln III and the spinning down of cell 
debris. At this stage, 300 - 400 pi phenohCIAA (1:1) were added to the supernatant (where 
CIAA refers to a 24:1 mixture of chloroform and isoamyl alcohol). The mixture was well- 
vortexed, and spun 1 min in a microcentrifuge. DNA in the aqueous phase was then 
precipitated with absolute EtOfrand dried as above. Resuspension was in 30 pi TErase 
(50 p.g/ml RNase A in TE buffer), followed by a 15 - 30 min incubation at 37°C. "Salty 
PEG" (12 p.1) was mixed in by pipetting, and the mixture left on ice for at least 1 h. DNA 
was spun down (13,500 rpm, 10 min, 4°C), the supernatant carefully removed from the 
(transparent) pellet, and a wash in 70% EtOH carried out. After airdrying, the pellet was 
resuspended in 11 pi TE.
2.10.4 Restriction analysis of plasmid DNA preps
Restriction digests were carried out on the minipreps in order to ensure that the Inserts had been 
maintained during culture. Enzymes used were Eco RI for the pCR™ll vector (Invitrogen) and, 
additionally, Pst\ for pTTBIue (Novagen) and pCR-Script (IStratagen). A typical reaction mix
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contained, in 11 pi total, 1 x buffer, 2 U enzyme, and 1 pi DNA prep, and incubation was at 37°C for 
30 min up to overnight. For double digests, Pst\ buffer was used and the Eco RI enzyme component 
increased to 4 U. All enzymes and buffers were from New England Biolabs. The size of the insert 
was determined from comparison with an appropriate standard run alongside digestion products on an 
analytical gel (see Section 2.8.1) after the addition of 2.5 pi tri-dye loading buffer. For simple 
minipreps, the tri-dye used contained 100 pg/ml RNase A and the samples were incubated, after its 
addition, at 37°C for at least 15 min before being run on the gel.
211 NUCLEOTIDE SEQUENCING
The enzymatic method of Sanger (1981) generates four separate populations of radiolabelled oligos 
that begin from a fixed point and terminate randomly at a fixed residue. The length of oligos is 
determined by the location of a particular base along the length of the template. Every base in 
template has equal chance of being the terminus. Populations are resolved by electrophoresis. When 
populations are loaded onto adjacent lanes of a sequencing gel, the order of nucleotides along the DNA 
can be read directly from an autoradiograph of the gel.
Sequenase Version 2.0 is a genetically engineered form of bacteriophage T7 DNA polymerase with a 
wide tolerance for nucleotide analogs (e.g. dITP) used to resolve regions of compression. The very 
high processivity and high polymerization rate of this enzyme were exploited by carrying out the 
reaction in two stages:- (i) a phase involving low dNTP concentrations and low temperature in order 
to limit the extent of synthesis and ensJre efficient incorporation of a radiolabelled dNTP (resulting in 
primers extended by only 20 - 30 bps) ; (ii) division of each reaction into four tubes, each containing 
high concentrations of dNTPs and a single ddNTP. This allowed polymerization to continue until a 
chain-terminating nt was incorporated into the growing chain. The Sequenase®* Version 2.0 DNA 
sequencing kit (USB) was used for all sequencing.
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Polyacrylamide gel electrophoresis was used to separate DNA fragments resulting from the 
sequencing reaction. The resolving power of this kind of gel is great enough to separate DNA 
molecules with 1 nt difference. DNA fragments were visualized by autoradiography, which produces 
a permanent record of the two-dimensional distribution of radioactive atoms on photographic film.
{35g} (incorporated into dATP) was use'd: B particles emitted by this isotope are known to penetrate 
film emulsion to a depth of 0.25 mm, sufficient to allow interaction with silver halide crystals therein 
when film and source were directly apposed. X-ray film was developed in an automatic X-ray film 
processor (X-Ograph Compact X2).
211.1 RNase treatment and dénaturation of miniprep DNA solutions
To 20 III of miniprep DNA was added 1 p.1 of a 10 mg/ml solution of RNase A (10 pg). After 
incubating the mixture at 37*0 for 20 min, 8 pi of a basic mix (stock solution contained 1 M NaOH 
and 0.5 mM EDTA) were added. Alkaline dénaturation of the DNA (5 min at room temp) was 
followed by the addition of 4 pi 2 M sodium acetate and 116 pi absolute EtOH. The solution was 
incubated on dry ice for 10 min then spun down for 10 min at 4°C. It was washed once in 75% EtOH, 
and resuspended in 15 pi UHPW.
211.2 Chain extension reaction
For a typical sequencing reaction, 5 prtibles of primer were added to a 3 pi aliquot of alkaline 
denatured, RNase-treated DNA prepared as described above. The mixture was heated in a 65*0 
water bath for 2 min, and allowed to cool slowly (over 30 - 45 min) to below 30°C. It was pulsed 
briefly and chilled on ice. Labelling mix (7.5 pM each of dGTP, dCTP and dTTP) was diluted 5-fold 
to working concentration. To the ice-cold DNA/primer hybrid (10 pi) were then added 1 pi 0.1 M 
DTT, 2 pi of diluted labelling mix, 0.5 pi of ps jdA T P  and 2 pi of a 1/6 dilution, in enzyme dilution 
buffer (10 mM Tris-HCI, pH 7.5; 5 mM DTT; 0.5 mg/ml BSA) of Sequenase version 2.0. Extension 
was carried out at 17*C for 2 - 5 min.
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2.11.3 Chain termination reaction
To 2.5 pi of each termination mix, dispensed.into wells of a.microtitre plate (Falcon 3911) or 0.5 ml 
Eppendorf tubes and pre-warmed to 37 - 42‘C, were transferred 3.4 pi of the extension reaction.
The mixture was incubated a further 3 - 5 min at the same temperature. Reactions were stopped by 
adding 4 pi of Stop Solution (0.05% each of bromophenol blue and Xylene Cyanol FF, 20 mM EDTA 
and 95% formamide), and stored at -20*0 until run.
2.11.4 Casting, ioading, running and autoradiography of sequencing gels
Sequencing reaction products were subjected to electrophoresis on denaturing polyacrylamide gels 
containing 6 M urea using vertical gel tanks (Cambridge Electrophoresis Ltd). Gels were cast between 
20 cm X 40 cm or 20 cm x 50 cm glass plates separated by 0.4-mm thick spacers (Bio-Rad). The top 
plate was treated with silicone solution to allow its easy detachment from the gel at the end of the 
run. A 50 ml gel solution was made up by adding 20 ml UHP water to 23 g urea (Gibco-BRL), 
followed by 150 pi of 10% ammonium peroxodisulphate (ammonium persulphate - BDH), 5 ml of 10 x 
TBE and 7.5 ml of 40% acrylamide (Severn Blotch Ltd - stock solution contained 40% acrylamide 
and 2.105% bis acrylamide). Just before pouring the gel, TEMED (100 pi. Sigma) was added to the
solution. The gel was left to dry, with^sharkstoothxomb in place, for at least an hour. Samples were
■ ■ ^ '
heated to 75*C for 5 min immediately before loading (1.5 pi of each) onto lanes created by the 
sharkstooth comb.
Gels were run at constant power (37 W) for 90 min (40 cm gel) or 140 min (50 cm gel), or until the 
BPB band reached the end of the gel. The plates were carefully separated and the spacers 
removed. The plate to which the gel remained attached was balanced, gel side up, on 25 mm-high 
supports (empty racks from the Sarstedt Tip Stackpack were used) located in a shallow tray. 
Enough fixing solution (10% each of mlthànôl and acetic acid in water) was dispersed onto the gel to 
cover it completely (50 - 60 ml). After 5 - 15  min, the liquid was drained off by tilting the plate, and 
the fixing process repeated with a fresh layer of fixing solution. Excess fluid was removed from the 
surface of the gel, which was then dried onto a piece of Whatmann 3 MM paper using a commercial
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dryer (Atto Rapidry, supplied by Genetic Research Instrumentation). Saran wrap placed round the gel 
on the paper before drying prevented spread of radioactivity.
212 ANALYSIS OF SEQUENCING RESULTS
Nucleotide sequences were aligned and checked using the IBI sequence analysis software programs 
AssemblyLIGN™ and MacVector™ (International Biotechnologies Inc). Typing was based on a 
previously-described amino acid sequence homology scheme (Okamoto etal. 1992; Bukh etal. 1993). 
Figure 2.1 shows primer sequences and locations for the E1/E2 PCR product encompassing HVRi. 
Type-specific sequence homologies contained within the amplified region enabled a simultaneous 
determination of the HCV sub-type (figure 2.2). The PCR product was cloned into a bacterial vector, 
and sequenced by the dideoxy nucleotide chain termination method.
Figure 2.1 : HCV genomic organisation showing location of E1/E2 PCR primers
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Figure 2.2: Type-specific amino acid sequence homologies in 3'E1
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HVR nl
Typing region
"11332 Type I: ALVMAQLLRIPQAILDMIAO
Type II: ALWSQLLRIPQAWDMVAG 
Type IIIrTMILAYAMRVPEVIIDIIGQ 
Type IV: TMILAYAAKVPELVLEWFG
1371(aa
Part of HCV genome showing type-specinc amino add homologies within PCR product One-letter amino add code depicts residues peculiar to 
he various sutJtypes. Absolutely conserved amino adds in bddface. Ref; Okamoto sf all, VIrdogy 188: 331-341 (1892).
The nucleotide sequence diversity in each set of sequences was calculated as the mean of the total 
number of mutated nucleotides between all possible combinations of two sequences. The ratios of 
replacement to silent mutations (R/S ratios ) were calculated for clones corresponding to each 
sample, and the significance of conservative vs non-conservative amino acid replacements was ' 
analysed.
Statistical analysis: Fisher's exact probability test was used in all statistical analysis.
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CHAPTER THREE: OPTIMIZATION OF REACTION PROTOCOLS
The research which formed the basis of this thesis involved the generation and amplification 
of HCV cDNA from a large number of samples, as well as the sequencing of the EME2 region 
from multiple clones derived from individual samples. Special attention was therefore given to 
optimizing efficiency and effectiveness at every stage of the procedure. The optimization of 
reaction protocols led to the discovery of two atypical phenomena, described in this sections
3.2 and 3.3.
3.1 RNA extraction & RT-PCR
The two methods of HCV RNA extraction used in the study employed either proteinase K or 
guanidinium thiocyanate as the denaturing agent. The guanidinium-based protocol gave the 
most consistent results. In amplifying sequences from the HCV NCR and Ef/E2, RNA was 
reverse-transcribed, to give cDNA, which was then subjected to two rounds of amplification. 
Alternatively, the reverse transcription reaction was combined with the first PCR round in a 
single tube, after which second PCR was carried out. The two protocols gave identical 
results, as shown in Fig 3.1. In addition, for the EVE2 region, only the protocol involving a 
combination of reverse transcription and PCR gave positive results. Hot start PCR is 
described in chapter 2. In an alternative protocol, assessed because of its relative simplicity, 
all reaction components were assembled on ice, then transferred rapidly to the PCR block at 
dénaturation temperature, for the amplification reaction. The results of both protocols were 
identical single, distinct PCR bands with no smearing, as depicted in Fig 3.2. An absence of 
cross contamination was demonstrated by sequencing of the "fingerprint" HVR1 region.
3.2 Effects of heat or chemical dénaturation on amplification of HCV RNA
It was discovered that the difference between a positive and a negative amplification signal, 
for the E1/E2 PCR product only, was critically dependent on heating the RNA at 70°C for a
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relatively long period before the combined RT-PCR step. Four different heat dénaturation 
regimes were compared to test this effect.
Fig. 3.1 : Results of PCR of the HCV non-coding region - a comparison of separate PCRs and 
combined RT-PCR1
1 2  3  4  5  6  7  8  9  I Q  1 1  1 2  1 3  1 4
Lanes 1,14 = 123-bp ladder; lanes 7,13 = negative controls (plasma from non-HCV-infected donors); lanes 2 - 6 
= cDNA derived by separate RT and nested PCRs; lanes 8 - 12  = cDNA derived by combined RT-PCR1 and 
nested PCR. Note that the cDNAs in lanes 8 -12 are the same as those in tracks 2 - 6, respectively.
In an experiment involving 12 isolates, RNA was extracted from 250 1^ plasma, and 
dissolved in 20 jil water. 5 pil aliquots from each sample were then subjected to RT-PCR as 
described in section 2.6.2, except that in three cases (i.e., for each of the remaining 5 pil 
aliquots) the RNA was first heated at 70°C for 1 h, 65°C for 5 min or 90°C for 5 min.
Plasma samples used in this experiment came from asymptomatic blood donors (Ad, Har, 
Wad): HCV-infected liver transplant recipients (Cap, DK, GS); and individuals who had been 
repeatedly seropositive for HCV by first and second generation ELISA and RIBA, as well as 
by PCR of the non-coding region (V, W, X, Y and Z). Gio was a patient seropositive for HCV 
by both screening and confirmatory tests (see section 2.2), but repeatedly negative by PCR 
of the non-coding region. D was an isolate from a non-carrier of HCV, used as negative 
control in all extraction/amplification reactions. Results are shown in Table 3.1(a), and 
indicated that heating the RNA for 1 h at 70°C (regimen II) was considerably more effective 
than any of the other treatments.
To further assess the effect of dénaturation on the outcome of RT/PCR and nested PCR, 
RNA was extracted from 6 samples (including 1 negative control, D), in duplicate. The 
procedure was as given in section 2.4.2, except that for one set of samples, the RNA was
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dissolved in 4 jil of the strong denaturing solvent formamide instead of 20 jil water (i.e., in 
each case, 25% of the RNA obtained from 250 jil plasma or serum).
Fig. 3.2: Results of PCR of the E1/E2 region by combined RT-PCR1 and nested PCR
1 2  3  4  5  6  7  8
Lanes 1,8  = 123-bp ladder; lanes 2 - 6 = 571-bp product of E1/E2 amplification from 5 different plasma 
samples; lane 7 = negative control
RT-PCR was carried out on 5jil water-dissolved or 1 jil formamide-dissolved RNA, and was 
preceded by heat-denaturation as in regimen II of Table 2.2 for the aqueous solution. The tube 
containing the 1 jil RNA solution in formamide was floated for 35 s or 45 s in a boiling water 
bath, then snap-frozen on ice before RT-PCR, which was carried out in a total volume of 
20 jil containing the same reagents in the same concentrations as in Section 2.6.2. Results, 
shown in Table 3.1(b), indicated that although the 70°C heating step still gave the best 
outcome, heating in formamide for 35 s was a viable option. The heat-denaturation period 
could be decreased to 30 min without affecting results, and the majority of the amplification 
reactions in this study were accordingly carried out with an initial RNA dénaturation of 
30 min at 70°C.
3.3 Effects of heparin on amplification of HCV sequences from plasma
Mg2+ concentration is known to be a critical factor affecting PCR outcome. In PCR mixes 
containing otherwise optimal amounts of Mg2+, it is often necessary to increase Mg2+ 
concentrations where EDTA is present in the sample, due to the chelating effect of EDTA on 
divalent cations. In a preliminary study to determine the relative effects of the 
anticoagulants heparin and EDTA on amplification of HCV RNA, six different plasma 
samples were subjected, in duplicate, to RNA extraction and RT-PCR as described in
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sections 2.4.2 and 2.6.2. The samples had been collected in either heparin or EDTA, and the 
protocol followed was otherwise identical for all 12 initial plasma aliquots. It was found that 
bands of the relevant size (the region amplified was a 237-bp segment of the NCR) were 
obtained only from heparinised samples. In contrast, no PCR bands were obtained when 
RT/PCR and nested PCR of the E1/E2 region were carried out on aliquots from the same 
samples. Experiments had been carried out in exactly the same way for both sets of 
experiments, except for the specific PCR primers used. Hence, heparin was found to inhibit 
HCV amplification differentially, depending on the region of the genome targeted. This 
difficulty was resolved by replacing all heparinised samples with serum samples obtained 
from similar time points, or by using plasma derived from citrate-preserved blood, for E1/E2 
PCR.
Table 3.1 : Results of amplifying HCV E1/E2 fragments from various isolates using different 
RNA dénaturation regimes. "Patient samples" refers to isolates from asymptomatic carriers 
or liver transplant recipients; "Controls" = isolates routinely used as positive or negative 
controls (D = single negative control); "+", "-" = positive, negative E1/E2 PCR result, 
respectively. Programs i - V refer to different RNA dénaturation regimens, where i = no 
dénaturation; ii = 70°C 1 h; Hi = 65°C 5 min; IV = 90°C 5 min; & V = RNA dissolved in 
formamide before heating in boiling water for 45 s (a) or 35 s (b).
(a) Comparison of 4 heat-denaturation programmes
Pro- Patient samples
gram Ad Cap DK Gio GS Har
IV
V
Controls 
W X Y D
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(b) Comparison of heat- and chemicai-denaturation effects on RT-PCR of HCV 
RNA: PCR ofE1/E2 region.
Ad Har Wad V________W_______ D_
II + + + + + -
V(a) - + + -
V(b) + + +
The results depicted in Table 3.2(b) were obtained from fresh plasma aliquots of each sample, different from 
the aliquots of 3.2(a). Note that samples Ad and Har are PGR-positive with program 11 on this, as well as on 
subsequent, occasions.
3.4 Cloning and sequencing of PCR products
Three commercial kits were compared for efficacy of cloning PCR products. The 571-bp 
product of E1/E2 PCR was cloned into vectors provided with the Invitrogen, Stratagene and 
Novagen kits according to manufacturers' instructions (see Section 2.10.1). Only Invitrogen 
showed consistent incorporation of the PCR fragment, with a false positive level of virtually 
less than 1% for the white colonies. For this reason, it was possible to dispense with the 
colony screening assay (Section 2.10.2) for all recombinant clones. Throughput time from 
PCR to cloning was also decreased by carrying out the cloning reaction with the amplified 
DNA still in the GELase-digested gel, without further purification.
The Wizard™ PCR preps DNA purification system for rapid purification of cloned plasmid 
DNA (Promega) was compared with the simple minipreps protocol of 
Section 2.10.3(a). Similar yields were obtained with both systems, although more 
uniform bands were obtained with Wizard™ preps. When using the vacuum manifold 
according to manufacturer's instructions, the Wizard™ preps were two-thirds faster 
to produce, and purer than those obtained by the simple protocol. Surprisingly 
however, these preps gave a much poorer read-though when equivalent amounts 
were sequenced, as depicted in Figure 3.3.
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Fig 3.3: Sanger sequencing of the HCV HVR1: 
Effect of DNA preparation method on 
sequencing read-through
5 ' = 1 S.L Î
i i
l o  - 1
I - I
C C
«  #
Lanes were loaded in the order:TCGA. •
Nos. 1 -4  = simple minipreps. • '
Nos. 5 - 8 = Wizard^preps !
The relative advantages of Wizard™ preps and simple minipreps are summarised below:-
Advantages Disadvantages
Wizard' '^  ^ preps
Simple minipreps
- faster
- purer preps
- cheaper
- less labour-intensive
- better read-though on 
sequencing
-more expensive
- more labour-intensive
- poorer read-through on 
sequencing
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3.5 Choice of methods
The method used for RNA extraction is an important concern when optimizing HCV PCR. 
Direct comparison of different isolation methods for HCV RNA showed that of the 4 
commercially available kits for nucleic acid isolation (RNAzol B, TRISOLV and 
ULTRASPEC for RNA and IsoQuick for total nucleic acid), RNAzol B was the most 
efficacious (Nolte etal. 1994). In the author's experience, more consistent results were 
obtained with guanidinium buffer prepared as in Section 2.4.2 than with RNAzol B.
In PCR, problems often arise from the annealing of primers to each other (primer dimer 
formation) or to non-target areas of the template under non-stringent conditions, giving rise to 
amplification of spurious sequences, and is especially problematic in the presence of low 
amounts of starting template. This happens because Taq DNA polymerase can act outside 
its optimal temperature of 72°C, retaining significant activity even at room temperature. In 
hot start PCR, a subset of the reaction components is assembled to lie under a wax barrier.
A key constituent is added to the top of the barrier such that all components only mix when 
the temperature is above the annealing temperature (i.e., when the wax melts). This method 
has been found to significantly reduce the formation of non-target PCR products (Saldanha 
and rVinor 1994). In the current investigation, it was found that, despite the low viral titres 
associated with HCV, a hot start technique was not necessary to ensure highly-specific 
amplification of HCV DNA fragments, as long as all reaction components were assembled on 
ice, and were transferred rapidly to the pre-heated heating block at the dénaturation 
temperature. Clear bands of the right size with no smearing were consistently obtained by 
this method, which was simpler, faster and more convenient than hot start.
Heparin has been described as a potent inhibitor of both Taq DNA polymerase and reverse 
transcriptase (Willems et al. 1994). The mechanism of this inhibitory effect is unclear.
Heparin may act by directly blocking the enzymes reverse transcriptase and DNA 
polymerase. Alternatively, it may interact with DNA or RNA to prevent transcription. 
Divalent cations such as Mg2+ may mediate the interaction between heparin and nucleic acid,
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both negatively charged macromolecules. In human population genetic studies involving 
amplification of blood-derived DNA, the time between blood collection and DNA extraction 
was found to be critical, implying an interaction between heparin and DNA as a mechanism of 
inhibition (Satsangi etal. 1994). Although the effects of heparin could be reversed by 
treatment of affected DNA or RNA with heparinase, results were often inconsistent (Izraeli 
etal. 1991; Satsangi etal. 1994).
Despite the data on the inhibitory effects of heparin, there are reports of successful 
amplication of HCV NCR sequences from heparinised blood (Takehara etal. 1992; Ouanian 
et al. 1995). Indeed, the preliminary experiments described in section 3.2 indicated that, when 
amplifying the HCV NCR, more consistent results were obtained with heparinised than with 
EDTA-containing blood. The author's results with amplification of different areas of the 
HCV genome suggest that the inhibitory effect of heparin may be template-dependent to 
some extent, in particular that the NCR is, perhaps anomalously, resistant to this effect.
The latter view is buttressed by evidence of peculiar secondary structure at 5' end of HCV 
genome that might contribute to the decreased capability of heparin-binding (Brown et al. 
1992). Magnesium ion concentration is known to have profound effects on PCR (Innis etal. 
1990), which may explain the initial negative PCR results obtained for HCV NCR 
amplification described in section 3.2. It is possible that chelation of Mg2+ ions by EDTA 
altered PCR conditions sufficiently to prevent the generation of visible products from the non 
coding region.
In summary, these preliminary experiments led to the consistent use of:-
• serum samples, or plasma obtained from non-heparinised (usually citrate-preserved) 
blood, for PCR of the E1/E2 region enclosing the HVRI;
• a heat dénaturation temperature of 70°C, applied for 30 - 60 min, for denaturing 
extracted HCV RNA prior to RT/PCR; and
• simple minipreps of section 2.10.3(a) for sequencing using the Sequenase kit.
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4.1. PCR of the non-coding region (NCR) and E2 region
Blood samples were obtained prospectively from 14 patients with HCV-associated, end-stage 
liver disease who were scheduled for orthotopic liver transplantation (OLT) at Addenbrooke's 
Hospital (see also Table 2.1, category "Tx" patients). All were seropositive for anti-HCV 
antibody by ELISA and RIBA assays. Following blood separation into plasma and leukocytes 
as described in chapter 2, section 2.3, HCV RNA extraction was carried out on plasma (or 
serum) samples by the methods described in section 2.4. cDNA synthesis and nested PCR, 
or combined RT-PCR followed by a second round of amplification, were carried out as 
described in section 2.6. In addition, batch processing of serial samples was performed by 
G. Pearson, using the methods of section 2.7. Results are shown in Table 4.1.
Table 4.1 : Results of PCR of the NCR (N) and E1/E2 region (E) of 5 OLT candidates when 
heparinised (hep) or non-heparlnised (NH) blood was used as HCV nucleic acid source.
Patient 
A1 (hep)
Pre-
OLT
N E
1
N E
2
N E 
[ + ]
Moi
3
N E
iths post-( 
6
N E
DLT
12
N E
18
N E
24
N E
Cl (hep) 
(NH)
+ +
[ + ]
+ + + +
FI (hep) + + +? + ? - +
LI (hep) 
(NH)
+
+ +
L2 (NH) N.A. + + + + + +
L3 (NH) + +
"+“ and signs indicate, respectively, positive and negative PCR results. N.A. = not available. [+] indicates 
that HCV sequences were amplified from PBMC for that sample.
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• 6 of 14 patients (A1, B1, C2, C3, De and M2) were repeatedly negative for serum or 
plasma HCV by PCR of the non coding region. In A1, however, HCV was isolated from 
PBMC. It should be noted that this patient, originally seropositive for HCV, had 
undergone two previous OLTs for HCV-related disease over a three-year period.
• 2 patients did not receive transplants because liver disease was too advanced (A2) or 
due to the lack of a suitable donor (W1). Although the initial sample was PCR-positive 
for both the NCR and the E1/E2 region, no further samples were drawn after the first.
• 1 patient (M l) was PCR-positive pre-transplantation, and at 193 days post-OLT. 
However, only heparinised samples were available for the pre-OLT time points (see 
chapter 3, section 3.2). Although the NCR could be amplified from these, attempts to 
amplify E1/E2 6\6 not succeed, despite heparinase treatment of the RNA obtained.
• In 1 patient (FI), non-HCV sequences were obtained from PCR-amplified, cloned cDNA 
corresponding to the E1/E2 region (see section 4.1.5).
Positive E1/E2 PCR bands were obtained for serial samples from 3 of the remaining 4 
patients (Cl, LI and L3), each set including a pre-OLT sample. The last of these 4 patients 
(L2) was a candidate for retrospective analysis of HCV genomic evolution in 10 serum 
samples kindly provided by P. Evans. Although no pre-OLT sample was available for L2, all 
10 post-OLT samples, obtained between 31 and 435 days post-OLT, were positive for HCV 
E//E2 sequences by PCR. cDNA bands corresponding to 5 of these time points were cloned, 
and nucleotide sequences were obtained for the first hypervariable region (HVRI), together 
with corresponding sequences from C l, in an analysis of the long-term effects of 
immunosuppression on HVRI sequence variability, discussed further in chapter 5.
The mean time to reinfection was 67±62 days, although the high standard deviation reflected 
the variability in this parameter among the 6 patients (Cl, FI, LI, L2, L3 and M l) considered 
in the analysis.
4 patients (Cl, LI, L2 and L3) were included in the study. None had any identifiable risk 
factor for HCV infection. Samples were also obtained from 3 apparently healthy blood
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donors (Wad, Fra and Dix) who had a past history of intravenous drug abuse (IVDA), and 
provided the data for non-transplanted controls.
4.2 Liver function in OLT recipients and asymptomatic subjects as determined from 
serum ALT values
Serum alanine aminotransferase (ALT) concentrations range from 7 - 50 lU/ml in normal, 
healthy individuals. For all patients described in Section 4.1.1 above, serum ALT values 
corresponding to several time points post-OLT were obtained from clinical records at the 
Addenbrookes Flospital transplantation ward. Data on 8 asymptomatic FICV-infected blood 
donors were obtained from the East Anglian Blood Centre (EABC), for samples obtained 
between 1991 and 1993. 7 were confirmed positive for anti-FICV, while the eighth (Dix) was 
indeterminate. An ALT value above twice the upper limit of normal was considered to 
constitute liver dysfunction. Figures 1 to 4 depict serum ALT and bilirubin concentrations 
plotted against number of days post-OLT for C l, L2, L3 and LI.
Patient C1: This was a 56-year-old man who had his first transplant in March 1994 for 
FICV-related end-stage cirrhosis complicated by hepatocellular carcinoma. Serum ALT rose 
from 79 lU/ml 11 days post-OLT to 195 lU/ml by one month post-OLT (figure 4.1a). Values 
peaked at 57 days (319 lU/ml), before falling gradually over the next three months, 
stabilising at 94 lU/ml by 135 days post-transplantation. Although fluctuating, ALT values 
remained between 43 and 95 lU/ml for the next year. Deteriorating liver function tests, 
followed by graft failure, led to a second transplant in patient 01, carried out 386 days after 
the first.
After the second liver transplant, serum ALT in patient Cl remained much higher and for a 
longer period than after the first transplant, as shown in figure 4.1b. Serum bilirubin 
concentrations, also depicted, showed a profile parelling that of ALT levels, except that 
peaks of bilirubin lagged behind the ALT peaks. Although serum ALT had fallen from 
493 lU/ml on the day of transplantation to 144 lU/ml by day 7, it remained quite high 
throughout the period of follow-up. The 390 lU/ml value recorded 125 days post-OLT2 was
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more than three times higher than that taken at a similar time interval from the first 
transplant (116 lU/ml at 127 days post-OLTI), The patient subsequently died of graft 
failure due to HCV infection.
Figure 4.1 (a):/ALT, bilirubin and HCV PCR profiles for patient C1 after 1st transplant
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Figure 4.1(b): ALT, bilirubin and HCV PCR profiles for patient C l after 2nd transplant
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Patient L2: This was a 48-year-old man who, like patient C l, received two liver grafts.
ALT and bilirubin levels in the serum of L2 are shown in figure 4.2. 99 days after the first 
transplant (0LT1), a high ALT level (395 lU/ml) was observed. ALT levels remained high 
over the next year, with peaks above 300 lU/ml in the month preceding graft failure due to 
graft infection with HCV (figure 4.2a). After the second transplant (0LT2), the biochemical 
course of disease was poor, with ALT peaking at 1300 ID/ml after 40 days (figure 4.2b).
Over the next two weeks, serum ALT concentrations fell rapidly, reaching a value of 
81 lU/ml within 6 days, and with a mean value of 63+11 lU/ml thereafter. The corresponding 
values for bilirubin, however, showed a rapid increase. The mean bilirubin concentration of 
292+124 |liM was an almost 10-fold increase over its mean value (30±12 jiM) in the 2 
weeks before the ALT peak. The patient died of chronic hepatitis C two months after the 
second transplant.
Figure 4.2a: ALT, bilirubin and PCR profiles for patient L2 after 1st transplant
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Patient L3: This 46-year-old woman underwent liver transplantation for HCV-related 
cirrhosis in February 1994. Data were obtained for the first five months post-OLT, as 
shown in figure 4.3. A serum ALT value of 153 lU/ml at 7 days post-OLT had normalised by
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50 days post-OLT by 14 days post-OLT. Values were fluctuating (92±29 lU/ml) over the 
next 4 months. At 145 days, when the last record was taken, serum ALT concentration 
was 65 lU/ml. The patient remained clinically well 12 months post-transplantatlon.
Figure 4.2b: ALT, bilirubin and PCR profiies for patient L2 after 2nd transpiani
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Figure 4.3: Post-transplantation ALT, bilirubin and PCR profiies for patient L3
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Patient L1: Patient LI, a 66-year-old man, underwent OLT in April 1994 for HCV-related,
end-stage cirrhosis. 7 days post-transplantation, ALT concentration remained relatively high 
in this patient, but had fallen to normal (57 lU/ml) by two weeks post-OLT (see figure 4.4).
It remained within the normal range at 1, 2, 3 and 6 months post-OLT. The last serum ALT 
value recorded (89 ID/ml at 277 days post-OLT) was within acceptable limits. The patient 
remained well two years post-OLT.
Figure 4.4: Post-transplantation ALT, bilirubin and PCR profiles for patient L 1
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By way of contrast. Table 4.2 shows ALT values for 8 blood donors discovered to be HCV- 
infected during routine blood screening at the EABC. ALT values were mildly elevated in all, 
with values from 2 to 4 times the upper normal limit of 50 ID/ml.
Detailed sequence analysis was carried out on three apparently asymptomatic blood donors, 
described below:-
Patient Wad: This 46-year-old male blood donor had HCV-related chronic hepatitis, detected 
in February 1993. Although only moderately symptomatic at the biochemical level, liver 
biopsy revealed chronic active hepatitis with mild fibrosis (stage 2).
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Patient Dix: This is a 42-year-old male blood donor found HCV antibody positive in 
November 1993. He was cryoglobÏÏlinaémic, and experienced fatigue and arthralgia.
Patient Fra: This is a 37-year-old woman found HCV antibody positive in a blood donation 
obtained in September 1994. ALT levels remained persistently normal, but liver biopsy 
revealed mild, chronic active hepatitis with moderate liver fibrosis (stage 3).
Table 4.2: ALT levels in asymptomatic, HCV-infected biood donors
Subject Age ALT (lU/ml)
Ad '3 2 100
Wad 22
Dix 41 75
Z 22 159
X 33 184
Y 35 109
V 32 194
W 38 141
Ml.
The mean age of the non-transplanted patients above was 32 (S.D. = 6), compared with a 
value of 55±7 for the six OLT recipients (A1, C l, LI, L2, L3 and M l) from whom HCV 
HVR1 sequences were obtained.
4.3 Genotyping of HCV sequences
HCV genotype was determined in 13 infected individuals (6 asymptomatic blood donors and 7 
OLT candidates) by the Bukh-Okamoto method, which is based on amino acid sequence 
homologies exclusive to the distinct types and subtypes (Bukh et ai. 1993; Okamoto et al. 
1992). See figure 2.2 and appendix A for a comprehensive list of region-dependent amino acid 
sequence variations as reported by Okamoto et al.
The stretch of 26 - 43 amino acids used for typing was deduced from nucleotides 1332 - 1457 
of the prototype HCV isolate HCV-1 (Choo et al. 1991), located at the presumptive 3'
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terminus of the E 1 gene (see section 1.5.6). It included a 10-residue motif (amino acids 342 - 
351) previously shown to be sufficient by itself for HCV genotyping (Bukh et al. 1993). In 6 
individuals - Ad, Har, Wad, Z1, L3 and W1 - the isolated HCV fragment was classified as 
Okamoto type I. This corresponds to subtype la  of Simmonds et ai. (1995).
Figure 4.5: Nucleotide (a) and amino acid (b) sequences used for genotyping HCV type I.
(a) Alignment of reference, sequence HCV-1 (nts 1332 - 1454) against homologous 
sequences from presumptive HCV type 1/1 a isolates
331 335 340 345
A la  Leu V a l M et a la  G in  Leu Leu A rg  H e  Pro G in  A la  H e  Leu  
1332 1376
HCV-1* GCG TTG CTA ATG GCT CAG CTG CTC OGG ATC CCA CAA GCC ATC TTG
H ar
Wad ■ • • C . . . . . GC.
Ad
Z
Wl / / / / / .
L3 / / / / / . / / /  / / / / / / / / / / / / / / / C . .
350
I
355 360
HCV-1
H ar
Wad
Ad
Z
W1
L3
Asp M et H e  A la  G ly  A la .H is  Txp G ly  V a l Leu A la  G ly  H e  A la  
1377 1421
GAC ATG ATC GOT GOT GCT c fc  TGG GGA GTC CTG GCG GGC ATA GCG 
..............................c ................................................................................................
L - c  a  . . g  . . .  / / /  I f f  / / /  / / /  / / /  / / /  / / /  / / /  i n
365 370
T y r  Phe S er M et V a l G ly  Asn T rp  A la  Lys V a l Leu 
1422 1457
HCV-1 TAT TTC TCC ATG CTG GK3G AAC TGG GCG AAG GTC GCG
H a r ................................ ................................................................................
Wad . . c ......................................... c .............................................
Ad  '
z  ^ ..................... ! ! ! ! ! ! ! ! !
w i  t ..................................................................... a
<■,  .
(b) Typing of HCV by amino acid sequence comparisons
330 340 350 360
HWGVLAGIAYFSMVGN 
...... V .......
////////////////
* Reference sequence = HCV-1 (Choo etai., 1991). For the remaining sequences, oniy points of nucleotide 
sequence diveigence from HCV-1 are shown. Upper case letters indicate that changes would give a replacement 
of the eroded amino acid(s).
HCV-1 ALVMAQLLRIP QAILDMIAGA
Har • • •
Wad • • .  . .  • • .  •
Ad f t .  V^ . • • • • • • .....V. . .
Z .....V. . .
Wl //.V...... .....V. . .
L3 ////////... ....I___
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Figure 4.5 shows the nucleotide (a) and deduced amino acid (b) sequences of the 6 type 1/1 a 
isolates, aligned against the corresponding region in HCV-1. By comparison with amino acids 
336 - 361 (nucleotides 1330 -1425) of the type II isolate HCVJK1G (M. Honda, 1991, 
unpublished; EMBL accession # X61596), HCV derived from 5 isolates (Har, Wad, Ad, Z2 and 
W l) was classifiable as type II (subtype la). The sequence alignments are depicted in 
figure 4.6.
Figure 4.6: Nucleotide (a) and amino acid (b) sequences used for genotyping HCV type II.
(a) Alignment of reference sequence HCV-JK-1G(nts 1330 - 1425) against 
homologous sequences from presumptive HCV type ll/lb  isolates
336 340 345 350
G in  Leu Leu Arg H e  Pro G in  A la  V a l V a l Asp M et V a l A la  G ly  A la  
1330 1377
HCVJK-IG* CAG TTA CTC CGG ATC CCA CAA GCC GTC GTG GAC ATG GTG GTG GGG GCC
F ra
L I
M l
C l
L2
. t  . . .  ... 
. t  ..
, t ............
, t  A . . . .  
, t  . . .  A.
355 360 365
H is  T rp  G ly  V a l Leu A la  G ly  Leu A la  T y r  T y r  S er M et V a l G ly  Asn 
1378 1425
HCV-1 CAC TGG GGA GTC CTG GCG GGC CTC GCC TAC TAT TCC ATG GTG GGG AAC 
F ra   t .............................................................................
L I
M l
C l
L2
(b) Typing of HCV by amipp acid sequence comparisons
340
I
HCVKJ-IG QLLRIP
Fra...... .....
LI .....
Ml .....
Cl .....
L2 .....
350
I
QAWDMWGA 
. . A .  .
. .A. .
« « A « « 
I....A. . 
.M...A..
360
I
HWGVLAGLAYYSMVGN
...... V .......
/ / / / / / / / / / / / / / / /
* Reference sequence = HCVJK-1G (M. Honda, 1991 ; EMBL accession # X61596). For the remaining sequences, 
only points of nucleotide sequence divergence from HCVJK-IG are shown. Upper case letters indicate that 
changes would give a replacement of the encoded amino acid(s).
, 'V r
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Criteria for type designations were as follows:-
Type 1/1 a has the invariant residues QAILD from positions 341-435, respectively. The 
criteria for designating an isolate £i,s type ll/lb  included the presence of Val at position 148 
and at either position 345 or 346. Type IV/2b had a distinct amino acid sequence pattern 
between residues 342 and 351.
The HCV strain in Dix was genotyped as type IV/2b. Nucleotide and amino acid sequence 
alignments are shown (fig 4.7) for its coordination with reference type IV sequence HC-J7 
(Okamoto etal. 1992). Amino acids 331 - 360 (nucleotides 1332 - 1421) were compared.
Figure 4.7: Nucleotide (a) and amjpp acid (b) sequences used for genotyping HCV type IV.
(a) Alignment of reference sequence HC-J7 (nts 1331-1421) against homoiogous 
sequences from a presumptive HCV type IV/2b isolate
331 335 340 345
I I I I
T h r M et H e  Leu A la  T y r  A la  A la  A rg  V a l Pro G lu  Leu V a l Leu G lu  
1332 1379
H C -J7* ACC ATG ATC CTC GCC TAT GCC GCT CGT GTT CCT GAG CTA GTC CTT GAG
D ix  ..................................................... c . . a .....................................................................................a
347 350 355 360
I I  I I
V a l V a l  Phe G ly  G ly  H is  T rp  G ly  V a l V a l Phe G ly  Leu A la  
1380 1421
HC-J7 GTT GTC TTC GGC GGC CAT TGG GGC GTG GTG. TTT. QGC TTG GCC
D ix  . . .  C .........................................! . .  . . .  . . t  . . .  . . .  ................................
(b) Typing of HCV by amino acid sequence comparisons
3 3 0  3 4 0  3 5 0  3 6 0
I I  I I
HC-J7 TMILAYAARVP ELVLEWFGG HWGWFGLA
Dix      L. . . .........
’  Reference sequence = HCV-J7 (Okamoto era/., 1992). For Dix, only points of nucleotide sequence divergence 
from HC-J7 are shown. Upper case letters indicate that changes would give a replacement of the encoded amino 
acid(s).
Analysis of the number and types of changes in the region upon which typing was based 
revealed a high degree of intratype conservation. The 5 type 1/1 a isolates differed from the 
prototype by 4 - 9 (3 - 7%) of the 121-126 nucleotides sequenced. A similar degree of 
divergence was found in the types ll/lb  and IV/2b isolates. The differences were exclusively
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base substitutions, with transitions occurring overall 3.8 times as frequently as 
transversions. Where amino acid divergence occurred, the replaced residue was usually 
conserved in character. Amino acid sequence diversity ranged from 2.7 to 3.3%.
In contrast, nucleotide and putative amino acid sequence variability between the reference 
sequences representing the three (sub)types of figures 4.5 - 4.7, ranged from 27 - 60% and 40 
- 80%, respectively. The difference between types was greater than that between subtypes. 
Thus, the HCV-1 (type 1/1 a) nucleotide and deduced amino acid sequences differed from 
those of HCVJK-IG (type ll/lb) by 27% and 40%, and from HC-J7 (type IV/2b) by 60% and 
80%, respectively.
4.4 Intra-genotype HVR1 sequence diversity
The sequences from the genotyping region contrasted sharply with amino acid sequence 
divergence in the hypervariable region 1 (HVR1), which lies about 60 residues downstream of 
the region in E1 used for typing, from positions 384 - 410.
Figure 4.8: Deduœd amino acid sequenœs of the dominant HVR1 variant in several HCV 
isolates. (Absolutely conserved residues are emt)oldened. Underlined Gly residues 
were invariant in most (85%) of the sequences).
10 2 0
I I
BOV-l^E T H V T S A G H T V S G F V S L L A P G A K Q N
Har : Q . Y V S . . S Q A fl G A S I I T s't F S P . A Q . N
Wad : T. YTS . . S A A R D T A G L A S L F N L .  PK. T
Ad: E . H V T ..V A A H A T R G L S S L F S L .A Q .N
L3 : G . Y T T  . . A A G Q T T S G L A G L F N S  . AR . H
IGf: G . Y V S  V . H A S Q T T R R V A S F F S P .  SA. K
Fra: Q. HTT. . A V A R N T Y G N T A L L T R .  PS. Q 
LI: Q . H T V ..V A G S T T S G F A S L F K L . P S . K
Ml: G . Y V T . . A S G R T V H G F T G L F S L . P L . T
Cl: T . Y V T  . . S A A R R T Q H V T  S I F S F . S S . N
L2: Q . Y V T . . A S A R N T H G I A S L F A F . P A . K
J?3: S . Q V T .  . Q A A H T V R G V A S I F S P . S R . D
Dl: T . Y T T . A Q M G R G I F G F S N L F N L . S Q . K
-
1 HCV-1 (Choo eta/., 1991) -
2 HCVJK-IG (M. Honda, 1991; EMBL accession # X61596).
3 HC-J7 (Okamoto ef a/., 1992).
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Figure 4.8 shows the HVR1 amino/acid sequences for the types 1/1 a, ll/lb  and IV/2b isolates 
discussed above. A consensus HVR1 sequence was derived by determining the amino acid 
occurring with the highest frequency at each of the 27 HVR1 amino acid positions. The 
consensus sequence is shown in table 4.3, as well as the % frequency of occurrence in the 13 
samples analysed:-
Table 4.3: Consensus amino acid sequence for HVR1 derived from 13 HCV isolates
HVR1 position 1 2 3 ' . . A . 5 6 - ■ Z . 8 r 9 10 11 12
Consensus G T Y V : T G G S A A/G R T
% frequency 31 100 62 69 69 92 92 31 62 46 54 38
HVR1 position 13 14 15 16 17 18 19 20 21 22 23 24
Consensus T S G F A S L F S L G P
% frequency 54 31 70 38 46 77 77 92 46 46 100 38
HVR1 position % 26 27
1 ,
V,
Consensus S/Q Q N
% frequency 23 100 33
3 of the 27 HVR1 residues (Thr-2, Gly-23 and Gln-26, where the figures refer to the relative 
positions within HVR1) were consistently conserved in all 13 isolates compared. The amino 
acid Gly was usually (11 of 13 isolates) found in positions 6 and 7 of the HVR1. However, 
amino acid sequence divergence between any two isolates was never less than 41% in this 
region, and reached 67% in several intratype comparisons. There was no significant 
difference between intra- and inter-type variation in this region. The degree of divergence of 
these isolates from prototype sequences of other subtypes was not different from intra-
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subtype differences, strongly suggesting that the sequence variability in the HVR1 is 
independent of HCV genotype.
4.5 Variations in HCV antibody levels post-transplantation
Table 4.2 depicts values for antibody levels as determined by the ABBOTT anti-HCV 2nd 
generation kit. Values are determined for liver transplant recipients A1, C1, C2, F1, L1, M1 
and M2, as well as candidates for gLT A2, B1 and C3i and asymptomatic blood donors Dix, 
Ad and Wad. All determinations are given as ratios of sample absorbance reading to cut-off 
value. All assays were performed by G. Pearson.
Table 4.4: Absorbance readings for HCV. Dotted lines demarcate pre- from post-OLT 
readings.
Patient Sample Days post-OLT OD/cut-off ratio
A1 A1B1 -8 0.678
A1B2 -3 0.897
A1A1 - 0.383
A1A2 12 0505
A1A3 18 0.380
A1A4 25 0.429
A1A5 32 0550
A1A6 42 0.608
A1A7 49 0.535
A1A8 56 0.574
A1A9 70 0.696
A1A10 74 0.608
A1A11 96 0.620
A1A12 109 0.729
Cl C1B1 -24 5210
C1A1 8 4.529
C1A2 14 4.483
C1A3 38 4.319
C1A4 45 4.125
C1A5 83 5.532
C1A6 86 5283
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C1A7 218 6.626
C2 C2B1 -18 5.942
C2B2 -10 6.328
C2A1 3 6.161
C2A2 10 >6.687
C2A3 20 >6.687
C2A4 27 6.371
C2A5 41 5.967
C2A6 52 6.562
C2A7 55 6258
C2A8 69 6.316
C2A9 77 >6.687
C2A10 80 >6.687
C2A11 83 >6.687
FI F1A3 52 4.058
F1A5 120 6.134
F1A6 144 6.067
F1A7 234 - 4.514
LI L1B1 -17 >6.687
L IA I 8 >6.687
L1A2 36 6.450
L1A3 64 6289
LI A4 88 5.796
Ml M1B2 -24 3.763
M1B3 -15 3.769
M1B4 -9 3.702
M1A1 ' 4 1.714
M1A2 12 1.334
M1A3 18 1.641
M1A4 25 1.918
M1A5 32 2660
M1A6 42 2419
M1A7 49 2.836
M1A8 94 3.sæ
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M2 M2A1 3 0.927
M2A2 10 1.116
M2A3 14 0A14
M2A4 31 0.948
A2 A2-X NTx* 5.456
B1 B IX ND* 1.796
0 3 C3-X ND 5599
Ad . NA* 6.06
Wad NA >5.54
Dix D1N2 NA >6.687
* NTx = not transplanted; ND = not done; NA = not applicable
The correlation between absorbance (OD) readings and antibody concentrations was 
explained in chapter 2 (section 2.2).
These results helped to explain some of the puzzling PCR results from section 4.1.1. A l was 
antibody-negative both pre- and post-OLT, for all samples tested, a finding which is 
consistent with PCR results showing no evidence of HCV viraemia. However, analysis of 
peripheral blood leukocytes revealed the presence, confirmed by sequencing of the HVR1, of 
HCV in the lymphocytes. _
Antibody levels were high for 4 patients C l, C2, FI and LI. For the three patients (C l, C2 
and LI) for whom both pre- and post-OLT samples were available, post-OLT antibody 
levels, as assessed by OD readings, were similar to pre-transplantation values. OD/cut-off 
ratios apparently fell post-OLT in one patient (Ml), and tended to dip 1 - 3 months post-OLT 
in patients 01, C2 and LI. However, since no proper titration was performed, these 
differences were not considered significant.
As discussed in section 4.1.1 above, pre-transplantation samples for B1, C3 and M2 wore 
repeatedly PCR-negative for HCV sequences. One possible reason is a level of viraemia too
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low for detection by the method used, at least for both M2 and B1. Although unlikely, another 
possible reason is infection by an HCV strain sufficiently divergent to prevent annealing of 
the PCR primers, and which induces antibodies that do not react with the kit antigens. M2, 
who is of Egyptian origin, may have been infected with the predominant type 4 Egyptian 
strain. This would also explain the patient's borderline antibody response.
4.6 Spurious sequences amplified with HCV E1/E2 primers
Primer 3766 (inner sense primer, see section 2.6.1, table 2.1) was used as a sequencing primer 
to determine the HCV genotype in all samples. In a significant number of cases, a non-HCV 
sequence was obtained from white blood cells. The spurious sequence, which was amplified 
from leukocytes of 4 patients (Al, C l, C2 and Dix) and from plasma of patient FI, is 
depicted in figure 4.9.
Figure 4.9: Non-HCV sequence amplified from white blood cells of HCV-infected subjects
CACCCTTGAG AGTTGAAGGG TCGGAAACGC CCTACGTGGA
CAGGACACCC GGCCCAGCTT TTAAGGTGGG TTGTGGTGAT
This finding was surprising in view of the high specificity of the RCp primers, combined with 
the fact that nested PCR with two sets of primers was carried out, and that the PCR DNA 
band which gave rise to non-HCV sequences was indistinguishable by size from the HCV- 
specific band. Indeed, mixed HVR1 and spurious sequences were obtained from clones 
originating from the same amplicon (figure 4.10). The unusual sequence is most likely a part 
of the human genome because:-
• it was obtained mostly from leukocytes and not plasma, consistent with the human 
genomic content of the former;
• it was identical in 5 unrelated patients
Where the leukocytes had been sub-divided into lymphocyte- or polymorph-enriched 
populations, the non-HCV sequence was found exclusively in the polymorph fraction. 
Submission of the sequence to the various data banks revealed a lack of coding potential for 
this fragment.
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Figure 4.10: Sequences derived from Dix using E1/E2 primers showing random distribution of 
HCV and non-HCV sequences.
'  f  ^  ■ r # r
i l
r i .  1 1 - 1 I .
Lanes were loaded in the order; TCGA. Nos. 1 - 5 = non-HCV sequences. Nos. 6 - 8 -  HCV sequences
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CHAPTER FIVE: HVR1 SEQUENCE VARIABILITY IN IMMUNOSUPPRESSED AND 
UNTREATED SUBJECTS
The HCV HVR1 is known to induce neutralising antibodies (Shimizu etal. 1994; Zibert etal. 
1995). In order to assess the effect of host immune pressure on genomic variability in this 
region, serial samples obtained from immunosuppressed liver transplant recipients were 
analysed. Sets of at least 8 HVR1-containing cDNA clones were sequenced for each patient, 
and compared with similar data obtained from untreated, asymptomatic blood donors infected 
with HCV. For each set, the typing region (nucleotides 1330 - 1425) was also sequenced, to 
confirm that it remained essentially unchanged. Table 5.1 sums up the clinical histories of the 
seven individuals from whom serial samples were obtained. Asymptomatic individuals were 
designated patients 1 - 3, while the immunosuppressed patients were designated patients 4 -7.
Table 5.1 : Clinical histories of immunosuppressed and untreated HCV-infected subjects
Subject Sex Age Diagnosis^
HCV
subtype^
Clinical
outcome
Country of 
origin
Asymptomatic HCV hosts - untreated
1 Wad M 32 CAH l/ la alive UK
2 Dix M 44 CAH IV/2b alive UK
3 Fra F 37 CRH ll/lb alive UK
Immunosuppressed OLT recipients
4 01 M 56 CIRR/HCC ll/lb dead Italy
5 L2 M 48 CIRR ll/lb dead UK
6 LI M 66 CIRR ll/lb alive Italy
7 L3 F 46 CIRR l/ la alive Italy
1 CIRR - cirrhosis; HCC - hepatocellular carcinoma; CAH - chronic active hepatitis; 
CRH - chronic persistent hepatitis (defined on the basis of liver biopsies).
Roman and Arabic numerals refer, respectively to the Okamoto (Okamoto et al. 
1992) and Simmonds (1995) classification systems - see section 1.5.3.
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Figure 5.1 : Nucleotide (a) and deduced amino acid (b) sequences for HVR1 of
asymptomatic blood donor Wad (patient 1)
(a) HCV HVRl NT SEQUENCES: Reference 1 (Wad)
1 10 20
I I I
Hu: Thr Tyr Thr Ser Gly Gly Ser Ala Ala Arg Asp Thr Ala Gly Leu Ala Gly Leu Rte Asn Leu Gly Pro lya Gin Thr 
0 days I -  Ho. of
ACT ACC TAC ACC AGC GGG GGG ACT OCT GCC AGO GAC ACQ OCT GGA CTC GCC GGC CTA TTC AAC CTG GGC OCC AAG CAG ACA clones
WADlOl
267 days I-
.C. ... T.. .CG ... .T. ..g ... C.. .0. .C. ... G.
(b) HCV HVRl AMINO ACID SEQUENCES: Reference 1 (Wad)
+ 1 1 0  2 0
I I I
T T Y T S G G S A A R D T A G L A G L F N L G P K Q T  No.  of  
0 days: -  c lo n o s
WADI01   4
WADOOl/114.............................................  S . . .    5
267 days I-
WAD203 ...................................................................................................................................................................................  7'-
WAD202 ...................................................................... A . S A . V . . L S P . A . . N  4
Dots (.) indicate nucleotide (a) or deduced amino acid (b) sequence Identical to 
dominant sequence of first time point. Silent mutations shown In lower case. Nt. 1 
corresponds to nt 1489 of HC-J8 (Okamoto et al., 1992).
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&1 HVR1 sequence variability in asymptomatic HCV-infected individuals
Patient 1 (Wad): Three HVRl genomic variants were detected in the first plasma sample 
from patient 1 (Wad). As depicted in figure 5.1, these species coexisted in a ratio of 4:4:1, 
represented by WADI01, -001 and -114, respectively. All three were similar (maximum 
nucleotide sequence diversity = 2.5%). The second sample was obtained 267 days after the 
first. At this time point, two variants were present, in a ratio of 7:4 (represented by 
WAD203 and 2 0 2 , respectively). One (WAD203) was identical to WADI01, but the other 
(WAD202) was extensively mutated, with 14 base substitutions in the 81-nucleotide HVRl. 
Most (9/14 or 64%) of the changes were in the first or second codon positions, leading to the 
replacement of 9 of the 27 deduced amino acids. Furthermore, most (6/9) of the amino acid 
changes were non-conservative. Nucleotide sequence diversity in this sample reached 17.3%. 
The sequences corresponding to WAD001 and WAD114 were undetectable at time point 2.
Patient 2 (Dix): The HVRl quasispecies population in untreated patient 2 was determined at 
three time points, the second and third time points being 457 and 719 days after the first. 
Results are depicted in figure 5.2. At the first time point, two genomic variants were 
observed. The minor sequence (represented by PDN113) differed from the first (PDN111) by 
11 nucleotides (13.6%), leading to a deduced amino acid sequence diversity of 7/27, or 26%. 
The quasispecies population changed considerably in the 14 months between the first and 
second time points. By time point 3, even greater diversity was found (up to 21% nucleotide 
difference), with the number of unique HVRl species rising from 4 to 10.
Nucleotide sequence diversity between PDN113 and the original dominant sequence PDN111 
occurred at HVRl positions 25,26,27,37,38,48,49,55,62,66 and 81. The mutations in 6 
of these positions (26,38,48,49,55 and 62) were retained in 11 of 14 clones of time point 
two, implying the same lineage for both sets of sequences despite the 457-day interval. The 
lineage apparently persisted until time point 3, as most of these mutations were maintained in 
a significant number (6/11) of clones obtained at the final time point.
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Figure 5.2: Nucleotide (a) and deduced amino acid (b) sequences for HVR1 of
asymptomatic blood donor Dix (patient 2)
(a) HCV HVRl NT SEQUENCES : Reference 2 (Dix)
1 10 20
I I I
H it Thr Tyr Thr Thr Gly Ala Gin Met Gly Arg Gly lie Thr Gly Phe Ser Aen Leu Phe Asn Leu Gly Ser Gin Gin lys 
0 days I -
PONlll ACA ACC TAT ACC ACC GGA GCA CAA ATG GGC AGA GGC ATT ACG GGG TTT TCT AAC CTC TTC AAC TTG GOT TOC CAG CAG AAG
rawiii .......................................................................................................................................
 GC..........G G.....T....... G. . a ................ CÏTO113
457 day#: -
FCN268 G. . 
FDN265
TCA
.C. G.. .CA ..G G. • G. T. 
. .G . .
A .G.
PT»319
FDN320
... A.. .C. TG. .C. ..G G. 
CA. .C. GC. GG...... c G.
.G. CC. 
•G. ...
PCN266 .G. . ....... C. . GC. 0. .A. . ..G G.. .0.
PCH267 G. . . .CC ..G G.. .G. T.. . A .0. .. c.. .
719 days : -
nxool ... . ... T.. , ,A .0. .. c.. .
PON302 ... . ..... GC. . .... A. . .r. TG. • C. ..c G.. ... T.. .0. CC. ... G.. .
HM303 ... . .... A.. .c. TG. ,c. Ilf Q*1 Ill Til 1 1 1 iG, CC, 11 ! Gl 1 !II III 1 1 1
nxoo4 ... . ..... GC. . • C. IT. • C. . G G. . ..G T.. .0. .. G.. . . ./
FCN305 ... .
PDN307 ... . GC. ,T .G.
PDN316 ... . ..... GC. . ....A ,c. TG. .C. ..G G.. ... A. . .G.
1PIM31B ... . GC. .T. . . AC.
Ho. of
3
2
11
1
1
1
2
1
1
1
1
1
1
1
1
1
PDNlll 
0 days I-
PDNlll
PDN113
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES: Reference 1 (Wad)
+ 1 1 0  2 0
I I I
T T Y T T  G A Q M G R G I  T G F S N L F N L G S Q Q K
457 days I-
PDN268 A 
PDN265 
PDN266 R 
PDN267 A 
719 days I- 
PIR«301 
PDN302 
PI»n03 
PCN304 
PDN305 
Piai307 
PDN316 
IPDN318 
PDN319 
PDN320
T A A L A S F L S  .
Q ................. K . . . M
N . A A R L A S F . S .
T A A L A S F L S
T A A L A 
S T W A . A
S T W A . A
S S T L A L A
K A ............
G . A M . . .
S T W A L A
A M . . .  
S T W A L A
Q A A G . A
F L S .
F . S P
S P 
S 
K 
S 
S
S P
s
Ho. of 
clones
3
2
11
1
1
1
D o ts  C) Ind ica te  nuc leo tide  (a) o r  d e d uce d  am ino  a c id  (b) sequence  Id e n tica l to
d o m in a n t sequence  o f firs t tim e po in t. S ilen t m u ta tions  show n In lo w e r case. Nt. 1
co rresp on ds  to  n t 1489 o f H C -J8  (O kam oto  e t al., 1992).
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Patient 3 (Fra): Figure 5.3 shows the HVR1 quasispecies distributions in three samples 
collected from patient 3 during a three-month period. Dynamic fluctuations were observed - 
none of the quasispecies detected in the final sample had been present at the initial sample 
time point. Interestingly, the number of molecular species detected rose from 3 to 8  in the 4- 
week period between the first and second samples. By the third time point (approximately 
two months after the second), the number of species had fallen to 2 . Considerable nucleotide 
and amino acid sequence diversity was observed at all time points, similar to that found in
patient 2, although in patient 3 the samples were obtained over a considerably shorter period.
.
f  r -
In the initial sample, the dominant sequence (denoted by FRA104) represented 9 of 11 clones, 
a tenth clone (FRA101) differing by only one nucleotide. The other minor variant (FRA110) 
was considerably different, with a nucleotide sequence divergence of 22% (18 of 81 
nucleotides) from the dominant sequence. Replacement mutations in this sequence 
corresponded to 13/27 (48%) amino acid changes, only 4 of them conservative. A decline in 
the relative proportion of the FRA104 sequence (which made up 82% of the initial population) 
was noted at the intermediate time point, when it comprised 25% of the population sequenced. 
Only 5 of 12 clones were still cleady related to the initially dominant FRA104 quasispecies at 
time point 2. All five had none or a single base substitution, and a deduced amino acid 
sequence identical to the FRA104 sequence. The remaining 7 clones, which sometimes 
differed substantially from each other, appeared nevertheless to be mutants of FRA110, a 
minor variant of the first time point. Index mutations at nucleotide positions 1,22,25,37,43, 
52,58,62,63,65 and 79 were present in all. Furthermore, they shared 6 amino acid 
replacements, as well as up to 8  additional amino acid changes.
In the third sample, collected two months after the second, each of the two molecular species 
(symbolised by FRA301 and 302) was clearly related to either FRA104 or FRAUD, the 
major and minor variants, respectively, of the first time point. However, the lineage of 
FRAUD (FRA3D1 and others) had become dominant, accounting for 7 of the 12 clones 
sequenced. The “FRA3D2 series" showed amino acid sequences Identical with that of 
FRA1D4.
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Figure 5.3: Nucleotide (a) and deduced amino acid sequences (b) for HVR1 of
asymptomatic blood donor Fra (patient 3)
(a) HCV HVRl NT SEQUENCES: Reference 3 (Fra)
1 10 30
I I I
Gin Thr His Thr Thr Gly Gly Ala Val Ala Arg Asn Thr TVr Gly Leu Thr Ala Leu Leu Thr Arg Gly Pro Ser Gin Gin
0 days 1
FRA104
CAA ACC CAC ACG ACA GGG GGG GCA GTC GCC CGC AAC ACC TAC GGG CTT ACG GCC CTC CTC ACA OGT GGG CCG TCT CAO CAA
9
FRAlOl 1
FRAllO G.... GC. G. . AA. T. . T.... T. . .AC .T....... ..C ... A.. 1
24 daysi-
FRA202 ..... 3
FRA201 G.... . . . O T ............................. CAA • G. • T. GT. A. . A.A T. . T.. T.. T. . .AC •T....... ... AG. 2
FRA206 G.... GC. G. . AA. .AC .T....... ... A.. 2
FRA211 •G. QT....... ... A. . CAA • G. • T. GT. A. . A A T. . G. . T.. T.. T. . .AC • T....... ... A 1
FRA203 1
FRA210 G.... CAA .G. • T. GT. A. . A.A T. . T.. T.. T. . .AC • T....... . . .  A 1
FRA312 ..C 1
FRA205 G.... ... QT....... ... A. . CAA • G. • T. QT. A . A A T.. T.. T. . .AC • T....... ... AG. 1
87 daysi-
FRA301 G.... ... GT....... ... A. . CAA • G. • T. GT. A . A A T, . T T .AC • T....... ... A.. 7
FRA302 5
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES: Reference 3 (Fra)
+ 1 1 0  2 0
I I IO T H T T Q Q A V A R N T Y G L T A L L T R G P S g Q
0 days I-
FRA104
FRAlOl
FRAllO E . 
24 days I-
T L H A A
P
S S . F N L .
No. of 
d o n a s
9
1
1
FRA202 3
FRA201 E V T Q G I V N R F S F F N L R 2
FRA206 E . T L . H A A K S S F N L K 2
FRA211 E R V T Q G . I V N R F A s F F N L . K 1
FRA203 1
FRA210 E . V T Q G I" :vr N R F s F F N L K 1
FRA212 1
FRA205 E V . T Q G I V N R s F F N L R 1
87 days I-
FRA301 E V T Q G I V N R F s F F N L K 7
FRA302 5
D ots  (.) ind ica te  nuc leo tide  (a) o r  ded uce d  am ino  a c id  (b) sequence  Id e n tica l to
dom in a n t sequence  o f firs t tim e po in t. S ilen t m u ta tions  show n In lo w e r case. Nt. 1
co rresponds to n t 1489 o f  H C -J6  (O kam oto  er a l., 1992).
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Figure 5.4: Evolutionary tree of HVR1 sequences in asymptomatic blood donor Fra (patients)
l:C-0 
22:G-A 
25:6-C 
27:Q-ft 
32:0-A 
34:A-0 
35:A-C 
37:A-0 
43:G-A
[1 ]
FRA
110
44:G-A 
49:A-T 
52:G-T 
58:C-T 
62:C-A 
63 :A-c 
65:G-T 
75:T-C 
79:G-A
(d 0)
[9]
FRA
101
27:A-g
-75:C-t
73:T-C
[1 ]
FRA
101
[2 ]
(d24)
FRA
206
[3]
FRA
202
75 :T-C27 :C-t[1 ]
FRA
210
[1 ]
FRA
212
[1 ]
FRA
203
-46:T-C
75:T-c
80:A-O
80:A-O
[1 ]
FRA
205
[1 ]
FRA
211
[2 ]
FRA
201
42:C-t (d87)
[5]
FRA
302
[7]
FRA
301
Nature and positions of nucleotide sequence divergence from major quasispecies (FFIA101 sequence) shown for 
three time points. Replacement mutations indicated by capitalized, emboldened letters, silent mutations by smail 
ietters. Eg., *35;T-c* = silent T to C mutation at position 39 of HVR1. In reverse mutation pos'rtions, the minus 
(■) sign precedes the HVRl nucieotide position. Boxed mutations (prst time point only) represent posilions of 
nucleotide sequence divergence from dominant quasispecies.
Figure 5.4 shows the deduced evolutionary relationships between the various clones from Fra. 
It can be seen that underlying the numerous mutations is a certain degree of consistency.
The sequences of the first time point, as well as all mutants observed thereafter, may be 
roughly divided, on the basis of nucleotide sequence similarities, into two groups or "families".
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corresponding to either FRA104 orJ^pA110. Thus, of the 8  variants detected at time point 2, 
the FRA202, -203 and -212 entities, representing 5/12 clones, or 42% of the quasispecies 
population, are identical with, or unambiguously related to, the FRA101 "family". The remaining 
5 species, represented by FRA201, -206, -211, -210 and -205, are evidently derived from 
FRAllO, despite a nucleotide and amino acid sequence divergence reaching 31% and 67%, 
respectively. Likewise, the FRA301 set of clones for time point 3, which constitute a single 
variant representing 7 (52%) of 12 clones, are related to FRAllO, while the FRA302 variants 
have the FRA104 progenitor.
5,2 HVRl sequence variability in HCV-infected liver transplant recipients
HCV HVRl sequences were obtained from four patients, who each received a liver allograft for 
end-stage cirrhosis and were followed up for 3 to 15 months. Sequences were obtained within 
the month preceding and by two months following OLT for 3 patients (01, LI and L3). For an 
additional liver transplant recipient, L2, sequences were obtained corresponding to five time 
points spanning one year post-OLT.
Patient 4 (C1): A marked lack of nucleotide sequence diversity was evident in sequences 
obtained from immunosuppressed OLT recipient 01, which was even more pronounced at the 
amino acid level (Fig 5.5). Although 6  molecular variants were detected pre-OLT, they differed 
from each other and from the major sequence by no more than 5 nucleotides, and 8 of 9 points 
of nucleotide sequence diversity gave the same deduced amino acid as the major sequence. 
The number of variants detected had fallen to two by 8 days post-OLT, and a minor pre-OLT 
species, carrying a replacement mutation (lie to Leu) had become the predominant post-OLT 
strain.
Prior to transplantation, 6 variants were detected among 13 clones derived from recipient 01. 
Distributed in the ratio 7:2:1:1:1:1, they are represented by SCB002, -004, -010, -012, -013 and 
-014 in figure 5.5. As observed with the asymptomatic HCV hosts, there appeared to be two 
■families" of HVRl sequences. The first comprised the dominant sequence (SCB002)
, . _ 1 2 6.(fU . . -.4.. u
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Figure 5.5: Nucleotide (a) and deduced amino acid sequences (b) for HVR1 of liver
transplant recipient C1 (patient 4)
(a) HCV HVRl NT SEQUENCES: Cl
1 5  10 15 20 25
I I I I I I
Hir Thr IVr Val Thr Gly Gly Ser Ala Ala Arg Arg Thr Gin Hie Val Thr Ser lie Phe Ser Phe Gly Ser Ser Gin Asn
Pre-OLTI -
SCB002 ACC ACC TAC CTO ACG GGG GGG TCA GCA GCC CGC GGA ACT CAG CAT GTG ACA TCC ATC TTT TCA TTT GGG TGG TCT CAG AAC
SCB004 . . t .......................... g ............c .................................................
SCBOlO ........................................... c ......... a
SCB012 ........................................ c ..........
SCB013 .............. a .......................... c ..........
9CB014 ........................................................
8 days poat-OLTi-
PCA115 .........
PCA116 .........
86 day# poat-OLTi-
PCA605 ...........
218 day# post-OLTi-
PCA702 ............
FCA704 III III 111 III 
PCA707 ............
329 days poat-OLTi-
PCA801 ............
PCA809
PCAB08
.t C. 
• t C. 
■ t C.
• t C. 
.t C.
• t C. 
.t C.
• t C.
• t C.
.. c.
.t c. 
• t c.
Ho. of 
clone#
7
2
1
1
1
1
10
1
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES: Cl
+ 1 1 0  2 0 
P re -O L T I -  I I I
SCB002/ T T Y V T G G S A A R R T Q H V T S I F S F G S S Q N
004/014 ....................................................................................
SCBOlO/0
0 1 2 / 0 1 3 .......................................................L .........................
8 day# po#t-OLTt-
PCA115/16.......................................  L .........................
86 day# po#t-OLTi-
PCA605 .................................   L .........................
218 day# po#t-OLTi-
PCA702/4 .......................................................L .........................
PCA707 ............................................ Y . . . L .........................
329 day# po#t-OLTi-
PCABOl/04
09/08  L .........................
No. of 
clone#
10
3
11
10
1
12
D ots  (.) in d ica te  n uc leo tide  (a) o r  d educed  a m ino  a c id  (b) sequence  id e n tic a l to
dom in a n t sequence  o f  firs t tim e po in t. S ilen t m u ta tions  show n in  lo w e r case. N t. 1
co rresponds  to n t 1489 o f H C -J8  (O kam oto  e t a l., 1992).
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and two minor species (SCB004 and -014), and accounted for a total of 10 clones, or 77% of 
the 13 clones sequenced. The second "family" shared divergence from SCB002  at positions 
39,54,55 and 6 6 . Only one divergent nucleotide (C for A at position 55) led to an amino acid 
replacement - Leu for lie at amino acid 19 of the HVRl.
Figure 5.6: Evolutionary tree of HVR1 sequences in patient C1
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(218 d)
27:A-g 63:A-g
[7]
PCA
801
[2 ]
PCA
809
[1 ]
PCA
808 (329 d)
Nature and positions of nucleotide sequence divergence from major species (SCB002 sequence) shown for pre- 
OLT time point, as well as for mutants seen thereafter. Silent mutations indicated by smail letters, replacement 
mutations capitalized and emboldened. In reverse mutation positions, the minus (■) sign precedes the HVR1 
nucleotide position. Boxed mutations (first time point only) represent points of nucieotide sequence divergence 
from major pre-OLT variant.
128
Chapter 5: Immunosuppressbn & the HVR1
By 8 days post-OLT, the minor "family" of variants had become exclusive, remaining so 
throughout the approximately one year of follow-up. The highest value for HVRl nucleotide 
sequence divergence was 8 .6% for the first sample, and never exceeded 2.5% in any 
subsequent sample. Nucleotide sequence diversity was reduced to 0% in the population of 
clones obtained 86  days post-OLT, and maximal amino acid sequence diversity for any time 
point was 4%. This was in marked contrast with HVRl sequences from patient 3 (Fra), in 
whom maximal nucleotide sequence diversity at the 3 time points (1 - 3) sampled were 23.5%, 
30.9% and 28.4%, respectively. The corresponding values for amino acid sequence 
divergence were 58%, 67% and 59%. As with patient 1 (Fra), the sequencing results can be 
presented as an evolutionary tree, shown in Figure 5.6.
Patient 5 (L2): As with patient 01, HVRl mutations observed in patient L2 during a year of 
follow-up were few and predominantly silent (see fig. 5.7). The dominant sequence remained 
essentially unchanged for all time points examined.
5 serum samples, collected 1 ,3 ,6 ,12 and 15 months post-transplantation, were anafysed. A 
pre-OLT sample could not be obtained for this patient. In the first sample, obtained 31 days 
post-OLT, the 5 detected HVRl variants were arranged in the ratio 8:2:1:1:1, represented, 
respectively, by XL2A05, -A04, -AOJ, -A13 and -AI4  (figure 5.7). 11 of the 13 clones fell into
I, ■
the same "family", 8  of them constituting the dominant species. A minor "family" of two clones 
had in common nucleotide mutations at positions 3,6,10,11,22,25,26,30,35 and 40 (also 
see figure 5.8).
At three months post transplantation, the XL2A05 sequence remained dominant (see 
XL2C02) in a species partitioning of 6:5:1 representing XL2C02, -C03 and -Cl 6 , respectively. 
The latter two, although mutated, were clearly derived from the same “family" as XL2A05.
In samples taken at 6 and 12 months post-OLT, the XL2A05 sequence persisted as the 
dominant species (7 7% and 93% of the respective populations), with a maximum nucleotide 
sequence diversity of only 1.2%. Amino acid sequence diversity remained 0%, as for the 
preceding time point. The last time point corresponded to two weeks following a second
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Figure 5.7: Nucleotide (a) and deduced amino acid (b) fsequences for H VR l o f liver
transpiant recipient L2 (patient 5)
(a) HCV HVRl NT SEQUENCES: L2
10 20
Gin Thr lyr Val Hir Gly Gly Ala Ser Ala 
31 daya poat-OLTl i-
CAA ACT TAT GTG ACA GOO GGG GOG TCA GCC
rr.ganR
Arg Aan Thr Hi# Gly lie Ala Ser Leu Phe Ala Phe Gly Pro Ala (Ün 14m 
AGA AAC ACC CAC GGG ATA GCG TCC CTC TTT GCC TTT GGA CCG GCT CAG AAA
XL2A04 g
XL2A07 • T . .c ... AC...........T.. CA. ..t .C. ... T
XL2A13 ... G..
XL2A14 .T . .c ... AC...........T. . CA. . .t CC. ..g ... T........
97 day#
XT.3r03
poat-OLTl:-
rr.gmi c g .... t g
XL2C16 g
180 day# 
XL2F02
poat-OLTl1-
XL2F05
334 day#
XL2Y03
poat-OLTli-
XL2Y10
435 day#
PL2102
poat-OLTl (17 day# poat-OLTZ):-
FL2109 g .G. ...
PL2115 g
PL3118
Ho. of
clone#
8
2
1
1
1
10
3
13
1
11
1
1
1
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES: L2
+ 1 1 0  2 0
I I I
Q T Y V T G G A S A  R ^ N  T H G I A S L • • F A F G P A Q K No. Of
31 day# po#t-OLTlt- olonoa
XL2A05/04 : .    10
XL2A07 H . . T . . . S Q . . T . Y ....................................... 1
X L 2 A 1 3 .......................   A ............................................... / 1
XL2A14 H . . T . . . S Q . . T . Y ......................P .  . S . . /  1
97 daya post-OLTl
XL2C02/03/
1 6  "   12
180 daya poat-OLTl
XL2F02/05....................................................................................  13
334 daya poat-OLTl
XL2Y03/10................................................................... ■ .............. 14
435 daya poat-OLTl (17 daya poat-OLT2)
PL2102 : ................................................................................   11
RL2109 S . . . . . . . . . .  1
P L 2 1 1 5 .................................. ^  . . . V  ' . S .............  1
P L 2 1 1 8 ..........................................................L ......................  1
Dots (.) indicate nucleotide (a) or deduced amino acid (b) sequence identical to
dominant sequence of first time point. Silent mutations shown in lower case. Nt. 1
corresponds to nt 1489 of HC-J8 (Okamoto et al., 1992).
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transplant, 0LT2 (435 days post-OLTl). Nucleotide and deduced amino acid sequence 
diversity increased slightly to 2.5% and 3.7%, respectively, but the "XL2A05" sequence 
represented 78.5% of the sequenced clones.
Figure 5.8: Evolutionary tree of HVR1 sequences in patient L2
31 d post-OLT
[8] 
XL2 
AO 5
[1 ]
XL2
A07
[1]
XL2
A14
fcU :T-c
6 4 :T -C
65:T-C
69:A-0
73;G-T
3:A-T
6:T-c
10:G-A
11;T-C
22:G-T
75TT=Ü"
26:C-A*
30:C-t
35:A-C
40:C-T
[1]
XL2
A04
37 :A-0
[1 ]
XL2
A13
[6 ]
XL2
C02
33 : A-g 6:T-c
63:C-t
[1 ]
XL2
C16
[3 ]
XL2
[10]
XL2
97 d post-OLT
I 6:T-c 
27:A-g 
39:C-t 
[5 ] 60:T-c 
XL2 
C03
180 d post-OLT
F05
334 d post-OLT27 ;A-t
[13 ]
XL2
Y03
[1 ]
XL2
,Y10
435 d post-OLT65:T-C 35:A-0
58:t-C
[1 ]
PL2
118
[1]
PL2
115
[11]
PL2
102
Nature and pos'rtions of nucleotide sequence divergence from major species (XL2A05 sequence) shown for five 
post-OLT time points. Silent mutations indbated by small letters, replacementMutations capitalized and 
emboldened. * indbates mutation produces stop codon. In reverse mutation positions, the minus (-) sign 
precedes the HVRl nucleotide position. Boxed mutations (first time point only) represent points of nucleotide 
sequence divergence from major variant at 31 days.
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Patient 6 (LI): Two samples were obtained from this patient, one pre- and one post-OLT. The 
3  molecular species observed pre-transplantation are represented in figure 5.9 by SLB001,
-003 and -015, found in the ratio 8:3:2, respectively. SLB003, which differed from SLB001 at 
one nucleotide position encoding a silent mutation, together with it comprised a single family 
representing 85% of the clones sequenced. The second minor variant detected (SLB015) 
accounted for a nucleotide sequence divergence of 9.9%. 7 of its 8  nucleotides which diverged 
from SLB001 were replacement mutations, leading to an amino acid sequence divergence of 
6/27, or 22.2%.
The second sample from patient 6  was taken 3 months post-OLT (four months after the first 
sample). The number of HVRl sequences detected had increased to 6 . in the ratio 6:4:1:1:1:1, 
represented in fig. 5.8 by PLA402, -404, -424, -420, -403 and -406, respectively. However, 
maximal nucleotide sequence diversity had decreased slightly, from 9.9% pre- to 7.4% post­
transplantation. All post-OLT variants had been undetectable in the pre-OLT samples.
However, PLA402, -404, -424 and -420 were clearly mutants of SLB015, while PLA403 and 
-406 were probably derived from SLB003. Therefore, as in patient 4 (01) and patient L3 
(discussed below), a pre-OLT minor species became dominant after transplantation.
Patient 7 (L3): The 10 clones sequenced pre-OLT showed significant homogeneity of the 
HCV HVRl population. Two variants were observed, in a ratio of 9:1, represented in figure 5.9 
by PL3001 and -022, respectively. By A7 days post-OLT, the minor pre-OLT variant had 
become almost exclusive, constituting 11 of the 12 clones sequenced (represented by 
PL3101). A minor (8.3%) species (PL3107) was also detected at this time point, which may 
have arisen independently of PL3022. All 3 amino acid changes were unique, and two effected 
non-conservative changes, including a Ser to Pro alteration. Nucleotide and amino acid 
sequence diversities were comparable pre- and post-transplantation.
•
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Figure 5.9: Nucleotide (a) and deduced amino acid (b) sequences for HVR1 of liver
transplant recipient L1 (patient 6)
(a) HCV HVRl NT SEQUENCES: LI
1 5  10 15 20 25
I I  I I I  I
Oln Thr His Tlir Val Gly Oly Val Ala Gly Ser Thr Thr Ser Gly Pbe Ala Ser Leu Phe lya Phe Gly Pro Ser Gin lya Bto. of 
Pre-OLTi clonei
33 days pre-OLTi
SLBOOl TAA ACT CAC AOG GTA GOG GOG GTG GCA GGC TOC ACC ACC TCT GGG TTT GOG TOC CTO TTC AAG TTT GGQ CCO TOT CAG AAA 8
SLB003
SLB015 .T T. T................ A CA CG.
Poat-OLT (88 days)I-
PLA402 ................
PLA404 ............... g
PLA424 .............. G.
PLA420 ............... r
PLA403 ...............................................
PLA406 ............. A. .
A..............GA C.
A..............GA C.
A..............GA C.
A..............GA C.
............... a C.
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES: LI
1 1 0  .. 2 0 
Pre-OLTi I I I
SLB O O l/ Q T H T V G G V A G S T T S G F A S L F K F G P S Q K
003 ...................................................................................................................................................................
SLB015 ............................................  V . F S . . . . T . . . T R .............................
Poat-OLT (88 days)I
P L A 4 0 2 /0 4 .............................................................L ...............................T
PLA424 . . . . G ............................. L ...............................T
PLA420 . . . . T ........................................................................T
PLA403 .....................................................................................................
PLA406 . . . .  I  .....................................................................
R L 
R L 
R L  
. L  
. L
N o . o f  c lo n e s
11
2
10
1
1
1
1
Dots (.) indicate nucleotide (a) or deduced amino acid (b)- sequence identical to 
dominant sequence of first timè point. Silent mutations shown in lower case. Nt. 1 
corresponds to nt 1489 of HC-JS'(Okamoto et al., 1992).
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Figure 5.10: Nucleotide (a) and deduced amino acid (b) sequences for HVR1 of liver
transplant recipient L3 (patient 7) f
(a) HCV HVRl NT SEQUENCES: L3
1 10 15 20 25
I I I  I I I
Oly Thr Tyr Ibr Ihr Gly Gly Ala Ala Gly Gin Thr Thr Ser Gly Leu Ala Gly Leu Phe Aan Ser Gly Ala Azy Oln Hia I Ho. of 
Pre-OLTi- clones
31 61 91
PL3001 GQC ACT TAC ACC ACC GOG GGA GCT OCC GOA CAG ACC ACA AGC GGG CTC GOC GGC CTC TTT AAT TCA GGG OCT AGA CAG CAC A 9
PL3022 .............................................C......................... C A ......................  1
Poat-OLT (47 days)i-
PL3101 .............................................C......................... C A ......................  11
PL3107 /// /.................................................A.................. A C ..................... 1
(b) HCV HVRl DEDUCED AMINO ACID SEQUENCES : L3
+ 1 1 0 2 0 No. of
I I I clones
P L 30 01  G T Y T T G G A A G Q T T S G L A G L F N S G A R Q H  9
P L 3022  R .T .............................. 1
P L 31 01   R .T .............................  11
P L 3107  /  / ............................................................................... I . . . . K P .............................  1
Dots (.) indicate nucleotide (a) or deduced amino acid (b) sequence identical to 
dominant sequence of first time point. Silent mutations shown in lower case. Nt. 1 
corresponds to nt 1489 of HC-J8 (Okamoto et al., 1992).
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5.3 Long-term evolution of HVRl quasispedes populations In Immunosuppressed liver 
transplant recipients
In two patients (C1 and L2), HCV HVRl sequences were determined from serial samples 
obtained over 5 time points spanning approximately onp year. In‘both cases, the dominant 
molecular species found immediately post-OLT remained virtually unchanged over the 
observation period. The few detected mutants differed from the major sequence at no more 
than one of 27 deduced amino acid positions. This relative sequence homogeneity contrasted 
markedly with results from the asymptomatic HCV hosts Wad, Dix and Fra (patients 1 - 3), 
who had received no immunosuppressive treatment and were followed up over similar time 
intervals. In Wad (patient 1), after 9 months a previously-undetected variant accounted for 4 
of 11 sequences (Figure 5.1). Similarly, in Dix (patient 2, see figure 5.2), after 14 months, the 
initially-dominant variant had become undetectable, while the minor variant had acquired a 
substantial number of mutations. In both untreated casés, these mutations effected nine 
deduced amino acid substitutions of the 27 total amino acids comprising the HVRl 
(Figures 5.1(b) and 5.2(b)).
5.4 HVRl quasispedes distribution pre- and immediately post-transpiantation
The HVRl sequences of C l, L3 and LI (patients 4, 6  and 7, respectively) were determined 
within the month preceding and 2 - 3 months post-OLT. In each case, a minor species or 
closely related variant of the pre-OLT population became dominant or exclusive post-OLT. 
However, the total number of variants was reduced only in one patient (01), from 6  pre-OLT 
to a single variant at time points one week and 3 months post-OLT (Table 5.2). The number 
of variants remained the same in L3, and increased from 3 to 6  in LI. In C l, only one of 5 
observed mutations led to an amino acid replacement, which was a conservative He to Leu 
change (figure 5.5(b)). In both C l and L3, mutations of pre-OLT minor variants produced 
deduced amino acid replacements that persisted post-OLT, which were still detectable in 01 
after one year of follow-up. In LI (patient 6 ), on the other hand, the dominant HVRl 
sequence observed three months post-OLT (4 months after the pre-transplant sample) was
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different from the pre-OLT minor species, albeit apparently derived from one of them (SLB015), 
with identical replacement mutations at four positions (figure 5 .9 ).
Tabie 5.2: HCV HVR1 molecular species in immunosuppressed and untreated subjects
Subject No. of quasispecies:
Pre-OLT Post-transolantation
SI* 82 S3,; S4 S5
1(Wad) NA* 3 2
2 (Dix) NA 2 4 10
3 (Fra) NA 3 8 2
4(C1) 6 2 1 3 4
5(L2) _* 5 3 2 2 4
6  (LI) 3 5
7(L3) 2 2
NA = not applicable; (-) = not available; S1 etc. = sample #.
5.5 HVRl mutation patterns in immunosuppressed and untreated subjects
The HVR1 nucleotide and amino acid sequence diversities of the 4 immunosuppressed and 3 
untreated carriers of HCV were compared. As detailed above, the average number of 
genomic variants per sample was lower (range 1 - 6 ,  mean 3.14) in the immunosuppressed 
patients than in the untreated individuals (range 2-10, mean 4.25). The maximum nucleotide 
sequence diversity ranged from 1 -19.8% for immunosuppressed patients (mean 2.3%), as 
compared with 2.5 - 30.9% (mean 20.2%) for untroatod subjects. Tho contrast was more 
marked when considering sequence diversity at the putative amino acid level: Mean values 
were 2.3% in immunosuppressed patients and 43.5% in untreated HCV hosts. Tables of 
HVR1 nucleotide and amino acid sequence diversities in all possible pairwise combinations are 
given in appendix B. The values are for each set of clones, and include those between 
Individual clones In different populations (from serial samples) obtained from the same 
individual. Table 5.3 gives the values for maximal nucleotide and amino acid sequence
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diversities within the various populations of HCV HVR1 sequences obtained from the seven 
individuals discussed in this chapter. When the periods of observation were summed up for 
each group of patients, non-immunosuppressed individuals and OLT recipients had an 
average of 2.58 and 1.61 substitutions per month, respectively (Table 5.3). These mutations 
corresponded to 1.94 and 0.4 deduced amino acid substitutions/month in the untreated and 
immunosuppressed groups, respectively.
Table 5.3: Maximum % nucieotid%/amino acid) differences withimpopulations of HCV HVRl 
sequences from immunosuppressed patients and untreated HCV infected subjects
Pre-OLT Post-transplantation
Host SO* 81 82 S3 84 85
Immunocompetent:
Wad N.A. 2.5 (3.7) 17.3 (33.3)
Dix N.A. 13.6(25.7) 222(55.6) 23.5(51.9)
Fra N.A. 23.5(51.9) 30.9(66.7) 1627(59.2)
Immunosuppressed:
C l 8.6  (3.7) 1.2 (0 )''' 0  (0) 2^(3.7) 2.5(0)
LI 9.9(22.2) 7.4 (14.8) “
L2 N.A. 19.8(29.6) 4.9 (0) 1.2 (0) 1.2 (0 ) 3.7 (3.7)
L3 3.7 (7.4)* 4.9 (14.8)
* so to 35 refer to individual sample HVR1 populations; N.A. = not applicable
Other parameters of comparison between the two groups of HCV-infected individuals were 
investigated. As shown in Table 5.4, a significant difference was found between the ratios of 
replacement (R) and silent (S) mutations (R/S ratios), which were 8.22  In untreated subjects, 
versus 1.33 in transplant recipients (p < 0.01). The ratios of transitions (Tg) to 
transversions (Ty) were also significantly different, at 0.98 and 2.57 for untreated and 
treated subjects, respectively (p < 0.02). There was also a difference in ratios of 
conservative vs non-conservative amino acid substitutions between samples taken from 
immunosuppressed patients (61:34 or 1.79) and untreated individuals (15:10 or 1.5).
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Table 5.4: HCV HVR-1 mutations in untreated and immunosuppressed subjects
- - ■ Untreated Immunosuppressed
Total no. of nt mutations per
monthi 2.58 1.61
Transition/transversion ratio
1.21 2.57
Average no. of quasispecies 4.25 3.14
R:S ratio 3.70 1.21
Total no. of aa replacements .  V 1.75 0.94
Conservative:non-conserv.
aa replacement ratio 2 1.79 1.50
1 In each group, the time intervals between the first and last samples were summed up for all the patients.
2 For the immunosuppressed group, pre-OLT (i.e., pre-immunosuppression) data were left out of the calculations.
When comparing pre-transplant samples from OLT recipients with the first available samples 
from untreated individuals, the number of molecular species was similar in both groups. The 
maximum number of nucleotide substitutions was higher in the untreated group (13.2 and 7.4 
for untreated and immunosuppressed individuals, respectively). This difference, due to the 
large difference in the ratio of replacement to silent mutations (R/S ratio) between the two 
groups (9.7 vs 1.4 in untreated and transplanted subjects, respectively), became significant 
only at the amino acid level: 27.1% maximal amino acid sequence diversity in untreated 
subjects vs 11 .2% in transplanted patients.
5.6 Localisation of HVRl nucleotide mutations
The HVR1 sequences de^ribed in this chapter totalled 255 - 85 from untreated asymptomatic 
HCV-infected individuals and 170 from transplanted patients. Each mutated HVRl position 
was scored, and the values depicted as in figure 5.11. From this, an interesting pattern of 
HVRl mutability emerged. Of the 81 nucleotide positions of the HVRl sequence, 25 (31%)
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were absolutely conserved, 12 of them encoding 5 inferred amino acids at HVRl positions 2 ,6 , 
7,23 and 26 (Thr, Gly, Gly, Gly and Gin, respectively).
Some degree of variability was observed in all other areas of the HVRl. In particular, analysis 
of sequences from both groups of patients revealed two mutational hotspots, located at HVRl 
positions 25-40, and 62-65. The mutation rate was particularly high in the latter region, and 
led mostly to amino acid replacements. A difference between the two groups was found in the 
region spanning nucleotide positions 43-55: a marked drop in variability of this area occurred 
only in the immunosuppressed group. Similarly, the variability of nucleotides 70-81 in untreated 
patients, albeit lower than in the hotspots, far exceeded that found in immunosuppressed 
patients. At the first mutational hotspot, R/S ratios were 6.25 and 1.57 for Immunocompetent 
and immunosuppressed patients, respectively (p = 0.0024). In contrast, there was no 
significant difference in R/S values between the two groups at the second hotspot. Multiple 
mutations at a single nucleotide position were found in two immunosuppressed and two 
immunocompetent patients. They were more common in the untreated group.
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DISCUSSION 
CHAPTER SIX
This Investigation revealed marked differences between the patterns of HCV mutability of 
immunosuppressed patients and nen-transplanted individuals. Due to the large number of 
nucleotide sequencing reactions carried out in this investigation, care was taken to optimise 
individual steps in the protocol to obtain maximum efficiency. This included a study of the 
effect of various anticoagulants, and of stringent RNA dénaturation on HCV sequence. 
amplification from plasma, described below.
Differential effects of tieparin on HCV NCR and E1/E2 amplification:’
A striking finding was the apparent selective inhibition of PCR by heparin. As discussed in 
section 4.1, amplification of the HCV E1/E2 region was not possible when plasma derived
0?^*» . M r
from heparinised blood was used. However, heparin appeared to have no inhibitory effect on 
amplification of NCR sequences. In seven consecutive isolates from one patient, for example, 
the HCV NCR was repeatedly amplified, while E1/E2 PCR was negative. Similarly, the use 
of heparinised blood prevented amplification of E1/E2, but not NCR, sequences from samples 
obtained from other patients. That this effect was differential, and that it was due to 
heparin, was implied by the fact that non-heparinised samples obtained from time points close 
to those for heparinised samples were consistently PCR-positive for E1/E2.
Heparin is a proteoglycan composed of a glycosaminoglycan (GAG) chain which is covalently 
linked to a single-chain protein core. The mechanism whereby it inhibits the various steps of 
RT- PCR is unclear. It is highly negatively charged due to its many sulphate and carboxyl 
groups, suggesting that it may compete with DNA (or RNA), also negatively-charged, for 
binding to the enzymes reverse transcriptase or Tag polymerase. Alternatively, it may bind 
to nucleic acid, preventing polymerase activity. Binding may be mediated by cations or by 
positively-charged portions of the component polypeptide core. There is evidence suggesting 
that the inhibitory effect of heparin is more pronounced in samples exposed to heparin for
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longer periods (Satsangi et al. 1994), implying that DNA binding is the primary mechanism 
whereby it exerts its effects.
The differential inhibitory effect of heparin observed in this study may be due to topological 
constraints on binding of heparin to the' NCR, which is believed to have a complex secondary, 
and perhaps tertiary, structure including a configuration characteristic of an internal 
ribosome entry site. However, it is impossible to state definitively that this is the case in the 
absence of quantitative data on viraemia levels in the samples analysed. Factors affecting 
PCR outcome include the size and location of the targeted amplicon. The size of the NCR 
amplicon in these experiments was less than half that of the E1/E2 amplicon. Furthermore, 
tho NCR is located at the end of the RNA molecule, which would render it more easily 
accessible to the enzymes involved in RT-PCR. Hence the observed positive results for NCR 
amplification may reflect the fraction of total template NCR segments that escaped binding 
by heparin, rather than a lack of inhibitory effect in this region, and quantitative data may 
show this effect.
In a single heparinised sample (Cl), it was possible to obtain an E1/E2 PCR band from RNA 
obtained using the magnetic bead method described in section 2.7, but not from RNA obtained 
by guanidinium thiocyanate dénaturation followed by alcohol precipitation. The positive E1/E2 
PCR result from a heparinised sample indicated that the magnetic bead method, which 
involves selective binding of HCV RNA to, and subsequent elution from, streptavidin-coated 
magnetic microparticles, is able to reduce or eliminate the inhibitory effect of heparin on 
RT/PCR. It is likely that extensive washing of the beads pre-elution of RNA dislodged the 
heparin from the RNA. The effect was not reproducible, and for further studies it was 
necessary to use non-heparinised samples.
Importance of stringent RNA dénaturation conditions for E1IE2 amplification:- 
Another important factor in successful amplification of HCV cDNA was the application of 
stringent RNA dénaturation conditions, particularly for E1/E2 PCR. Although single­
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stranded, RNA contains local regions of short complementary base pairing that can form 
from a random matching process. Standard protocols for RT-PCR recommend a 5 min, 65‘C 
incubation of the RNA before reverse transcription (Innis etal. 1990). RNA pre-incubation 
regimes described in studies involving amplification of the HCV non-coding region range from 
room temperature for 15 min (Bouffard etal. 1992) to 94'C for 5 min (Hu etal. 1993). In 
reports describing amplification of HCV E1/E2 sequences, the corresponding regimes were 
65’C for 5 min (Feray etal. 1992); 70’C for 5 min (Ogata etal. 1991; Driesel etal. 1994); and 
80*C for 5 min (Van Doom et ai. 1994). Following the fortuitous discovery in this study that 
Stringent heating of HCV RNA before cDNA synthesis strongly influenced the outcome of 
RT-PCR, a series of experiments, described in section 3, was carried out to validate this 
observation. Different heat and chemical dénaturation protocols were compared. The finding 
that stringent RNA heat or chemical dénaturation conditions (70’C for at least 30 min or 
35 s boiling of formamide-dissolved RNA) were necessary for positive E1/E2 PCR suggests a 
significant degree of higher order structural organisation for this region of HCV.
Genotyping of HCV via amino acid sequence homology in the E i carboxytenninus:- 
The phylogenetic classification system of Simmonds etal. (1995), involving "types" and 
"subtypes", was generated by computer. While isolates within subtypes had only 0 -12% 
nucleotide variation, subtypes within types had 14 - 26% difference. Each of the major 
genotypes differed by 28 - 44%. The three-tiered system was supported by the fact that 
analysis of several subgenomic regions revealed the same subdivisions, with no overlap in 
sequence variability between isolates, subtypes and types. The data suggested that genetic 
recombination between different HCV genotypes does not occur, and that classification can 
reliably be performed by analysis of informative subgenomic regions. This was the basis of 
classification in the Bukh-Okamoto system (Bukh etal. 1993; Okamoto etal. 1992), used in 
this study. The region for distinguishing between HCV genotypes in most cases could be 
narrowed down to a 10-amino acid domain from residues 342 - 351, which was previously 
described as sufficient to reliably type a large number of samples obtained from sources 
worldwide (Bukh etal. 1993).
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In the genotype determinations of chapter 4, amino acids 342 to 351 were able to type 12 of 
12 samples. An apparent ambiguity with one sample (01) was resolved by the finding, after 
comparing the 7 subtype la  and 6 subtype 1b sequences of figures 4.5 and 4.6 respectively, 
as well as the 8 subtype la  and 17 subtype la  sequences of Bukh etal., that subtype la  
could be distinguished by the invariable presence of Leu at position 345. This was confirmed 
by analysis of the regions flanking.this 10-residue sequence, in which Cl was more 
homologous with the subtype 1b. Because the region of E1 used for typing was located close 
to the HVRl, it was possible to classify HCV isolates and carry out HVRl analysis on the 
same PCR product, which significantly increased efficiency.
Independence of HVRl variability from genotypes: Implications for cross-reactivity and 
neutralization:-
V a j ;  . . . .  . , . 1 .  y
The results of section 4.1 indicated an apparent absence of subtype specificity in the HVRl 
region. However, constraints on the identity and hydropathic character of amino acids 
comprising HVRl were found. These included three absolutely conserved residues: Thr, Gly 
and Gin at HVRl positions 2,23 and 26, respectively. In addition, in 92% of isolates, Gly 
was found at both positions 6 and 7, Phe at position 21 and the hydrophobic residues Leu or 
Phe at position 20. These results suggest a degree of conservation within the HVRl region 
which is independent of HCV genotype, and point to a possible functional role for this region of 
E2, such as binding to a cellular receptor. Although the relatively high degree of conservation 
expected from a cellular receptor binding site is absent from the HVRl as a whole, conserved 
residues within it may interact with parts of E2 outside the HVRl to constitute the functional 
binding site. In this context, it was recently demonstrated that anti-HVRI antibodies were 
able to block recombinant E2 binding to susceptible MOLT-4 cells (Rosa et al 1996). The 
presence of conserved residues within the HVRl may have implications in the design of 
genetically engineered neutralising antibodies to HCV, which would widely cross-react with 
multiple subtypes. Progress in passive immunity as well as vaccine development may benefit 
from further determinations of consensus sequences from a large number of isolates, and
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clarification of the structural role of the conserved amino acids (which may specify widely- 
conserved tertiary structural motifs).
Observation of two intraisoiate viral ‘‘families" drifting in parallel':- 
The relatively frequent observation, among both transplanted and untreated subjects in this 
study, of two viral "families" apparently drifting in parallel was of note. This phenomenon 
could be related to initial infection with two equally infectious variants; superinfection over 
time; or adaptation to host. The simultaneous presence of HCV from different genotypes is 
not uncommon. However, experiments performed in chimpanzees successively infected with 
different strains of viruses of the same genotype suggest that, over time, one strain seems 
to take over (Farci etal. 1991). Hence, the hypothesis of a dual infection is unlikely. 
Superinfection of a previously infected individual by another strain of HCV has been 
observed in humans (Prince etal. 1992; Kao etal. 1993). Experiments in chimpanzees clearly 
showed that the level and the efficacy of neutralizing antibodies against HCV was 
insufficient to prevent superinfection (Farci etal. 1992; Okamoto etal. 1994). Untreated 
subject Wad (patient 1), in whom parallel drifting of two viral families was observed, had 
been infected through intravenous drug abuse more than 15 years before the study, and 
recent superinfection is very unlikely. There remains the possibility of two strains of escape 
mutants having drifted separately oyer a relatively long period of time. It is not inconceivable 
that two distinct mutated strains have become well adapted to the host and persisted.
Decrease in HCV genomic diversity post-OLT:-
The data collected in this study indicate a considerable reduction in HVRl genomic diversity 
of HCV isolated from liver transplant recipients when compared with isolates from 
chronically infected, untreated patients. This was especially remarkable in two of four
transplanted patients (Cl and L2, or patients 4 and 5, respectively). The HVRl
. . . .
quasispecies populations in both patients had become practically homogenous by one year 
post-transplantation. As shown in Figures 5.1 - 5.9 and Tables 5.1 and 5.2, the overall number 
of variants, as well as the frequency, type and location of nucleotide mutations appeared
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restricted post-transplantation. These observations can be explained by the following
mechanisms:
• restriction of infectious virus species infecting the grafted liver;
• primary infection of grafted liver;
• convergent evolution;
• attenuated host immune response;
• low viral diversity preceding liver transplantation.
Each of these possible factors is discussed below:
Restriction of infectious viral species:- The basic premise here is that only one or a few 
variants is capable of infecting the grafted liver. In 2 patients (01 (patient 4) and L3 
(patient 7)), a minor pre-OLT HVRl species became unique or dominant post-OLT. 
Similarly, for patient 5 (L2), a minor species observed 31 days post-OLT dominated all 
subsequent samples collected over a year. This apparent selection may be explained by a 
restriction in the number of viral species capable of, or available for, infecting the 
transplanted liver. Preliminary evidence has been provided that HCV in plasma circulates 
in two forms - as free virions or as virus-antibody immune complexes (Choo etal. 1995). 
Evidence from other investigators suggests that complexed viruses have decreased or no 
infectivity, while free viruses probably correspond to escape mutants not recognised by 
the immune system (Shimizu etal. 1994; Zibert etal. 1995). This hypothesis is supported 
by the observation that HVRl sequences of complexed and free HCV in plasma have 
different nucleotide and amino acid compositions. In liver graft recipients, free viruses 
may represent a selected, more infectious viral population which preferentially infects the 
grafted organ. During this primary infection, a limited.number of HCV variants replicate, 
producing viruses of limited diversity. This argument is based on the assumption that the 
viruses derived from plasma or serum represent an accurate picture of the hepatic HCV 
population. In the absence of good tissue culture systems for HCV, it is difficult to 
determine which genomic characteristics determine infectivity. Removing the infected liver 
of potential graft recipients would remove most of the virus. Selection may then operate
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on the basis of those variants surviving outside the liver (such as in PBMGs, or virions in 
circulation at the time of the operation).
Primary infection of grafted liver:- There is evidence to suggest that a relative homogeneity 
of viral genotype in the period immediately following virus transmission is a fairly common 
phenomenon (Feray etal. 1992; Gretch etal. 1995). Thus, a single predominant HVRl 
variant was found in the infant of à mother shown to have multiple predominant HVRl 
species (Weiner etal. 1993). The infant sequence was closely related to, but not identical 
with, the 9 variants identified in the mother at the time of birth, a situation closely mirroring 
that found in OLT recipient 01 (patient 4) in this study (figure 5.5). There appears to be a 
"bottleneck" effect in the transmission of virus so that the preferential replication of one or a 
few variants is favoured. The particular species transmitted could result from a completely 
random event, or may have a better replicative ability. In the latter context, it is notable
"*■ 'isthat a dramatic increase in HCV viraemia in the period following OLT of previously infected
* ta I . i
patients has been reported from several investigators (Alter and Seeff 1993; Duvoux etal. 
1994; Gretch et al. 1995). For a short period of time (1 - 2 months), during which restricted 
infectious HCV species explosively replicate in the target organ, a very high proportion of 
virus particles produced are identical to the species with replicative advantage. Competition 
experiments between mutant and wild-type Op RNA phages showed that mutants with a 
relative replication rate of up to 0.9 were nevertheless outgrown by the wild type, which 
formed the predominant sequence (Holland etal. 1982). Ordinary.sequencing methods would 
detect RNA heterogeneity only if the mutant-wild type growth ratios were very close (within
0.01 - 0.1%). This mechanism, applied to the post-OLT context, assumes that viral 
diversity would begin to reappear 4 - 6 months post-OLT (1 - 2 months following primary 
infection of the grafted liver), when the log phase of growth is over, and dynamic equilibrium 
of quasispecies variants may have shifted to favour the predominance of one or more new 
species. This is not the case in 01 and L2 (patients 4 and 5), who still show restriction of 
viral genomic diversity 1 year post-OLT, despite evidence, from quantitation studies, of 
increased viral load (see appendix D).
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Convergent evolution:- The final antigenic character of a given viral epitope results from a 
balance between two opposing trends, whereby the variability which enables escape from 
the host immune response is weighted against the need to conserve specific residues that 
are important for viral function. Hence, two or more distinct evolutionary lineages may 
give rise to a single antigenic epitope (Holmes etal. 1992). The apparent homogeneity of 
HCV variants in patients Cl and L2 may thus represent convergent evolution of different 
lineages to produce a preponderance of that variant which is best fit for survival within 
the specific host.
Decrease in the host immunological ability to select HCV strains:- In immunocompetent 
individuals, the emergence of new HCV variants appears to be essentially the result of 
immunologic selection. Dominant vàriants are quickly recognised by the immune system, 
which produces antibodies against antigenic motifs specific to each variant (anti-envelope, 
particularly anti-HVRI). Clearance of these complexed viruses allows the emergence of 
variants which are not immunologically recognised (escape mutants), and which circulate 
at levels high enough to be detected amongst the limited number of sequenced clones. The 
immunosuppressive regimen undergone by OLT recipients may interfere with their ability 
to recognise escape mutants and to mount an effective immune response. If this is the 
case, patients will have a decreased or non-existent capacity to select HCV variants as 
escape mutants. Since the immunoselective mechanism is impaired, the initially infectious 
species is (are) likely to keep replicating and to remain longer in circulation than prior to 
the onset of immunosuppression. Thus, only after a year post-OLT did the HCV 
population from patient 4 (Cl) begin to diversify, with the few observed mutations mostly 
silent.
Pre-existing relative inability of transplanted patients to select divergent variants:- In three 
patients examined pre-OLT several Indicators suggest that genomic diversity Is less than 
in the three untreated patients. In 01, for example, although 6 species were detected pre- 
OLT, only two variants were represented at the amino acid level. Similarly, for the 
remaining transplant recipients, the degree of amino acid diversity was lower than that
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found in the non-transplanted subjects. The maximum percentage nucleotide diversity in 
the immunosuppressed patients was 9.9%, compared with 23.5% in untreated subjects 
(corresponding to maximal amino acid sequence divergences of 22.2% and 52%, 
respectively). The ratios of transitional to transversional mutations (JsfTv ratios) were 
also higher in immunosuppressed patients. This scenario differs from that in the preceding 
paragraph in that here the restriction on immune selection of divergent strains is intrinsic 
to the individual patient (e.g., to a specific HLA haplotype), and not a result of the imposed 
immunosuppression. These observations suggest that patients who develop end-stage
I.,
liver disease have a lower HCV genomic diversity than those who do not, which might 
reflect their decreased capacity of their immune systems to recognise viral antigenic 
variants and select quasispecies populations. More data are necessary to substantiate 
this point.
Two mechanisms of virus evolution have been proposed. Random mutations occur in the 
absence of evolutionary pressure. In this process, the main viraLspecies remains essentially 
unchanged, with a gradual drift over long periods of time. Alternatively, in the presence of 
selective pressure, such as a host immune response, mutants which differ antigenically from 
the major variant and have not yet attracted the attention of the host immune response are 
selected. New, sometimes drastically different, species sequentially emerge as escape 
mutants which may ultimately be Identified and eliminated by the host immune system.
Evidence for both kinds of mechanism was found in this study, as outlined in chapter 5. The 
HVR1 sequences of patients 4 and.5 (C1 and L2) remained.remarkably stable throughout the 
one-year follow-up period (figures 5.5 and 5.7). Selective forces appeared to operate in the 
untreated subjects Wad, Dix and Fra (patients 1 - 3, figures 5.1 to 5.3, respectively), as 
evidenced by the rapid turnover of significantly different quasispecies populations. The 
mechanism of evolution in the two immunosuppressed OLT recipients LI (patient 6) and L3 
(patient 7) was difficult to determine, as a long-term study was not carried out on these 
patients. However, from the sequencing data for the initial post-OLT sample from each
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patient, selective pressure appeared to play some role. As seen from figures 5.9 and 5.10, 
there were significant differences in antigenic potential among the post-OLT HVRl genomic 
variants in both patients. Hence, the possibility of immune selection cannot be ruled out for all 
OLT patients.
The HVRl is by far the most variable part of the HCV genome, with a very high degree of 
sequence heterogeneity detectable among multiple clones (Ogata etal. 1991; Weiner etal. 
1991; Honda et al. 1994; Kato etal. 1994). Variant composition was found to change 
temporally, in a process involving selection of particular amino acids at specific positions 
which had represented only a minor fraction or had been absent in previous clones. 
Furthermore, this heterogeneity could be decreased by IFN treatment (Higashi etal. 1993). 
RNA-dept RNA polymerases have a bias towards base transitions, implying that HVRl is 
not a section of redundant RNA thât arose due to random infidelity of the virus polymerase, 
with no constrainst on its sequence. The segmental evolution of HCV must have undergone 
positive selection. The low Ts/Tv ratio in HVRl highlights the possibility that the mechanism 
for generation of this diversity involved a different replication strategy. The finding of 
constant regions and hotspots intorsporsod within HVRl further highlights the critical role of 
this region in the immune response.
The HCV subtype 1b is believed to be more pathogenic than other subtypes (Pozzato etal. 
1994). However, this could merely reflect the length of incubation rather than viral 
pathogenicity. HCV infection follows a slow, insidious course, with evidence of liver disease 
often taking decades to develop. The lack of extensive long-term studies could mask the 
possibility that the subtype 1b (which, incidentally, is widely distributed globally) has simply 
been present much longer. In this context, it may be significant that the population of patients 
in this study infected with subtype 1b was, on average, 20 years older than those with other 
subtypes.
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In two untreated subjects, Wad and Dix, 14 and 23 HVRl mutations, respectively, were 
observed between sequences from two time points. This was consistent with results from a 
12-patient study in which 7 - 15  HVRl mutations (median 10) were observed in consensus 
sequences obtained from paired samples separated by a one-year interval (Kurosaki et ai. 
1994). The numbers of mutations obsenred in immunosuppressed patients 01 and L2 were 
lower (6 and 4, respectively). Temporal changes in deduced amino acids in the untreated 
subjects also corroborated other published reports, and were clearly higher than changes 
observed in the immunosuppressed OLT recipients (Higashi etal. 1993; Kato etal. 1994 ; Kao 
etal. 1995).
Comparison of tho two groups of patients was even more striking when samples collected at 
relatively close intervals over periods of several months were analysed. In untreated subject 
Fra for example, amino acid sequence divergence reached 67% in less than a month, while 
two immunosuppressed patients 4 and 5 (Cl and L2) showed a maximum change of 4% 
throughout a follow-up period of almost one year. Two overlapping epitopes, corresponding 
to amino acid positions 11-21 (epitope I) and 14 - 24 (epitope II) of the HVRl, have been 
previously described (Kato et al. 1994). It is of interest to note a general correspondence 
between these epitopes and the mutational hotspots found in both groups of patients in this 
study. It is also striking that the decrease in mutability in immunosuppressed patients was 
most conspicuous in the overlap region of epitopes I and II.
All criteria examined for the comparison of HVRl sequences revealed a difference between 
immunosuppressed and immunocompetent patients. The average number of variants, 
nucleotide mutation rate and sequence diversity were lower in the immunosuppressed group.
In addition, mutations in immunosuppressed patients tended to be mostly transitional and more 
often silent, while replacement mutations tended to favour conservative substitutes. These 
elements suggest that a normal immune system plays a critical role in the determination of 
the quasispecies distribution of HCV infected individuals. It is unlikely, however, that 
immunosuppression alone accounts for this remarkable difference. One possible additional
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influence is the individual patient's immune repertoire - patients who reach the stage of 
terminal liver disease at a relatively young age may represent a selection of people whose 
immune response, both humoral and cellular, is particularly inefficient. Limited data obtained 
from different chimpanzees inoculated with the same viral population suggest that an 
unfavourable clinical outcome is correlated with low levels of HVR1 variability (Van Doom et 
al. 1994; Van Doom etal. 1995). The low HVRl variability observed in the OLT recipients 
described in his study may have preceded the period of immunosuppression and may be 
related to the end stage liver disease requiring liver transplantation. It may have been 
caused by the host inability to contain HCV (hence the cirrhotic state), or to the 
immunosuppressive treatment given for transplantation, or both.
These data need to be substantiated in more patients, both OLT recipients and untreated, 
chronically infected subjects. However, they suggest that patients who develop end-stage 
cirrhosis have a lower genomic diversity of HCV, which might reflect a decreased capacity 
of the host immune system to recognise viral antigenic diversityrand to complex HCV.
Patients 4, 5 and 7 who developed end-stage cirrhosis at a relatively young age, may 
represent a subgroup of HCV-infected individuals whose immunological response is 
ineffective, hence the lower viral diversity and genetic drift. In addition, it should be noted 
that Cl (patient 4), who had the lowest level of genomic diversity, rapidly developed HCV- 
related graft failure, requiring re-transplantation after one year. In a Scandinavian study, 
HCV-infected patients with congenital hypogammaglobulinaemia were shown to undergo a 
severe, rapidly progressive course of hepatitis, with poor response to IFN (Bjoro et al. 1994), 
which accords well with the findings for patients 4 (Ci) and 5 (L2). Kumar et al. showed 
absolute homology of the HVRl nucleotide sequence in an agammaglobulinaemic patient 
followed for two years (Kumar etal. 1994). These results indicated that HCV persistence 
occurs in the presence or absence of a humoral immune response, and suggested a role for 
other factors in promoting viral persistence, such as the cellular immune response. Evidence 
from several sources points to the existence of T cell responses directed against HIV, a virus 
which, like HCV, is remarkable for its high rate of mutation in the region encoding envelope
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glycoproteins. (McMichael etal. 1994; Klenerman etal. 1995; McAdam etal. 1995; 
RowlandJones etal. 1995). Studies on HCV have produced similar findings (Kita etal. 1993; 
Koziel etal. 1993; Shirai etal. 1994; Shirai etal. 1995).
Although the number of patients in this investigation was not high enough to draw 
statistically relevant conclusions, it was notable that the two transplanted patients followed 
up for a year, who were both infected with HCV subtype 1b and showed a similar pattern of 
HCV quasispedes evolution, had identical haplotypes at the HLA-A locus. The fact that 
they both required re-transplantation within a year of the first transplant further suggests a 
possible link between host factors and the increasingly evident subset of HCV-infected OLT 
recipients who develop very aggressive liver disease post-transplantation.
The data presented suggest a model for the difference in HCV HVRl evolution between 
untreated and subjects at least a subset of immunosuppressed patients (figures 6.1 and 6.2).
At any time point, the viral population is composed of multiple variants. In the kinetics of 
these molecular species, only mutations affecting epitopes and, particularly, functional 
epitopes of the viral structural proteins are of importance in the host-virus interaction. 
mediated by the immune system. This is especially relevant for the HVRl region. Viral 
particles circulate either as free, infectious virions or complexed with specific antibodies, 
which prevent their replication within cells and are therefore neutralising. Variants generated 
during the replication process are eliminated in immune complexes, or temporarily evade 
neutralisation. The constant clearance from circulation of immunogenic variants complexed 
with specific antibodies allows new variants to emerge and replicate for various periods of 
time in sufficient amounts to become detectable as quasispecies variants.
The model predicts that in the context of immunosuppression or a failure of the immune 
system to recognise and clear HCV variants, the most infectious mutant (i.e., uncomplexed 
escape mutant) will preferentially replicate, leading to a homogeneous viral population. Under 
these conditions, although other species may be present, their lack of infectivitiy advantage
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over the escape mutant which colonises the allograft means that they are present at levels 
too low for detection by the methods used in this study. t*" v
It should be emphasized that this model represents but one of the many possible mechanisms 
of viral quasispecies evolution, the one which best fits the situation found in patients 01 and 
L2. These patients were followed up long-term, unlike patients LI and L3, for whom a single 
post-OLT sample was analyzed. For the latter two patients, these preliminary findings 
suggest that HVRl sequence heterogeneity, high in both cases, is predictive of an 
uncomplicated post-OLT course. While the two patients with relatively high HCV HVRl 
sequence homogeneity remain walkover two years post-OLT, both patients with homogenous 
quasispecies populations developed severe recurrent hepatitis which proved lethal despite re­
transplantation carried out within a year of the first transplant,.
Extensive clinical data review is required to substantiate the hypothesis of differential 
quasispedes evolution patterns in different subsets of liver transplant recipients, especially in 
view of its possible high impact on OLT outcome. Although IFN therapy, currently the only 
treatment for HCV infection, is expensive and of low effectiveness, the application of 
combined IFN/ribavirin therapy is reported to have significantly better results, even within 
the context of OLT and its attendant complications. As more effective therapies for HCV 
infection emerge, it will become increasingly important to pinpoint those patients most likely to 
suffer a complicated post-OLT clinical course, in order to assist selection of OLT recipients 
and/or choice of patients in whom more aggressive anti-HCV therapy should be carried out.
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CONCLUSION
In conclusion, evidence is presented for different patterns of HCV sequence evolution in 
untreated subjects and some immunosuppressed patients. On the basis of HVRl sequences, 
it is suggested that viral diversity is largely driven by immune pressure. However, the data 
indicate that patients showing less diversity of HVR1 sequences post-OLT may progress to a 
more severe clinical disease. The data validate and substantiate findings that the occurrence 
of changes in the HVR1, which encodes epitopes for neutralising bodies, reflect the efficacy of 
the immune system. Longer follow-up studies involving larger cohorts of patients are needed 
to clarify which viral and host factors are predictive of clinical outcome of infection in both 
asymptomatic HCV carriers and HCV-infected OLT candidates. In particular, clarification of the 
role of the cellular immune response, and the host immune repertoire, may help in the design 
of therapeutic strategies for the prevention and possible cure of hepatitis C.
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APPENDIX A
Region of HCV genome showing deduced amino acid sequences of putative E1 and E2 
proteins from 9 HCV isoiates representing 4 genotypes.
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The relative degree of amino acid sequence variations was calculated for the four major Isolates rICV (HCV-1, 
HCV-J, HC-J6 and HC-J8. Sites having variation values of 3 or higher are shaded In the diagram shown at the 
top. Sequences 1-9 were from HCV-1, HCV-H, HC-J4, HCV-J, HOV-BK, HC-J6, HC-J5, HC-J8 and HC-J7, 
respectively. Conserved amino acids are shown In the sequence o Putative N-glycosulatlon sites are toxed; 
conserved Cys residues are Indicated by . A transmembtrane-llke sequence Is Indicated by a, possible 
recognition sites for signal peptidase by b and d, and HVRI by c. Down arrow Indicates the beginning of the 
sequence used for type designation (amino acids 341 - 351).
Ref; Okamoto etal., Virology 188:338 (1992)
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Appendix B:
Nucleotide and amino acid substitution tables for HCV-infected individuals in study.
Table .8.1 Nucleotide (a) and amino acid (b)substitution tables for patient 1(Wad)
Boxed regions represent intraisolate sequence diversity. * T=no. of days since first sample; 
R = ratio of quasispecies; Q = designation of representative quasispecies.
(a)
T*:
R*:
Q*:
203
202
4:
101
0
4:
001
1
114
267
7 4
203 202
101 0 2 \ ■ 1
001 2 0 1
114 1 1 0
203 0 2 1
202 14 16 15
(b)
T*: 0
R*: 4: 4: 1
Q*: 101 001 114
•— — '
101 0 1 1
001 1 0 0
114 1 0 0
0
14
14 
16
15
14
0
267
?. 4
203 ' 202
187
Appendix B
Table B.2 Nucleotide (a) and amino acid (b)substitution tables for patient 2 (Dl)
Boxed regions represent intraisolate sequence diversity. * T=no. of days since first sample; 
R = ratio of quasispecies; Q = designation of representative quasispecies.
T Z
R*: 3: 2
Q*: 111 113
268 14 13
265 4 15
266 13 10
267 14 13
11:
457 
1: 1:
111 0 11
113 11 0
2: 1: 1: 1:
719 
1: 1: 1: 1: 1:
268 265 266 267 301 302 303 304 305 307 316 318 319 320
14 4 13 14 12 14 13 14 3 5 11 3 16 10
13 16 10 13 11 13 12 12 14 10 10 10 13 12
0 18 11 1 4 13 13 10 17 15 11 15 15 15
18 0 15 18 16 17 16 16 5 8 15 7 19 10
11 15 0 11 11 15 15 12 14 12 12 12 17 10
1 18 11 0 4 13 13 12 17 15 11 15 15 15
301 12 11 4 16 11 4 0 11 11 10 15 .5ija 9 13 13 13
302 14 13 13 17 15 13 11 0 1 6 17 ' i4 5 14 4 13
303 13 12 13 16 15 13 . 11 T b • 6 16 13 5 13 4 14
304 14 12 10 16 12 12 10 6 6 0 17 13 5 13 8 15
305 3 14 17 5 14 17 15 17 16 17 0 8 14 6 19 9
307 5 10 15 8 12 15 13 14 13 13 8 0 11 2 16 7
316 11 10 11 15 12 11 9 5 5 5 14 11 0 11 5 11
318 3 10 15 7 12 15 13 14 13 13 6 2 11 0 16 8
319 16 13 15 19 17 15 13 4 4 8 19 16 5 16 0 16
320 10 12 15 10 10 15 13 13 14 15 9 7 11 8 16 0
v r
R*: 3: 2
Q*: 111 113
457
11: 1: 1: 1 
268 265 266 267
719
2: 1: 1: 1: 1: 1: 1: 1: 1: 1
301 302 303 304 305 307 316 318 319 320
111
113
13 3
10 10
11 13* 
7 10
268 13 10 3 5 7 0
265 3 10 15 0 12 15
266 11 7 7 12 0 7
267 13 10 0 15 7 0
12 10 10 12 3
9 9 9 9 9
3 10 10 9 15
15 12 12 12 5
9 11 11 9 12
3 10 10 9 15
13 9 14 10 13
6 12 6 13 7
9 9 11 11 9
13 9 14 10 13
301 12 9 3 15 9 3 0 9 9 9 14 12 8 13 9 12
302 10 9 10 12 11 10 9 0 0 5 11 10 4 11 2 9
303 10 9 10 12 11 10 9 0 0 6 11 10 4 11 2 9
304 12 9 9 12 9 9 9 5 5 0 12 11 5 13 5 10
305 3 9 15 5 12 15 14 11 11 12 0 5 10 6 12 6
307 4 7 13 6 9 13 12 10 10 11 5 0 9 3 11 4
316 9 7 9 12 9 9 8 4 4 5 10 9 0 10 2 6
318 3 8 14 6 11 14 13 11 11 13 6 ■*•'3 10 0 12 10
319 11 9 10 13 11 IQ. '9 2 2 8^ 12 11 2 12 0 10
320 6 7 13 7 9 13 12 9 9 10 6 4 8 . 6 10 0
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Table B.3 Nucleotide (a) and amino acid (b)substitution tables for patient 3 (Fra)
Boxed regions represent intraisolate sequence diversity. * T = no. of days since first sample; 
R = ratio of quasispecies; Q = designation of representative quasispecies.
(a)
T*: 0
R*: a 1: 1
Q*: 104 101 110
3:
24
1: 1: 1: ' i:  1:
202 '201 -206 211 203 210 212 205
87 
?. 5
301 302
104
101
110
0 1 18 0 23 17 24 1 22 1 22 22 1
1 0 19 1 24 18 25 2 23 2 23 23 2
18 19 0 18 16 2 16 18 15 17 15 15 19
202 0 1 18 0 23 17 24 1 22 1 22 22 1
201 23 24 16 23 0 16 3 23 1 24 1 1 24
206 17 18 2 17 16 0 16 17 15 18 15 16 18
211 24 25 16 24 3 16 0 24 2 25 4 2 25
203 1 2 18 1 23 17 24 0 22 2 22 22 2
210 22 23 15 22 1 15 2 22 0 23 2 0 23
212 1 2 17 1 24 18 25 2 23 - 0 23 23 2
205 22 23 15 22 n 't -15 4 2 23 0 2 23
301 22 23 15 22 1 15 2 22 0 23 2 0 23
302 1 2 19 1 24 18 25 2 23 2 23 23 0
T*: 0
R*: a 1: 1
Q*: 104 101 110
24 87
3: 2 2 1: 1: 1: 1: 1: 7  5
202 201 206 211 203 210 212 206 301 302
104 0 1 13
101 1 0 14
110 13 14 0
16
17
13
14
13 .g  0
\  - . . .  . .V  .
18
19
12
16
17
13., 11
15
16 
11
16 0 
17 1
11 13
202 0 1 13 0 16 13 18 0 16 0 15
201 16 17 12 16 0 12 3 16 1 16 1
206 13 14 0 13 12 0 12 13 11 13 11
211 18 19 12 18 3 12 0 18 2 18 4
203 0 1 13 0 16 13 18 0 16 0 15
210 16 17 11 16 1 11 2 16 0 16 2
212 0 1 13 0 16 13 18 0 16 0 15
205 15 16 11 15 1 11 4 15 2 15 0
301 16 17 11 16 1 11 2 16 0 16 2
302 0 1 13 0 16 13 18 0 16 0
* V
15
16
1
11
2
16
0
16
2
0
16
13
18
0
16
0
15
0 16
16 0
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Table B.4 Nucleotide (a) and amino acid (b)substitution tables for patient 4 (Cl).
Boxed regions represent intraisolate sequence diversity. * T=no. of days post-OLT; R = 
ratio of quasispecies; Q = designation of representative quasispecres.
M ________
T*: -11
R*: 7: 2: 1: 1: 1: 1
Q*: 002 004 010 012 013 014
002 0 3 5 4 6 1
004 3 0 6 5 7 4
010 5 6 0 1 3 6
012 4 5 1 0 2 5
013 6 7 3 2 0 7
014 1 4 6 5 7 0
115 5 6 2 1 1 6
116 4 5 1 0 2 5
605 4 5 1 0 2 5
702 4 5 1 0 2 5
704 5 6 2 1 3 6
707 5 6 2 1 3 6
801 4 5 1 0 2 5
804 3 4 2 1 3 4
809 5 4 2 1 3 6
808 5 6 2 1 3 4
8
10: 1 
115 116
86
( 8 )
605
4
5 
1 
0 
2 
5
1
0 .
218
9: 1:
702 704 707
4 5 5
5 6 6
1 2 2
0 1 1
2 3 3
5 6 6
1 2 2
0 1
0 1 1
0 1 1
1 0 2
1 2 0
0 1 1
1 2 2
1 2 2
1 2 2
329
7: 2: 2: 1
801 804 809 808
4 3 5 5
5 4 4 6
1 2 2 2
0 1 1 1
2 3 3 3
5 4 6 4
1 2 2 2
0 1 1 1
0 1 1 1
0 1 1 1
1 2 2 2
1 2 2 2
0 1 1 1
1 0 2 2
1 2 0 2
1 2 2 0
M .
T *
R*
Q*
-11
7: 2: 1: 1: 1: 1
002 004 010 012 013 014
86 218, 329
002 0 0 1 1 1 0
004 0 0 1 1 1 0
010 1 1 0 0 0 1
012 1 1 0 0 0 1
013 1 1 0 0 0 1
014 0 0 1 1 1 0
115 1 1 0 0 0 1
116 1 1 0 0 0 1
605 1 1 0 0 0 1
702 1 1 0 0 0 1
704 1 1 0 0 0 1
707 2 2 1 1 1 2
801 1 1 0 0 0 1
804 1 1 0 0 0 1
809 1 1 0 0 0 1
808 1 1 0 0 0 1
10:, 1 ( 8 ) , '■9T 1: 1 7: 2: 2: 1
115 116 605 702 704 707 801 804 809 808
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
0 0 0 0 0 1 0 0 0 0
0 0 0 0 0 1 0 0 0 0
0 0 0 0 0 1 0 0 0 0
1 .1 1 1 1 2 1 1 1 1
0 0 0 0 0 1 0 0 0 0
0 0 0 0 0 1 0 0 0 0
0 0 m 0 0 1 0 0 0 0
.0 0 0 ... ..0 ... o ' 1 0 0 0 0
0 " 0 0 0 0 1 0 0 0 0
Î 1 1 1 1 0 1 1 1 1
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Table B.5 Nucleotide (a) and amino acid (b)substitution tables for patient 5 (L2)
Boxed regions represent intraisolate sequence diversity. * T=no. of days post-OLT; R = 
ratio of quasispecies; Q = designation of representative quasispecies.
(a)
f  : 
R*: 
Q*:
8:
A05
2:
A04
31
1:
A07
1:
A13
1
A14
6 :.
C02
97
5:
C03
1
Cl 6
180
10: '.  3 
F02 FÔ5
J134
1 3 :" 1 
Y03 Y10
11:
102
435
1: 1: 
109 115
1
118
A05 0 1 10 1 15 0 4 2 0 1 0 1 1 2 2 1
A04 1 0 9 2 14 1 3 1 1 2 1 2 2 3 3 2
A07 10 9 0 11 5 10 11 10 10 11 10 11 11 10 10 11
A13 1 2 11 0 16 1 5 3 1 2 1 2 2 3 3 2
A14 15 14 5 16 0 15 15 15 15 16 15 16 16 16 15 16
C02 0 1 10 1 15 0 4 2
C03 4 3 11 5 15 4 0 4
Cl 6 2 1 10 3 15 2 4 0
F02 0 1 10 1 15 0 4 2
F05 1 2 11 2 16 1 5 3
Y03 0 1 10 1 15 (X 4 2
Y10 1 2 11 2 16 1 4 3
102 1 2 11 2 16 1 5 3
109 2 3 10 3 16 2 6 4
115 2 3 10 3 15 2 6 4
118 1 2 11 2 16 1 5 3
1 2 0 1 1 2
2 3 1 0 2 3
2 3 1 2 0 3
1 2 2 3 3 0
i Ë l
V : 31
R*: 8: 2: 1:
Q*: A05 A04 A07 A13
A05 0 0 6 1 8
A04 0 0 6 1 8
A07 10 9 0 11 5
A13 1 2 11 0 16
A14 15 14 5 16 0
C02 0 0 6 1 8
COS 0 0 6 1 8
016 0 0 6 1 8
F02 0 0 6 1 8
F05 0 0 6 1 8
Y03 0 0 6 1 8
Y10 0 0 6 1 8
102 0 0 6 1 8
109 1 1 6 - 2 8
115 1 1 7 2 8
118 1 1 7 1 9
1
A14
97
6: 5: 1
C02 C03 Cl 6
0 0 
O' 0 
10 IT 
1 5
15 15
0 0
0 0
0 0
0 0
0 0
1: 1
1 ■1
1 1
180
10: 3
F02 F05
334
13: 1
Y03 Y10
435
11: 1: 1: 1
102 109 115 118
0 0 0 Q -. 0 0 1 1
0 0 Q' ' a  ' 0 0 1 1
10 10 11 10 11 11 10 10
3 1 2 1 2 2 3 3
15 15 16 15 16 16 16 15
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Table B.6 Nucleotide (a) and amino acid (b)substitution tables for patient 6 (L2)
. f : '
Boxed regions represent intraisoldte sequence diversity.' * T=no.  of days post-OLT; R 
ratio of quasispecies; 0  = designation of representative quasispecies.
M ______
T V  31 97 180 334
R*: 8: 2: 1: 1: 1 6: 5: 1 10: 3 13: 1
Q*: A05 A04 A07 A13 A14 C02 C03 C16 F02 F05 Y03 Y10
435
11: 1: 1: 1
102 109 115 118
A05 0 1 10 1 15
A04 1 0 9 2 14
A07 10 9 0 11 5
A13 1 2 11 0 16
A14 15 14 5 16 0
C02 0 1 10 1 15
C03 4 3 11 5 15
Cl 6 2 1 10 3 15.
F02 0 1 10 1 15
F05 1 2 11 2 16
Y03 0 1 10 1 15
Y10 1 2 11 2 16
102 1 2 11 2 16
109 2 3 10 3 16
115 2 3 10 3 15
118 1 2 11 2 16
0
1
10
1
15 15
1 5
2 6 
2 6 
1 5
2
1
10
3
15
4
'.0 >
0
1
10
1
15 16
0
1
10
1
15
O'" 
4 
2 .
0
1
1
2
11
2
16
1
4
3
1
2
1 
2 
11 
2
16 16
2 2 
3 3
10 10 
3 3
15
1
2
11
2
16
1 2 2 1
5 6 6 5
3 4 4 3
1 2 2 1
0 1 1 2
1 2 2 1
2 3 3 2
0 1 1 2
1 0 2 3
1 2 0 3
2 3 3 0
M i-
T*:
R*: 8: 2:
31
1:
Q*: A05 A04 A07 A13 A14
A05
A04
A07
A13
A14
0 0 6 1 8 0 0 0 0 0 0 0 0 1 1
0 0 6 1 8 0 0 0 0 0 0 0 0 1 1
10 9 0 11 5 10 11 10 10 11 10 11 11 10 10
1 2 11 0 16 1 5 3 1 2 1 2 2 3 3
15 14 5 16 0, 15 15 15 15 16 15 16 16 16 15
002 0 0 6 8
003 0 0 6 8
016 0 0 6 8
F02 0 0 6 8
F05 0 0 6 8
Y03 0 0 6 8
Y10 0 0 6 8
102 0 0 6 8
109 1 1 6 8
115 1 1 7 8
118 1 1 7 9
1
W ~
6: 5: 1
C02 C03 CIS
180
10: 3
F02 F05
334
13: 1
Y03 Y10
0. 0 0
o: 0
0 0 0
0 0 0
0 0 0
1 1 1
1 1 1
1 1 1
0 0
0 / 6
0
0
0
r
0
435
11: 1: 1: 1
102 109 115 118
0 1 
0 1 
0 1
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Table B.7 Nucleotide (a) and amino acid (b)substitution tables for patient 7 (L3)
Boxed regions represent intraisolate sequence diversity. * T = no. of days post-OLT; R 
ratio of quasispecies; 0  = designation of representative quasispecies.
(a)
T*
R*
Q*
a
001
1
022
11:
101
47
1
107
001
022
101
107
4
0
R*
Q*
a
001
1
022
11:
101
47
1
107
001
022
101
107
0
4
4
0
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Appendix C:
Raw data from electronic cell counting device, indicating purity of leukocyte sub- 
populations prepared from two HCV-infected patients by the method of section 2.3.2
Patient A1: Pre-OLT sample
ftlJH SESULFS 
WHOLE BLOOD SUH RESULTS 
WHOLE BLOOD
DATE: 0 2 / 2 1 / 9 ‘i 
TIME: 1 2 : ^ 0
PATIENT (Lymphocvtes)
SEQUENCE HO. 13?
CROWN NO.
TUBE NO.
WBC ■ 0 . 4
RBC 0 . 0 0
H63 0 . 0
HCT
MCU
MCH
MCHC
RDW
PLT , 5
MPU
.^v^JLVMPH 3 3 . 6
- '':MID 4 . 9
- ;:ORAN I I •
LVMPH o . ' 5
MID 0 . 0
GRAN 0 .  1
REVIEW D IF F
10''3/L
PG
O/DL
%
1 ■•3''? /  L
■•►^ '■^ DATE: 0 2 /2 1 /9 4  
TIM E :  1 2 : 4 6
PATIENT ID#: Oft 16a  (Polymorphs)
SEQUENCE NO. 133  
CROWN NO.
TUBE NO.
M F
WBC 5 . 3  1 0 ^ 9 / L
RSC 0 . 0 1  I 0 ' ' l 2 / L
HGB 0 . 0  O /D L
HCT %
MCU ■ FL
MCH PG
MCHC G/DL .
RDW %
PLT 3 1 0 - '9 /L
MPU
•:LVMPH 4 . 2  %
%MID 3 . 3
%GRAN 9 2 . 0  %
LVMPH 0 . 2  1 0 ' ' 9 / L  ■
MID 0 . 2  1 0 " 9 / L
GRAN 5 . 4  1 0 ' ' 9 / L
LOW LVMPH MODE
Patient F1 : Post-OLT sample.
RUN RESULTS 
WHOLE BLOOD
RUN RESULTS 
WHOLE BLOOD
A ' DATE: 0 2 / 2 1 / 9 4  
TIME: 1 2 : 4 9
PATIENT ID # :  (Lymphocytes)
SEQUENCE NO. 139  
CROWN NO.
TUBE NO. ■ p, p
DATE: 0 2 / 2 1 / 9 ' !
T IM E :  1 2 :5 1
P A T IE N T  ID#:OF'ftA (Polymorphs) 
SEQUENCE NO. 190  
CROWN NO.
TUBE NO.
M i
UBC
RBC
HOB
HCT
HCU -
nCH
MCHC
RDW
P'.T.
MPU
0 . 9  lO '^S /L  
o . o a  l O - ^ r i / L  
. 0 . 0  Q /DL  
%
FL
PO
6 /D L
%
7 1 0 ' ' 9 / L  
FL
% L Y M P H !.7 5 .8 '%
%MID 9 . 9  %
%@RAN 1 4 . >  X
LYMPH 0 . 7  1 3 - 9 / L
. .  •  -  r t  «  1  / I
WBC 4 .  1 l O ' S / L
RBC 0 . 0 1 I 0 ' ' 1 2 / L
HGB 0 . 0 G/DL
HCT %
■ MCU FL
. MCH PG
MCHC G/DL
. RDW y.
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APPENDIX D
HCV viraemia levels In HCV-infected asymptomatic subjects and OLT recipients
HCV
Viraemia level (genome equivalents/ml)
Non-recipients of OLT:
-
1(Wad) la 0 267
ND 7.0x105
2 (Dix) 2b 0 457 719
ND 8 .0x106 6 .0x106
3 (Fra) 1b 0 2A 87
7.0x106 1.5x107 5.0x106
OLT recipients:
-
4(01) 1b -111 8 86 218 329
2.5x104 5.0x105 7.0x106 5.5x106 7.0x106
5(L2) 1b 31 97 180 334 465
1.0x105 5.2x106 ND2 ND ND
6 (LI) 1b -33 88
5.0x106 7.0x108
7(L3) la -33 47
<1x103 4.5x105
. Time from OLT in days ( - indicates prior to OLT ). 2. Not done.
Quantitation was carried out by Dr. Dazhuang Shang using a chemoluminescent detection method (Petrik etal. 
1996).
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